WO2022159504A1 - Deuterated cannabinoid compounds - Google Patents
Deuterated cannabinoid compounds Download PDFInfo
- Publication number
- WO2022159504A1 WO2022159504A1 PCT/US2022/012997 US2022012997W WO2022159504A1 WO 2022159504 A1 WO2022159504 A1 WO 2022159504A1 US 2022012997 W US2022012997 W US 2022012997W WO 2022159504 A1 WO2022159504 A1 WO 2022159504A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- compound
- disease
- subject
- agent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 587
- 229930003827 cannabinoid Natural products 0.000 title description 11
- 239000003557 cannabinoid Substances 0.000 title description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 875
- 208000035475 disorder Diseases 0.000 claims abstract description 488
- 201000010099 disease Diseases 0.000 claims abstract description 387
- 238000000034 method Methods 0.000 claims abstract description 187
- 208000022531 anorexia Diseases 0.000 claims abstract description 102
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 102
- 208000002193 Pain Diseases 0.000 claims abstract description 90
- 206010061218 Inflammation Diseases 0.000 claims abstract description 88
- 230000004054 inflammatory process Effects 0.000 claims abstract description 88
- 206010047700 Vomiting Diseases 0.000 claims abstract description 86
- 230000036407 pain Effects 0.000 claims abstract description 83
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 78
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- 201000011510 cancer Diseases 0.000 claims abstract description 69
- 206010010904 Convulsion Diseases 0.000 claims abstract description 68
- 206010015037 epilepsy Diseases 0.000 claims abstract description 62
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 62
- 230000036506 anxiety Effects 0.000 claims abstract description 57
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 49
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 48
- 208000001914 Fragile X syndrome Diseases 0.000 claims abstract description 43
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract description 43
- 208000006289 Rett Syndrome Diseases 0.000 claims abstract description 43
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 43
- 208000036546 leukodystrophy Diseases 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 41
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 38
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 38
- 230000016571 aggressive behavior Effects 0.000 claims abstract description 35
- 208000008589 Obesity Diseases 0.000 claims abstract description 32
- 235000020824 obesity Nutrition 0.000 claims abstract description 32
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 32
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 28
- 208000019899 phobic disease Diseases 0.000 claims abstract description 23
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 22
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 19
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 19
- 208000023178 Musculoskeletal disease Diseases 0.000 claims abstract description 19
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 19
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 95
- 230000003405 preventing effect Effects 0.000 claims description 59
- 241001465754 Metazoa Species 0.000 claims description 57
- 239000003814 drug Substances 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 229940124597 therapeutic agent Drugs 0.000 claims description 52
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 208000019695 Migraine disease Diseases 0.000 claims description 48
- 206010027599 migraine Diseases 0.000 claims description 48
- -1 ketaprofen Chemical compound 0.000 claims description 45
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 38
- 208000005392 Spasm Diseases 0.000 claims description 36
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 36
- 210000000988 bone and bone Anatomy 0.000 claims description 36
- 230000015556 catabolic process Effects 0.000 claims description 36
- 230000036461 convulsion Effects 0.000 claims description 36
- 238000006731 degradation reaction Methods 0.000 claims description 36
- 208000028867 ischemia Diseases 0.000 claims description 36
- 208000020016 psychiatric disease Diseases 0.000 claims description 36
- 208000035143 Bacterial infection Diseases 0.000 claims description 35
- 206010017533 Fungal infection Diseases 0.000 claims description 35
- 208000031888 Mycoses Diseases 0.000 claims description 35
- 208000036142 Viral infection Diseases 0.000 claims description 35
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 35
- 230000009385 viral infection Effects 0.000 claims description 35
- 206010028813 Nausea Diseases 0.000 claims description 33
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 33
- 238000002512 chemotherapy Methods 0.000 claims description 33
- 229960004242 dronabinol Drugs 0.000 claims description 33
- 230000008693 nausea Effects 0.000 claims description 33
- 230000008673 vomiting Effects 0.000 claims description 33
- 241000283073 Equus caballus Species 0.000 claims description 30
- 238000001356 surgical procedure Methods 0.000 claims description 29
- 206010012289 Dementia Diseases 0.000 claims description 23
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 23
- 208000018198 spasticity Diseases 0.000 claims description 23
- 206010006895 Cachexia Diseases 0.000 claims description 22
- 208000003577 HIV wasting syndrome Diseases 0.000 claims description 22
- 208000019022 Mood disease Diseases 0.000 claims description 22
- 208000004296 neuralgia Diseases 0.000 claims description 22
- 208000021722 neuropathic pain Diseases 0.000 claims description 22
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 21
- 208000016620 Tourette disease Diseases 0.000 claims description 21
- 208000011580 syndromic disease Diseases 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 19
- 208000020925 Bipolar disease Diseases 0.000 claims description 19
- 206010012209 Delayed sleep phase Diseases 0.000 claims description 19
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 19
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 19
- 201000001388 Smith-Magenis syndrome Diseases 0.000 claims description 19
- 230000027288 circadian rhythm Effects 0.000 claims description 19
- 208000024732 dysthymic disease Diseases 0.000 claims description 19
- 208000026278 immune system disease Diseases 0.000 claims description 19
- 206010022437 insomnia Diseases 0.000 claims description 19
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 19
- 208000024714 major depressive disease Diseases 0.000 claims description 19
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 19
- 230000001850 reproductive effect Effects 0.000 claims description 19
- 208000019116 sleep disease Diseases 0.000 claims description 19
- 206010003805 Autism Diseases 0.000 claims description 18
- 208000020706 Autistic disease Diseases 0.000 claims description 18
- 206010020772 Hypertension Diseases 0.000 claims description 18
- 229960003604 testosterone Drugs 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 208000009575 Angelman syndrome Diseases 0.000 claims description 17
- 208000004550 Postoperative Pain Diseases 0.000 claims description 17
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 16
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 15
- 239000001961 anticonvulsive agent Substances 0.000 claims description 15
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 15
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 14
- 208000012672 seasonal affective disease Diseases 0.000 claims description 14
- 241000282326 Felis catus Species 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000003018 immunosuppressive agent Substances 0.000 claims description 11
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 11
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 10
- 208000000810 Separation Anxiety Diseases 0.000 claims description 10
- 239000002111 antiemetic agent Substances 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 230000000399 orthopedic effect Effects 0.000 claims description 10
- 210000004872 soft tissue Anatomy 0.000 claims description 10
- 239000000730 antalgic agent Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 229940125683 antiemetic agent Drugs 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
- 239000000935 antidepressant agent Substances 0.000 claims description 8
- 239000000164 antipsychotic agent Substances 0.000 claims description 8
- 229940124575 antispasmodic agent Drugs 0.000 claims description 8
- 239000002249 anxiolytic agent Substances 0.000 claims description 8
- 239000000812 cholinergic antagonist Substances 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 7
- 230000002253 anti-ischaemic effect Effects 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 7
- 230000002980 postoperative effect Effects 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 230000003556 anti-epileptic effect Effects 0.000 claims description 6
- 229940125708 antidiabetic agent Drugs 0.000 claims description 6
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 229960003965 antiepileptics Drugs 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 6
- 239000002948 appetite stimulant Substances 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 230000003262 anti-osteoporosis Effects 0.000 claims description 5
- 239000003529 anticholesteremic agent Substances 0.000 claims description 5
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- 239000002327 cardiovascular agent Substances 0.000 claims description 5
- 229940125692 cardiovascular agent Drugs 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 229960002870 gabapentin Drugs 0.000 claims description 5
- 230000000642 iatrogenic effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 229960003910 promethazine Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 3
- 229930192392 Mitomycin Natural products 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003184 carprofen Drugs 0.000 claims description 3
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000394 droperidol Drugs 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229960004391 lorazepam Drugs 0.000 claims description 3
- 229960001929 meloxicam Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 3
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003111 prochlorperazine Drugs 0.000 claims description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 3
- 230000020636 territorial aggressive behavior Effects 0.000 claims description 3
- 229960004380 tramadol Drugs 0.000 claims description 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 2
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960002632 acarbose Drugs 0.000 claims description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229960003687 alizapride Drugs 0.000 claims description 2
- 229960003896 aminopterin Drugs 0.000 claims description 2
- 229960001372 aprepitant Drugs 0.000 claims description 2
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 2
- 229960002430 atomoxetine Drugs 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960003778 casopitant Drugs 0.000 claims description 2
- XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 claims description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003564 cyclizine Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960004993 dimenhydrinate Drugs 0.000 claims description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229960003413 dolasetron Drugs 0.000 claims description 2
- 229960001253 domperidone Drugs 0.000 claims description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001208 eplerenone Drugs 0.000 claims description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 2
- 229960003727 granisetron Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001474 meclozine Drugs 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003793 midazolam Drugs 0.000 claims description 2
- 229960000600 milnacipran Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229960005343 ondansetron Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960002131 palonosetron Drugs 0.000 claims description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 229960004134 propofol Drugs 0.000 claims description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000371 rofecoxib Drugs 0.000 claims description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- 229960002646 scopolamine Drugs 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004161 trimethobenzamide Drugs 0.000 claims description 2
- 229960003688 tropisetron Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 239000003612 morphinomimetic agent Substances 0.000 claims 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 4
- 229930186147 Cephalosporin Natural products 0.000 claims 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 229940124587 cephalosporin Drugs 0.000 claims 3
- 150000001780 cephalosporins Chemical class 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229960001848 lamotrigine Drugs 0.000 claims 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 3
- 229960001816 oxcarbazepine Drugs 0.000 claims 3
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 3
- 229960002911 zonisamide Drugs 0.000 claims 3
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 2
- 229960004261 cefotaxime Drugs 0.000 claims 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 2
- 229960000484 ceftazidime Drugs 0.000 claims 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960001403 clobazam Drugs 0.000 claims 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 2
- 229960003120 clonazepam Drugs 0.000 claims 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 2
- 229960004170 clozapine Drugs 0.000 claims 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229960003529 diazepam Drugs 0.000 claims 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 2
- 229960001160 latanoprost Drugs 0.000 claims 2
- 229960002260 meropenem Drugs 0.000 claims 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 2
- 229960003085 meticillin Drugs 0.000 claims 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 2
- 229960002695 phenobarbital Drugs 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 229960004940 sulpiride Drugs 0.000 claims 2
- 229960004492 suprofen Drugs 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims 2
- 229960005318 vigabatrin Drugs 0.000 claims 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 claims 1
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 claims 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 claims 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 claims 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 claims 1
- KGSABFQIAANNPS-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-2-ol Chemical compound C=1C=CC(Cl)=CC=1C(C(O)CN(C)C)C1=CC=CC=C1 KGSABFQIAANNPS-UHFFFAOYSA-N 0.000 claims 1
- XGLHZTBDUXXHOM-WMZJFQQLSA-N 1-[(z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(/Cl)=C/N1C=NC=N1 XGLHZTBDUXXHOM-WMZJFQQLSA-N 0.000 claims 1
- STDYWHYUOSSCBO-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine Chemical compound C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 STDYWHYUOSSCBO-UHFFFAOYSA-N 0.000 claims 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 claims 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 claims 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 claims 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims 1
- TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 claims 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 claims 1
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 claims 1
- FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 claims 1
- MVVJINIUPYKZHR-UHFFFAOYSA-N 3-[[4-[5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]benzonitrile Chemical compound O=C1OC(COC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 MVVJINIUPYKZHR-UHFFFAOYSA-N 0.000 claims 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 claims 1
- NDPOGPAZKKPOPV-UHFFFAOYSA-N 4-(4-ethylphenyl)piperidine Chemical compound C1=CC(CC)=CC=C1C1CCNCC1 NDPOGPAZKKPOPV-UHFFFAOYSA-N 0.000 claims 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 claims 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 claims 1
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 claims 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 108030001720 Bontoxilysin Proteins 0.000 claims 1
- 101001011741 Bos taurus Insulin Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 239000004099 Chlortetracycline Substances 0.000 claims 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- 108010078777 Colistin Proteins 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010013198 Daptomycin Proteins 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 108010066671 Enalaprilat Proteins 0.000 claims 1
- 229930189413 Esperamicin Natural products 0.000 claims 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 claims 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 claims 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 claims 1
- NRIGRKAXOLMTSK-UHFFFAOYSA-N Lamtidine Chemical compound CN1N=C(N)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 NRIGRKAXOLMTSK-UHFFFAOYSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims 1
- RSHMQGIMHQPMEB-IXOXFDKPSA-N Montirelin Chemical compound N1C(=O)[C@@H](C)SC[C@H]1C(=O)N[C@H](C(=O)N1[C@@H](CCC1)C(N)=O)CC1=CN=CN1 RSHMQGIMHQPMEB-IXOXFDKPSA-N 0.000 claims 1
- JTAJFHGSVCEPKC-KUHUBIRLSA-N N,N-dimethyl-3-[(9S,10R)-10-methyl-2-(trifluoromethyl)-9,10-dihydroanthracen-9-yl]propan-1-amine Chemical compound FC(F)(F)C1=CC=C2[C@H](C)C3=CC=CC=C3[C@H](CCCN(C)C)C2=C1 JTAJFHGSVCEPKC-KUHUBIRLSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims 1
- QSQQPMHPCBLLGX-UHFFFAOYSA-N N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine Chemical compound CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1 QSQQPMHPCBLLGX-UHFFFAOYSA-N 0.000 claims 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 229930195708 Penicillin V Natural products 0.000 claims 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 101000993800 Sus scrofa Insulin Proteins 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- 108010049264 Teriparatide Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 1
- FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 claims 1
- HLAFSNJRKZLMPT-UHFFFAOYSA-N [2-[2-(aminomethyl)phenyl]sulfanylphenyl]methanol Chemical compound NCC1=CC=CC=C1SC1=CC=CC=C1CO HLAFSNJRKZLMPT-UHFFFAOYSA-N 0.000 claims 1
- BVISQZFBLRSESR-XSCWXTNMSA-N abaloparatide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C1=CN=CN1 BVISQZFBLRSESR-XSCWXTNMSA-N 0.000 claims 1
- 229950001959 abaloparatide Drugs 0.000 claims 1
- 108010038051 abaloparatide Proteins 0.000 claims 1
- 229960004892 acemetacin Drugs 0.000 claims 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229960003148 adinazolam Drugs 0.000 claims 1
- GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 claims 1
- 229960003225 alaproclate Drugs 0.000 claims 1
- 229940092229 aldactone Drugs 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 claims 1
- 229950008673 alpidem Drugs 0.000 claims 1
- 229960000959 amineptine Drugs 0.000 claims 1
- VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004050 aminobenzoic acid Drugs 0.000 claims 1
- 229960005260 amiodarone Drugs 0.000 claims 1
- 229940042749 amitriptyline / chlordiazepoxide Drugs 0.000 claims 1
- 229960003022 amoxicillin Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 235000010208 anthocyanin Nutrition 0.000 claims 1
- 229930002877 anthocyanin Natural products 0.000 claims 1
- 239000004410 anthocyanin Substances 0.000 claims 1
- 150000004636 anthocyanins Chemical class 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125684 antimigraine agent Drugs 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 claims 1
- 229960003002 atipamezole Drugs 0.000 claims 1
- 229950010046 avasimibe Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960003623 azlocillin Drugs 0.000 claims 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003071 bacitracin Drugs 0.000 claims 1
- 229930184125 bacitracin Natural products 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- 229960000817 bazedoxifene Drugs 0.000 claims 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims 1
- KRNDIPHOJLIHRI-UHFFFAOYSA-N bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 claims 1
- 229950005683 bazinaprine Drugs 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960005430 benoxaprofen Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims 1
- 229960004933 bifemelane Drugs 0.000 claims 1
- SXYFFMXPDDGOEK-UHFFFAOYSA-N binedaline Chemical compound C12=CC=CC=C2N(N(C)CCN(C)C)C=C1C1=CC=CC=C1 SXYFFMXPDDGOEK-UHFFFAOYSA-N 0.000 claims 1
- 229950009454 bipenamol Drugs 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims 1
- 229960003679 brimonidine Drugs 0.000 claims 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 1
- 229960000722 brinzolamide Drugs 0.000 claims 1
- 229960002161 brivaracetam Drugs 0.000 claims 1
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims 1
- 229950004068 brofaromine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 229950005608 bucloxic acid Drugs 0.000 claims 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960003669 carbenicillin Drugs 0.000 claims 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims 1
- 229930188550 carminomycin Natural products 0.000 claims 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 claims 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 claims 1
- 229950006044 caroxazone Drugs 0.000 claims 1
- 229950001725 carubicin Drugs 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960003719 cefdinir Drugs 0.000 claims 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- 229960002129 cefixime Drugs 0.000 claims 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims 1
- 229960004682 cefoperazone Drugs 0.000 claims 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 claims 1
- 229960000466 cefpirome Drugs 0.000 claims 1
- 229960002580 cefprozil Drugs 0.000 claims 1
- 229940036735 ceftaroline Drugs 0.000 claims 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims 1
- 229960004086 ceftibuten Drugs 0.000 claims 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims 1
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 claims 1
- 229950004259 ceftobiprole Drugs 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- 229950000303 cericlamine Drugs 0.000 claims 1
- ZGLIFVFRIOKQLE-LVZFUZTISA-N chembl2104573 Chemical compound C=1C(Cl)=CC=C(O)C=1C(=N/CCCC)/C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-LVZFUZTISA-N 0.000 claims 1
- 229960004782 chlordiazepoxide Drugs 0.000 claims 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 1
- 229960001552 chlorprothixene Drugs 0.000 claims 1
- 229960004475 chlortetracycline Drugs 0.000 claims 1
- 235000019365 chlortetracycline Nutrition 0.000 claims 1
- LQXYCDLHSKICDY-UHFFFAOYSA-N cianopramine Chemical compound C1CC2=CC=C(C#N)C=C2N(CCCN(C)C)C2=CC=CC=C21 LQXYCDLHSKICDY-UHFFFAOYSA-N 0.000 claims 1
- 229950001408 cianopramine Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229950001660 cimoxatone Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229950009328 clemeprol Drugs 0.000 claims 1
- 229950010886 clidanac Drugs 0.000 claims 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 claims 1
- 229950001320 clinafloxacin Drugs 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- 229960001184 clopenthixol Drugs 0.000 claims 1
- 229960004362 clorazepate Drugs 0.000 claims 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 claims 1
- 229960003864 clotiapine Drugs 0.000 claims 1
- 229950002663 clovoxamine Drugs 0.000 claims 1
- XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 1
- 229960002604 colestipol Drugs 0.000 claims 1
- 229960003346 colistin Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 1
- 229960005484 daptomycin Drugs 0.000 claims 1
- 229950005551 dazepinil Drugs 0.000 claims 1
- 229960002887 deanol Drugs 0.000 claims 1
- SEDQWOMFMIJKCU-UHFFFAOYSA-N demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 claims 1
- 229950010189 demexiptiline Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims 1
- 229960003314 deracoxib Drugs 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 229960003075 dibenzepin Drugs 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229960001066 disopyramide Drugs 0.000 claims 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims 1
- 229960003933 dorzolamide Drugs 0.000 claims 1
- 229960001393 dosulepin Drugs 0.000 claims 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001389 doxazosin Drugs 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- 229960001104 droxidopa Drugs 0.000 claims 1
- 229960002472 eletriptan Drugs 0.000 claims 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960002680 enalaprilat Drugs 0.000 claims 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims 1
- 229950004233 enefexine Drugs 0.000 claims 1
- 229960002549 enoxacin Drugs 0.000 claims 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960002770 ertapenem Drugs 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims 1
- 229960002336 estazolam Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960005437 etoperidone Drugs 0.000 claims 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims 1
- 229950003930 femoxetine Drugs 0.000 claims 1
- 229950004395 fengabine Drugs 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002679 fentiazac Drugs 0.000 claims 1
- NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 claims 1
- 229950000761 fezolamine Drugs 0.000 claims 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 claims 1
- 229960002524 firocoxib Drugs 0.000 claims 1
- 229960000449 flecainide Drugs 0.000 claims 1
- 229960003306 fleroxacin Drugs 0.000 claims 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 claims 1
- 229950003678 flesinoxan Drugs 0.000 claims 1
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 claims 1
- 229950007979 flufenisal Drugs 0.000 claims 1
- 229950006420 fluotracen Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 claims 1
- 229960002419 flupentixol Drugs 0.000 claims 1
- 229960002690 fluphenazine Drugs 0.000 claims 1
- 229950001284 fluprofen Drugs 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 229960001430 garenoxacin Drugs 0.000 claims 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 229960003170 gemifloxacin Drugs 0.000 claims 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 229960000647 gepirone Drugs 0.000 claims 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000587 glutaral Drugs 0.000 claims 1
- 229960000642 grepafloxacin Drugs 0.000 claims 1
- 229960002706 gusperimus Drugs 0.000 claims 1
- 229960002158 halazepam Drugs 0.000 claims 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
- 229940091173 hydantoin Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical group C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 claims 1
- 229950001476 idazoxan Drugs 0.000 claims 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims 1
- 229950002473 indalpine Drugs 0.000 claims 1
- 229960004333 indeloxazine Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960004187 indoprofen Drugs 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 229960002844 iprindole Drugs 0.000 claims 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 claims 1
- 229950003599 ipsapirone Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229950002252 isoxicam Drugs 0.000 claims 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960002623 lacosamide Drugs 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 229950003849 lamtidine Drugs 0.000 claims 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229950003041 levoprotiline Drugs 0.000 claims 1
- FDXQKWSTUZCCTM-ZUIJCZDSSA-N levoprotiline Chemical compound C12=CC=CC=C2C2(C[C@@H](O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-ZUIJCZDSSA-N 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 229960005287 lincomycin Drugs 0.000 claims 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229960001078 lithium Drugs 0.000 claims 1
- MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 claims 1
- 229950004138 litoxetine Drugs 0.000 claims 1
- 229960002813 lofepramine Drugs 0.000 claims 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims 1
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- 229960001977 loracarbef Drugs 0.000 claims 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 claims 1
- 229950004164 loreclezole Drugs 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960000423 loxapine Drugs 0.000 claims 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002373 loxoprofen Drugs 0.000 claims 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims 1
- 229950001846 mabuprofen Drugs 0.000 claims 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 claims 1
- 229960000299 mazindol Drugs 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960003123 medifoxamine Drugs 0.000 claims 1
- QNMGHBMGNRQPNL-UHFFFAOYSA-N medifoxamine Chemical compound C=1C=CC=CC=1OC(CN(C)C)OC1=CC=CC=C1 QNMGHBMGNRQPNL-UHFFFAOYSA-N 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 1
- 229960000300 mesoridazine Drugs 0.000 claims 1
- YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 claims 1
- 229950006180 metapramine Drugs 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- GVXBHSBKKJRBMS-UHFFFAOYSA-N metralindole Chemical compound C1CN(C)C2=NCCC3=C2N1C1=CC=C(OC)C=C13 GVXBHSBKKJRBMS-UHFFFAOYSA-N 0.000 claims 1
- 229950006787 metralindole Drugs 0.000 claims 1
- 229960000198 mezlocillin Drugs 0.000 claims 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims 1
- 229960003955 mianserin Drugs 0.000 claims 1
- 229960004758 minaprine Drugs 0.000 claims 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 229960005170 moexipril Drugs 0.000 claims 1
- 229960004938 molindone Drugs 0.000 claims 1
- 229950004759 montirelin Drugs 0.000 claims 1
- 108700023195 montirelin Proteins 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
- XZOCIZHAHWDUPU-QWRGUYRKSA-N n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-2,4-dioxo-1h-pyrimidine-6-carboxamide Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C=1NC(=O)NC(=O)C=1)CC1=CN=CN1 XZOCIZHAHWDUPU-QWRGUYRKSA-N 0.000 claims 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960005254 naratriptan Drugs 0.000 claims 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 claims 1
- 229950010963 nebracetam Drugs 0.000 claims 1
- 229960000751 nefopam Drugs 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 229960000808 netilmicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 229960003057 nialamide Drugs 0.000 claims 1
- 229960000916 niflumic acid Drugs 0.000 claims 1
- 229960001073 nomifensine Drugs 0.000 claims 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 claims 1
- 229960001180 norfloxacin Drugs 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229950005403 orotirelin Drugs 0.000 claims 1
- 108700031265 orotirelin Proteins 0.000 claims 1
- 229960002019 oxaflozane Drugs 0.000 claims 1
- FVYUQFQCEOZYHZ-UHFFFAOYSA-N oxaflozane Chemical compound C1N(C(C)C)CCOC1C1=CC=CC(C(F)(F)F)=C1 FVYUQFQCEOZYHZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000464 oxandrolone Drugs 0.000 claims 1
- 229960002739 oxaprozin Drugs 0.000 claims 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 1
- 229960004535 oxazepam Drugs 0.000 claims 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229950003510 pactimibe Drugs 0.000 claims 1
- 229960002625 pazufloxacin Drugs 0.000 claims 1
- 229960004236 pefloxacin Drugs 0.000 claims 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims 1
- 229960000761 pemoline Drugs 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 229940056360 penicillin g Drugs 0.000 claims 1
- 229940056367 penicillin v Drugs 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960001412 pentobarbital Drugs 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229960000762 perphenazine Drugs 0.000 claims 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 229960001416 pilocarpine Drugs 0.000 claims 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 1
- 229960003634 pimozide Drugs 0.000 claims 1
- 229960002034 pinazepam Drugs 0.000 claims 1
- MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 claims 1
- 229960002508 pindolol Drugs 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims 1
- 229960004572 pizotifen Drugs 0.000 claims 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960004856 prazepam Drugs 0.000 claims 1
- 229960001289 prazosin Drugs 0.000 claims 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 1
- 229960002393 primidone Drugs 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- 229960003598 promazine Drugs 0.000 claims 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 claims 1
- 229960002443 propafenone hydrochloride Drugs 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 claims 1
- 229960002454 quinidine gluconate Drugs 0.000 claims 1
- 108700028429 quinupristin Proteins 0.000 claims 1
- 229960005442 quinupristin Drugs 0.000 claims 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 claims 1
- 229950001518 raclopride Drugs 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 229960003394 remifentanil Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 claims 1
- 229960000885 rifabutin Drugs 0.000 claims 1
- 229960002599 rifapentine Drugs 0.000 claims 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 claims 1
- 229950009626 ritanserin Drugs 0.000 claims 1
- 229960000425 rizatriptan Drugs 0.000 claims 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003014 rufinamide Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 229950000852 seletracetam Drugs 0.000 claims 1
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims 1
- FTKTZRKAVSDSRA-UHFFFAOYSA-N sercloremine Chemical compound C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 FTKTZRKAVSDSRA-UHFFFAOYSA-N 0.000 claims 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960000652 sertindole Drugs 0.000 claims 1
- GVPIXRLYKVFFMK-UHFFFAOYSA-N setiptiline Chemical compound C12=CC=CC=C2CC2=CC=CC=C2C2=C1CN(C)CC2 GVPIXRLYKVFFMK-UHFFFAOYSA-N 0.000 claims 1
- 229950002275 setiptiline Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 229960003177 sitafloxacin Drugs 0.000 claims 1
- 229940084026 sodium valproate Drugs 0.000 claims 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical class [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims 1
- 229960004954 sparfloxacin Drugs 0.000 claims 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 1
- 229960000268 spectinomycin Drugs 0.000 claims 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 claims 1
- 229950001675 spiperone Drugs 0.000 claims 1
- 229960001897 stiripentol Drugs 0.000 claims 1
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 229950005175 sudoxicam Drugs 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- 229960003211 sulbutiamine Drugs 0.000 claims 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004306 sulfadiazine Drugs 0.000 claims 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001975 sulfisomidine Drugs 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960003708 sumatriptan Drugs 0.000 claims 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960005240 telavancin Drugs 0.000 claims 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 1
- 108010089019 telavancin Proteins 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960004576 temafloxacin Drugs 0.000 claims 1
- 229960001114 temocillin Drugs 0.000 claims 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 claims 1
- OILWWIVKIDXCIB-UHFFFAOYSA-N teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 claims 1
- 229950003014 teniloxazine Drugs 0.000 claims 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 claims 1
- 229950009638 tepoxalin Drugs 0.000 claims 1
- 229960001693 terazosin Drugs 0.000 claims 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229960004412 thebacon Drugs 0.000 claims 1
- RRJQTGHQFYTZOW-ILWKUFEGSA-N thebacon Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C=C(OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC RRJQTGHQFYTZOW-ILWKUFEGSA-N 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
- JJSHYECKYLDYAR-UHFFFAOYSA-N thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- 229960005138 tianeptine Drugs 0.000 claims 1
- 229960001312 tiaprofenic acid Drugs 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229950008817 tiflucarbine Drugs 0.000 claims 1
- BNKIWXODDDABSJ-UHFFFAOYSA-N tiflucarbine Chemical compound N1C2=CC(F)=C3SC=C(C)C3=C2C2=C1CCN(CC)C2 BNKIWXODDDABSJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229950002345 tiopinac Drugs 0.000 claims 1
- 229960005013 tiotixene Drugs 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229960002872 tocainide Drugs 0.000 claims 1
- 229950010076 tofenacin Drugs 0.000 claims 1
- PNYKGCPSFKLFKA-UHFFFAOYSA-N tofenacin Chemical compound C=1C=CC=C(C)C=1C(OCCNC)C1=CC=CC=C1 PNYKGCPSFKLFKA-UHFFFAOYSA-N 0.000 claims 1
- 229960002501 tofisopam Drugs 0.000 claims 1
- 229960002277 tolazamide Drugs 0.000 claims 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims 1
- 229960002905 tolfenamic acid Drugs 0.000 claims 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 1
- 229960001017 tolmetin Drugs 0.000 claims 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 1
- 229960002309 toloxatone Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- 229960002324 trifluoperazine Drugs 0.000 claims 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims 1
- 229960003904 triflupromazine Drugs 0.000 claims 1
- 229960001082 trimethoprim Drugs 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 1
- 229960000497 trovafloxacin Drugs 0.000 claims 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 229960001968 veralipride Drugs 0.000 claims 1
- RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 claims 1
- 229950006360 viqualine Drugs 0.000 claims 1
- XFXANHWIBFMEOY-JKSUJKDBSA-N viqualine Chemical compound C12=CC(OC)=CC=C2N=CC=C1CCC[C@@H]1CCNC[C@@H]1C=C XFXANHWIBFMEOY-JKSUJKDBSA-N 0.000 claims 1
- 229950007802 zidometacin Drugs 0.000 claims 1
- 229960002791 zimeldine Drugs 0.000 claims 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- 229960001360 zolmitriptan Drugs 0.000 claims 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 1
- 229960001475 zolpidem Drugs 0.000 claims 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical group N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 1
- 229960003414 zomepirac Drugs 0.000 claims 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims 1
- CJGOZEVWXQGMCS-UHFFFAOYSA-N zometapine Chemical compound CN1NC(C)=C2C1=NCCN=C2C1=CC=CC(Cl)=C1 CJGOZEVWXQGMCS-UHFFFAOYSA-N 0.000 claims 1
- 229960000820 zopiclone Drugs 0.000 claims 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 29
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical class C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 abstract description 16
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 abstract description 13
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical class CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 9
- 241000124008 Mammalia Species 0.000 description 50
- 241000282472 Canis lupus familiaris Species 0.000 description 33
- 238000009472 formulation Methods 0.000 description 19
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 14
- 241000282341 Mustela putorius furo Species 0.000 description 14
- 229910052805 deuterium Inorganic materials 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 12
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 10
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 6
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 208000020685 sleep-wake disease Diseases 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 5
- 108010062431 Monoamine oxidase Proteins 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical class C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- ORIYPICUSOGUOA-UHFFFAOYSA-N cannabidiol propyl analogue Natural products CCCc1cc(O)c(C2CC(=CCC2C(=C)C)C)c(O)c1 ORIYPICUSOGUOA-UHFFFAOYSA-N 0.000 description 3
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 3
- 229940065144 cannabinoids Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 208000037870 generalized anxiety Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- YCBKSSAWEUDACY-IAGOWNOFSA-N 11-hydroxy-Delta(9)-tetrahydrocannabinol Chemical class C1=C(CO)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YCBKSSAWEUDACY-IAGOWNOFSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000000472 muscarinic agonist Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 231100000440 toxicity profile Toxicity 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 description 1
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 102100032645 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Human genes 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102100029361 Aromatase Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 description 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 description 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 description 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 description 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 description 1
- 102100038742 Cytochrome P450 2A13 Human genes 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 1
- 102100029368 Cytochrome P450 2C18 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102100031461 Cytochrome P450 2J2 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 description 1
- 102100027567 Cytochrome P450 4A11 Human genes 0.000 description 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 description 1
- 102100024918 Cytochrome P450 4F12 Human genes 0.000 description 1
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 description 1
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 description 1
- 102100024899 Cytochrome P450 4F8 Human genes 0.000 description 1
- 102100022027 Cytochrome P450 4X1 Human genes 0.000 description 1
- 102100022034 Cytochrome P450 4Z1 Human genes 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- 102100038698 Cytochrome P450 7B1 Human genes 0.000 description 1
- 102000023526 Cytochrome P450 Family 46 Human genes 0.000 description 1
- 108010036233 Cytochrome P450 Family 46 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000957389 Homo sapiens Cytochrome P450 2A13 Proteins 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 101000919360 Homo sapiens Cytochrome P450 2C18 Proteins 0.000 description 1
- 101000941723 Homo sapiens Cytochrome P450 2J2 Proteins 0.000 description 1
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 description 1
- 101000725111 Homo sapiens Cytochrome P450 4A11 Proteins 0.000 description 1
- 101000909108 Homo sapiens Cytochrome P450 4F12 Proteins 0.000 description 1
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 description 1
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 description 1
- 101000909112 Homo sapiens Cytochrome P450 4F8 Proteins 0.000 description 1
- 101000896935 Homo sapiens Cytochrome P450 4Z1 Proteins 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000957674 Homo sapiens Cytochrome P450 7B1 Proteins 0.000 description 1
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 1
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 description 1
- 101000855326 Homo sapiens Vitamin D 25-hydroxylase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 description 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102100033075 Prostacyclin synthase Human genes 0.000 description 1
- 102100026372 Putative inactive cytochrome P450 2G1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100497151 Rattus norvegicus Cyp4f1 gene Proteins 0.000 description 1
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 description 1
- 108010058254 Steroid 12-alpha-Hydroxylase Proteins 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 description 1
- 102100027545 Steroid 21-hydroxylase Human genes 0.000 description 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102100030973 Thromboxane-A synthase Human genes 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 102100026523 Vitamin D 25-hydroxylase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 108010026647 cytochrome P-450 4X1 Proteins 0.000 description 1
- 108010062869 cytochrome P-450 CYP2G1 Proteins 0.000 description 1
- 108010018719 cytochrome P-450 CYP4B1 Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000029640 digestive system melanoma Diseases 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 gemopatrilat Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006842 hematologic response Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
- 229950004274 ifetroban Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940041676 mucosal spray Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010064377 prostacyclin synthetase Proteins 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- This invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds, methods for preparation thereof, compositions comprising the same, and uses thereof for the treatment or prevention of numerous diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome- related disorders.
- diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodys
- ((6a R,10aR)-delta-9-Tetrahydrocannabinol (THC) is metabolized in the liver by enzymes of the cytochrome P450 (CYP) hepatic mixed-function oxidase family.
- CYP cytochrome P450
- THC is oxidized by CYP to active, equipotent 11-OH-THC metabolite, which is then rapidly metabolized to the inactive THC-COOH metabolite, resulting in low concentrations of THC and 11-OH-THC in blood and much higher concentrations of THC-COOH,
- the presence of the carboxyl group of THC-COOH resu lts in a loss of biological activity, since THC-COOH can no longer bind tightly to cannabinoid receptors. Because THC is subject to extensive CYP-mediated first pass hepatic metabolism following oral administration, its oral bioavailability is low.
- EPIDIOLEX (cannabidiol) has been approved for relief of spasticity in patients with multiple sclerosis. It is formulated in anhydrous ethanol, peppermint oil, and propylene glycol for buccal application. To date, no break-through in improving the bioavailability of THC has been reported.
- Current FDA approved THC product Dronabinol (Trade names: Marinol and Syndros), used as an appetite stimulant, is a synthetic form of THC dissolved in sesame oil that has an oral bioavailability of 10-20%.
- Cannabigerol is one of cannabinoid compounds found in the plant genus cannabis. It acts on specific physiological systems and the results for medicinal use are promising. Endocannabinoid receptors are prevalent in eye structures. Cannabigerol is considered to be particularly effective in treating glaucoma because it reduces intraocular pressure. It is also effective in decreasing the inflammation characteristic of inflammatory bowel disease in animal experiments involving mice.
- Cannabigerol has shown to protect neurons in mice with Huntington’s disease, which is characterized by nerve cell degeneration in the brain. Further, it is shown to block receptors that cause cancer cell growth. For example, it inhibits the gro wth of colorectal cancer cells in mice and also inhibits tumors and chemically-induced colon carcinogenesis.
- Cannabichromene also known as cannabichrome, pentylcannabichromene, or cannabinochromene, is one of major cannabinoids in Cannabis sativa L. and the second abundant cannabinoid in drug-type cannabis.
- Cannabichromene (CBC) outperforms other major cannabinoids in terms of anti-bacterial and anti-fungal activity.
- CBC also shows potent antiinflammatory activity in the carrageenan-induced rat paw edema assay.
- Deuterium has twice the mass of protium. A C-D bond is stronger than the corresponding C-’H bond. If a C- k H bond is broken during a rate-determining step in a chemical reaction (i.e., the step with the highest transition state energy), substituting a deuterium for that protium may lead to a decrease in the reaction rate.
- PK pharmacokinetics
- PD pharmacodynamics
- toxicity profiles has been investigated, deuteration is inherently unpredictable. Deuterium incorporation can only produce an effect if the incorporated deuterium is broken during a rate -determining metabolic step.
- deuterium incorporation may produce no improvement in PK, PD, or toxicity profile.
- deuterium incorporation can lead to metabolic switching. Metabolic switching occurs when xenogens, sequestered by Phase I enzymes, bind transiently and re-bind in a variety of conformations prior to the chemical reaction (e.g., oxidation). Metabolic switching can lead to different proportions of known metabolites as well as production of new metabolites. This new metabolic profile may impart more or less toxicity, or it may produce negative effects on PD and/or PD (Miwa et al., BioEssays 1987; 7(5), 215-19). Unsuccessful deuteration attempts have been reported.
- nevirapine deuteration resulted in increased metabolism, rather than decreased metabolism (Harbeson and Tung, 2011, 46, Annu. Rep. Med. Chern, 403-417).
- Deuterated versions of tramadol were not found to be superior to the parent compound. (Id,, at 409-410). Because of the unpredictable outcomes of deuteration, the pharmacokinetic and metabolic behaviors of a particular compound after deuteration can be very different, and PK / PD outcomes cannot be predicted before the compound is synthesized and tested in a series of in vitro and in vivo PK / PD experiments.
- the present invention provides deuterated cannabinoid compounds or derivatives thereof.
- Such deuterated cannabinoid compounds will maintain the beneficial aspects of the corresponding non-isotopically enriched cannabinoids while substantially slowing metabolism and improving half-life and bioavailability’ (via oral or other routes of administration).
- a combination of deuterated cannabinoid compounds with additional therapeutic agents may exhibit a therapeutic synergistic or additive effect and allow for an improved safety profile of said therapeutic agents.
- the required therapeutically effective amount of the therapeutic agents may also be less than current recommended and approved dosages, thus minimizing the toxicity during treatments.
- Such a combination therapy may also prevent or delay the onset of drug resistance and reduce potentially the side effects that arise from the use of the therapeutic agents alone.
- the invention provides a deuterated compound of (6aR,10a/?)-delta-9- tetrahydrocannabinol (THC), or a derivative thereof, represented by the compound of formula (A)
- R 1 -R 30 are each independently H or D.
- the invention provides a deuterated compound of (6aR,10aR)-delta-9- tetrahydrocannabinol (THC) represented by the compound of formula (I) wherein R 1 -R 14 are each independently H or D; and R 15 is D or OH; provided that when R 3 is H, R 15 is OH.
- THC deuterated compound of (6aR,10aR)-delta-9- tetrahydrocannabinol
- the invention provides a deuterated compound of delta-9- tetrahydrocannabivarin (THCV) represented by the compound of formula (B)
- R 1 -R 9 and R 16 -R 31 are each independently H or D; and R 15 is D or OH.
- the invention provides a deuterated compound of delta-9- tetrahydrocannabivarin (THCV) represented by the compound of formula (II): wherein
- R 1 -R 9 and R 31 are each independently H or D; and R 15 iS D or OH.
- the invention provides a deuterated compound of cannabigerol (CBG), or a derivative thereof, represented by a compound of formula (AA) wherein R 1 -R 32 are each independently H or D, provided that at least one of R 1 -R 17 is D.
- the invention provides a deuterated compound of cannabigerol (CBG) represented by a compound of formula (Al) wherein R 1 -R 20 are each independently H or D, provided that at least one of R 1 to R 17 is D.
- CBG cannabigerol
- the invention provides a deuterated compound of cannabi chromene (CBC), or a derivative thereof, represented by a compound of formula (AAA)
- R 1 -R30 are each independently H or D, provided that at least one of R 1 -R 25 is D.
- the invention provides a deuterated compound of cannabichromene
- (CBC) represented by a compound of formula (AA1) wherein R 1 -R2.5 are each independently H or D, provided that at least one of R 1 -R2.5 is D.
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection
- the present invention provides a method of treating or preventing seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is an animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- a disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag,
- the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising adminis tering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome- related disorders.
- a disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome- related disorders
- the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the pain or inflammation is associated with osteoarthritis.
- the pain or inflammation is a postoperative pain or postoperative inflammation.
- the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures.
- the subject is a dog.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
- the subject is a dog.
- the present invention provides a method of heating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
- the subject is a cat.
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) and at least one additional therapeutic agent,
- R 1 -R30 are each independently H or D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary' insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) and at least one additional therapeutic agent.
- R 1 -R9 and R16-R 31 are each independently H or D; and R 15 is D or OH.
- said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders
- R 1 -R 9 and R 31 are each independently H or D; and R 15 is D or OH.
- the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an anti-emetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti-dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an anti-osteoporosis agent, or a cardiovascular agent.
- an analgesic agent an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent,
- the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent, wherein R 1 -R32 are each independently H or D, provided that at least one of R 1 -R 17 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith
- said additional therapeutic agent is an analgesic agent, an antianxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, antiepileptics, an anti-inflammatory agent, an anti -depressant agent, an anti-emetic agent, an anti- ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodeeenerative diseases or disorders, an anti-dvskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an anti-osteoporosis agent, or a cardiovascular agent.
- an analgesic agent an antianxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, antiepileptics, an anti-inflammatory agent, an anti -depressant
- the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent tor treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent,
- R 1 -Rso are each independently H or D, provided that at least one of R 1 -R 25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia,
- the compound of formula (AAA) is represented by a compound of formula (AAI) OH
- R 1 -R 25 are each independently H or D, provided that at least one of R 1 -R 25 is D.
- the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti -depressant agent, an antiemetic agent, an anti -ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
- an analgesic agent an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti -depressant agent, an
- the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent tor treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
- the present invention relates to deuterated cannabinoid compounds.
- the present invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds.
- the deuterated compounds of the invention maintain the beneficial aspects of the corresponding non-isotopically enriched compounds while substantially increasing the maximum tolerated dose, decreasing toxicity, increasing the half-life (T1/2.), lowering the maximum plasma concentration (Cmax) of the therapeutically efficacious dose or the minimum efficacious dose (MED), lowering the efficacious dose, prevent or slow metabolism, and improving oral bioavailability and bioavailability following other routes of administration.
- the invention provides a deuterated compound of (6aR,10a/?)-delta-9 ⁇ Tetrahydrocannabinol (THC), or a derivative thereof, represented by a compound of formula (A): wherein R 1 -R30 are each independently H or D.
- R 15 is D or OH.
- R 15 is OH.
- Ri 5 is D or OH; provided that when R? is H, R 15 is OH.
- Ri and R2 are D,
- R 3 is D.
- R4 and Rs are D.
- R4-R14 are D.
- Rs -R14 are D.
- the invention provides a deuterated compound of (6aA’,10aR)-delta-9- Tetrahydrocannabinol (THC) represented by a compound of formula (I): wherein R 1 -R14 are each independently H or D; and R 15 is D or OH: provided that when R3 is H, R 15 is OH.
- THC Tetrahydrocannabinol
- Ri and R? are D.
- R 3 is D.
- Ri and Rs are D.
- R4-R14 are D. In some embodiments, Re -R14 are D.
- the compound of formula (I) is represented by compound 1-4, 1-6,
- the compound of formula (I) or the compound of formula (A) is represented by any one of the following compounds:
- the invention provides a deuterated compound of delta-9- tetrahydroeannabivarm (THCV) represented by a compound of formula (B):
- R 1 -R9 and Rie-Rsi are each independently H or D; and R 15 is D or OH.
- R 15 is D. In some embodiments, R 15 is OH. In some embodiments, R 3 is D. In some embodiments, Ri and R2 are D. In some embodiments, R4 and R5 are D. In some embodiments, R4- Rs and Rsi are D. In some embodiments, R and R2 are D; and R 15 is D. In some embodiments, R4 and Rs are D; and R 15 is D. In some embodiments, R+- R9 are D; and R 15 is D.
- the invention provides a deuterated compound of delta-9- tetrahydroeannabivarm (THCV) represented by a compound of formula (II):
- R 1 -R9 and R 31 are each independently H or D; and R 15 IS D or OH.
- R 15 is D. In some embodiments, R 15 is OH. In some embodiments, R3 is D. In some embodiments, Ri and R2 are D. In some embodiments, R4 and R5 are D. In some embodiments, Ra- Rs and R 3 i are D. In some embodiments, R and R2 are D; and R 15 is D. In some embodiments, R4 and Rs are D; and R 15 is D. In some embodiments, R4- R9 are D; and R 15 is D.
- the compound of formula (II) is represented by compound II-4, II-
- the compound of formula (B) or the compound of formula (II) is represented by any one of the following compounds:
- the invention provides a deuterated compound of cannabigerol (CBG), or a derivative thereof, represented by the compound of formula (AA) wherein R 1 -R32 are each independently H or D, provided that at least one of R.-R 17 is D.
- CBG cannabigerol
- R.-Rs are D.
- R 1 -Rs, R13, and R14 are D.
- R 1 -R 17 are D.
- R? and Rg are D.
- R9-R 17 are D.
- the invention provides a deuterated compound of cannabigerol (CBG) represented by the compound of formula (Al) wherein R 1 -Rzo are each independently H or D, provided that at least one of R 1 -Rn is D.
- CBG deuterated compound of cannabigerol
- Rt-Rs are D.
- R 1 -Ro, RB, and RM are D.
- R 1 -R 17 are D.
- R? and Rs are D.
- R9-R1 ? are D.
- the compound of formula (Al) is represented by compound A8, A13, Al 8, A19, A20, or A21 :
- the compound of formula (Al) or the compound of formula (AA) is represented by any one of the following compounds:
- the invention provides a deuterated compound of cannabichromene (CBC), or a derivative thereof, represented by a compound of formula (AAA)
- R 1 -R30 are each independently H or D, provided that at least one of R 1 -R 25 is D.
- R 1 -R13 are D.
- R 8 -Ru are D.
- Rs ⁇ Ri3, R20, and R21 are D.
- Rg-R?,4 are D.
- R 25 is D.
- the invention provides a deuterated compound of cannabichromene
- R 1 -R 25 are each independently H or D, provided that at least one of R 1 -R 25 is D.
- R 1 -Ri 3 are D.
- Rs ⁇ Ri3 are D.
- RS-RB, R20, and R21 are D.
- R 8 -R?4 are D.
- R2.5 is D.
- the compound of formula (AAI) is represented by compound AA7,
- the compound of formula (AAI) or the compound of formula (AAA) is represented by any one of the following compounds:
- the compound of the invention as described herein is deuterium- enriched at every position represented D.
- deuterium enrichment at any position represented as D in the compound of formula (II) or in the compound of formula (B) is at least about 1%; at least about 5%; at least about 10%; at least about 15%; at least about 20%; at least about 25%; at least about 30%; at least about 35%; at least about 40%; at least about 45%; at least about 50%; at least about 55%; at least about 60%; at least about 65%; at least about 70%; at least about 75%; at least about 80%; at least about 85%; at least about 90%; at least about 95%; at least about 98%; at least about 99%; or at least about 100%.
- deuterium enrichment at any position represented as D in the compound of the invention is from about 1% to about 100%; from about 1% to about 98%; from about 1% to about 90%; from about 1% to about 75%; from about 1% to about 50%; from about 1% to about 25%; from about 1% to about 20%; from about 1% to about 10%; from about 1% to about 5%; from about 5% to about 100%; from about 5% to about 99%; from about 5% to about 98%; from about 5% to about 90%; from about 5% to about 75%; from about 5% to about 50%; from about 5% to about 25%; from about 5% to about 20%; from about 5% to about 10%; from about 10% to about 100%; from about 10% to about 99%; from about 10% to about 98%; from about 10% to about 90%; from about 10% to about 75%; from about 10% to about 50%; from about 10% to about 25%; from about 10% to about 20%; from about 20% to about 99%; from about 10% to about 98%; from about 10% to about 90%; from about 10% to
- the positions that are specifically deuterated as shown in the compounds of the invention as described herein are deuterium- enriched at about the same percentage. In other embodiments, the positions that are specifically deuterated as shown in the compounds of the invention as described herein are differentially deuterium enriched.
- the overall deuterium enrichment of the compounds of the invention as described herein is no less than 1%; no less than 5%; no less than 10%; no less than 15%; no less than 20%; no less than 25%; no less than 30%; no less than 35%; no less than 40%; no less than 45%; no less than 50%; no less than 55%; no less than 60%; no less than 65%; no less than 70%; no less than 75%; no less than 80%; no less than 85%; no less than 90%; no less than 95%; no less than 98%; no less than 99%; or no less than 100 %.
- Overall deuterium enrichment of the compounds of the invention can be determined using mass spectroscopy, according to methods known in the art.
- delta-9-tetrahydrocannabivarin is a homologue of (6a/?,10a/?)-delta-9-tetrahydrocannabinol (THC) having a propyl (3-carbon) side chain instead of a pentyl (5-carbon) group on the molecule.
- the present invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound the invention as described herein and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (A) of the invention as described herein and a pharmaceutically acceptable earner.
- the invention provides a pharmaceutical composition comprising a compound of formula (B) of the invention as described herein and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a mixture of a compound of formula (A) and a compound of formula (B) and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (I) of the invention as described herein and a pharmaceutically acceptable earner.
- the invention provides a pharmaceutical composition comprising a compound of formula (II) of the invention as described herein and a pharmaceutically acceptable carrier. In certain embodiments, the invention provides a pharmaceutical composition comprising a mixture of a compound of formula (I) and a compound of formula (II) and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (AA) of the invention and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (Al) of the invention and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (AAA) of the invention as described herein and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula (A Al) of the invention as described herein and a pharmaceutically acceptable carrier.
- pharmaceutical composition refers to a therapeutically effective amount of a compound of the present invention, together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or earners.
- compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g.; Tris-HCL, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzy l alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid
- compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance.
- Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
- a "therapeutically effective amount” as used herein refers to that amount which provides a therapeutic effect for a given indication and administration regimen.
- the mode of administration and dosage form are closely related to the therapeutic amounts of the compounds or compositions which are desirable and efficacious for the given treatment application.
- compositions of the invention can be administered to a subject by any method known to a person skilled in the art. These methods include, but are not limited to, orally, parenterally, intravascularly, paracancerally, transmucosally, transderm ally, intramuscularly, intranasally, intravenously, intradermally, subcutaneously, sublingually, intraperitoneally, intra ventricularly, intracranially, intravaginally, by inhalation, rectally, or intratumorally. These methods include any means in which the composition can be delivered to tissue (e.g., needle or catheter). Alternatively, a topical administration may be desired for application to dermal, ocular, or mucosal surfaces.
- compositions may be administered topically to body surfaces and are thus formulated in a form suitable for topical administration.
- suitable topical formulations include gels, ointments, creams, lotions, drops and the like.
- the compositions are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical earner.
- Suitable dosage forms include, but are not limited to, oral, rectal, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdennal, spinal, intrathecal, intraarticular, intra-arterial, sub-arachinoid, bronchial, lymphatic, and intra-uterile administration, and other dosage forms for systemic delivery of active ingredients.
- the formulations are suitable for oral or topical administration.
- pharmaceutically acceptable carriers or diluents are well known to those skilled in the art.
- the carrier or diluent may be a solid earner or diluent for solid formulations, a liquid carrier or diluent for liquid formulations, or mixtures thereof.
- Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
- a starch e.g. corn starch, pregeletanized starch
- a sugar e.g., lactose, mannitol, sucrose, dextrose
- a cellulosic material e.g. microcrystalline cellulose
- an acrylate e.g. polymethylacrylate
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like.
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like. Due to their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form. If desired, tablets may be sugar coated or enteric coated by standard techniques.
- the carrier will usually comprise sterile water, though other ingredients may be included, such as ingredients that aid solubility or for preservation. Injectable solutions may also be prepared in which case appropriate stabilizing agents may be employed.
- the active agent in a "vectorized" form, such as by encapsulation of the active agent in a liposome or other encapsulant medium, or by fixation of the active agent, e.g., by covalent bonding, chelation, or associative coordination, on a suitable biomolecule, such as those selected from proteins, lipoproteins, glycoproteins, and polysaccharides.
- Methods of treatment using formulations suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, orally disintegrating tablets or films, or lozenges, each containing a predetermined amount of the active ingredient.
- a suspension in an aqueous liquor or a non-aqueous liquid may be employed, such as a syrup, an elixir, an emulsion, or a draught.
- a tablet may be made by compression or molding, or wet granulation, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which optionally is mixed with, for example, a binder, disintegrant, lubricant, inert diluent, surface active agent, or discharging agent.
- Molded tablets comprised of a mixture of the powdered active compound with a suitable earner may be made by molding in a suitable machine.
- a syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient/ s).
- a sugar for example sucrose
- Such accessory ingredients may include flavorings, suitable preservative, agents to retard crystallization of the sugar, and agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.
- flavorings can be added to all dosage forms when needed, including, but not limited to, solid oral forms and liquid oral forms.
- Formulations suitable for parenteral administration may comprise a sterile aqueous preparation of the active compound, which in some embodiments is isotonic with the blood of the recipient (e.g., physiological saline solution).
- Such formulations may include suspending agents and thickening agents and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- the formulations may be presented in unit-dose or multi-dose form.
- Parenteral administration may comprise any suitable form of systemic delivery.
- Administration may for example be intravenous, intra-arterial, intrathecal, intramuscular, subcutaneous, intramuscular, intra-abdominal (e.g., intraperitoneal), etc., and may be affected by infusion pumps (external or implantable) or any other suitable means appropriate to the desired admini stration modality.
- Nasal and other mucosal spray formulations can comprise purified aqueous solutions of the active compounds with preservative agents and isotonic agents. Such formulations are in some embodiments adjusted to a pH and isotonic state compatible with the nasal or other mucous membranes. Alternatively, they can be in the form of finely divided solid powders suspended in a gas carrier. Such formulations may be delivered by any suitable means or method, e.g., by nebulizer, atomizer, metered dose inhaler, or the like.
- Transdermal formulations may be prepared by incorporating the active agent in a thixotropic or gelatinous carrier such as a cellulosic medium, e.g., methyl cellulose or hydroxyethyl cellulose, with the resulting formulation then being packed in a transdermal device adapted to be secured in dermal contact with the skin of a wearer.
- a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acids.
- Transdermal formulations may be prepared by incorporating the active agent in a thixotropic or gelatinous carrier such as a cellulosic medium, e.g., methyl cellulose or hydroxyethyl cellulose, with the resulting formulation then being packed in a transdermal device adapted to be secured in dermal contact with the skin of a wearer.
- compositions of this invention may farther include one or more ingredient selected from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
- formulations may be of immediate release, sustained release, delayed-onset release or any other release profile known to one skilled in the art.
- the methods of the invention comprise administration of a compound at a therapeutically effective amount.
- the therapeutically effective amount may include various dosages.
- a dosage unit of the compounds used in the present invention may comprise a single compound or mixtures thereof with additional therapeutic agents.
- a "‘dose'’ or “‘dosage unit” or “unit dosage” of a compound of the in vention as measured in milligrams refers to the milligrams of the compound of the invention, present in a preparation, regardless of the form of the preparation.
- a dosage unit may comprise a single compound or mixtures of compounds thereof.
- a compound of the invention as described herein is administered at a dosage of 0.01-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.025-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.05-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.075-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01 -0.075 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01-0.05 mg per day.
- a compound of the invention as described herein is administered at a dosage of 0.01- 0.025 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.025-0.05 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.05-0.075 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1- 3000 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1-1000 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1-500 mg per day.
- a compound of the invention as described herein is administered at a dosage of 10- 500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 50-500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 5- 250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 10-250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 20-250 mg per day.
- a compound of the invention as described herein is administered at a dosage of 25- 250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-200 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-150 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25- 125 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-100 mg per day.
- a compound of the invention as described herein is administered at a dose of 1-10 mg per day, 3-26 mg per day, 3-60 mg per day, 3-16 mg per day, 3-30 mg per day, 10-26 mg per day, 10-100 mg per day, 15-60 mg per day, 15-100 mg per day, 25-100 mg per day, 50-100 mg per day, 50-200 mg per day, 100-200 mg per day, 100-250 mg per day, 125-300 mg per day, 20-50 mg per day, 5-50 mg per day, 200-500 mg per day, 125-500 mg per day, 500- 1000 mg per day, 200-1000 mg per day, 1000-2000 mg per day, 1000-3000 mg per day, 125-3000 mg per day, 2000-3000 mg per day, 300-1500 mg per day or 100-1000 mg per day.
- a compound of the invention as described herein is administered at a dosage of 25 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 40 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 50 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 67.5 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 75 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 80 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 100 mg per day.
- a compound of the invention as described herein is administered at a dosage of 125 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 250 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 300 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 500 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 600 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 1000 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 1500 mg per day.
- a compound of the invention as described herein is administered at a dosage of 2000 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 2500 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 3000 mg per day.
- the methods may comprise administering a compound at various dosages.
- the compound may be administered at a dosage of 3 mg, 10 mg, 30 mg, 40 mg, 50 mg, 80 mg, 100 mg, 120 mg, 125 mg, 200 mg, 250 nig, 300 mg, 450 mg, 500 mg, 600 mg, 900 mg, 1000 mg, 1500 mg, 2000 mg, 2500 mg or 3000 mg.
- the compound may be administered at a dosage of 0.1 mg/kg/day.
- the compound may be administered at a dosage between 0.2 to 30 mg/kg/day, or 0.2 mg/kg/day, 0.3 mg/kg/day, 1 mg/kg/day, 3 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, 50 mg/kg/day or 100 mg/kg/day.
- a dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, liquid suspensions, and granules.
- the pharmaceutical composition of the invention comprises from about 0.01 mg to about 250 mg compound of the invention as described herein. In some embodiments, the pharmaceutical composition of the invention comprises from about 0.05 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 0. 1 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 0.5 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 1.0 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 5 mg to about 250 mg compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 0.1 mg of compound of the invention.
- the pharmaceutical composition of the invention comprises about 0,5 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 1.0 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 5.0 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 10 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 25 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 50 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 75 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 100 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 150 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 200 mg of compound of the invention.
- the invention further provides a pharmaceutical composition comprising a compound of formula (1) or formula (II) for use in the treatment or prevention of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection
- the invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is an animal.
- the invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (IT) for use in the treatment or prevention of a disease or disorder selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm -related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelnian syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- a disease or disorder selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm -related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the pain is chronic pain. In some embodiments, the pain is acute pain.
- the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis.
- the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis.
- the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti-convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory agent. In some embodiments, the compound of the invention is an anti-depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some embodiments, the compound of the invention is an anti-ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent.
- the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an ocular hypotensive agent. In some embodiments, the compound of the invention is an immunosuppressive agent.
- the invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer,
- the invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any’ combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any’ combination thereof.
- the invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of aggression, fear, phobias, generalized anxiety- disorder, or separation anxiety’ in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is an animal.
- the present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep -wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of a disease or disorder in
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary’ insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (Al) tor use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically' effective amount of a compound of the invention as described herein.
- the pain is chronic pain.
- the present invention provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of multiple sclerosis ill a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (AT) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- AT formula
- the present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis.
- the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, tor example, Parkinson's disease, Huntington's disease, and/or Alzheimer’s disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis.
- the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti -convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory’ agent. In some embodiments, the compound of the invention is an anti- depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some embodiments, the compound of the invention is an anti-ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent. In some embodiments, the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an immunosuppressi ve agent.
- the invention further provides a pharmaceutical composition comprising a compound of formula (AAA) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- AAA formula
- the invention further provides a pharmaceutical composition comprising a compound of formula (AAA) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- AAA formula
- the invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- AAI formula
- the invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is an animal.
- the invention further provides a pharmaceutical composition comprising a compound of formula ( AAI) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- AAI formula
- the present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety’ disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- AAI a compound of formula
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety' disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the pain is chronic pain.
- the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of multiple sclerosis in a subject in need thereof) comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis.
- the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson’s disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis.
- the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti-convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory agent. In some embodiments, the compound of the invention is an anti-depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some embodiments, the compound of the invention is an anti -ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent. In some embodiments, the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an immunosuppressive agent.
- the pharmaceutical composition of the invention is in the form of a capsule, a tablet, or a liquid suspension. In other embodiments, the pharmaceutical composition of the invention is in an oral dosage unit form.
- composition will necessarily be dependent upon the therapeutic or nutritional effect to be achieved and may vary with the particular formula, the route of administration, and the age and condition of the individual subject to whom the composition is to be administered.
- a pharmaceutical composition is prepared for once daily administration. In another embodiment, a pharmaceutical composition is prepared for more than once daily administration, for example, twice daily, three times daily, four times daily, etc.
- the compounds of the invention as described herein, or pharmaceutical compositions containing either or both can provide an increased half-life in a mammal over the corresponding non-deuterated compound e.g., tetrahydrocannabinol or tetrahydrocannabivarin, as measured using an in vitro liver microsomal assay.
- a mammal e.g., tetrahydrocannabinol or tetrahydrocannabivarin
- the concentration of the compound of the invention as d escribed herein, in the pharmaceutical compositions of the present invention is about 100%, 90%, 80%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 22.5%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 1 1%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01 %, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 19%, 18%, 17%,
- concentration of the compound of the invention in the pharmaceutical compositions described herein can also be expressed as range defined by any two of the concentrations as described here. It should be further appreciated that the concentration percentages as described herein can be on a weigh (/weight, weighVvolume, or a volume/volume basis.
- the amount of the compound of the invention as described herein in the pharmaceutical compositions of the present invention is about 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 nig, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, 100 mg, 090 mg, 80 mg, 70 mg, 60 mg, 50 mg, 40 mg, 30 mg, 20 mg, 10 mg, 9 mg, 8 mg, 7 mg, 6 mg, 5 mg, 4 mg, 3 mg, 2 mg, 1 mg, 0.9 mg, 0.8 mg, 0,7 mg, 0.6 mg
- the administration of a compound of the invention provides one or more of the following: (1) a decrease in inter-individual variation in plasma levels of the compound or a metabolite thereof; (2) an increase in average plasma levels of the compound or a decrease in average plasma levels of at least one metabolite of the compound per dosage unit; (3) a decrease in the inhibition of, and/or metabolism by at least one cytochrome P450 or monoamine oxidase isoform in the subject; (4) a decrease in metabolism via at least one polymorphically- expressed cytochrome P450 isoform in the subject; (5) at least one statistically-significant improvement in disorder-control and/or disorder-eradication endpoint; (6) an improvement in clinical effect during the treatment of the disorder, (7) prevention of recurrence, or delay of decline or appearance, of abnormal alimentary' or hepatic parameters as the primary clinical benefit, or (8) reduction or elimination of deleterious changes in any adverse event, including diagnostic hepatobiliary function endpoints, as compared
- inter-individual variation in plasma levels of the compounds as disclosed herein, or metabolites thereof decreases; average plasma levels of the compound as disclosed herein increase; average plasma levels of a metabolite of the compound as disclosed herein decrease; inhibition of a cytochrome P450 or monoamine oxidase isoform by a compound as disclosed herein decrease; or metabolism of the compound as disclosed herein by at least one polymorphically-expressed cytochrome P450 isoform decrease; by greater than about 5%, greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, or by greater than about 50% as compared to the corresponding non-deuterated compound.
- the compound of the invention can provide about a 40% or greater increase in halflife in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 45% or greater increase in halt-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 70% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 75% or greater increase in half-life in a mammal over the corresponding non- deuterated compound.
- the percentage increase in half-life of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 40% and 75%; between 40% and 70%; between 40% and 45%; between 45% and 75%; between 45’% and 70%; or, between 70% and 75%.
- the compound of the invention can provide about a 30% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 35% or greater increase in halflife in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 100% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 105% or greater increase in half-life in a mammal over the corresponding non-deuterated compound.
- the percentage increase in halflife of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 30% and 105%: between 30% and 100%: between 30% and 35%; between 35% and 105%; between 35% and 100%.
- a pharmaceutical composition including the compound of the invention can provide about a 10% or greater increase in half- life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 20% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 30% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 40% or greater increase in half-life in a mammal over the corresponding non-deuterated compound.
- the pharmaceutical composition can provide about a 50% or greater increase half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 60% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 70% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about an 80% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 90% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 100% increase in half-life in a mammal over the corresponding non-deuterated compound.
- the percentage increase in half-life of a pharmaceutical composition including the compound of the invention over the corresponding non-deuterated compound is from about 10% to about 105%: from about 10% to about 100%; from about 10% to about 90%; from about 10% to about 80%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to about 105%; from about 20% to about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 70%; from about 20% to about 60%; from about 20% to about 50%; from about 20% to about 40%; from about 20% to about 30%; from about 30% to about 105%; from about 30% to about 100%; from about 30% to about 90%; from about 30% to about 80%; from about 30% to about 70%; from about 30% to about 60%; from about 30% to about 50%; from about 30% to about 40%; from about 40% to about 105%; from about 40% to about 100%; from about 40% to about 90%; from about 30% to about 80%;
- the disclosed percent increase in measured half-life in a mammal can also be expressed as a range including any of the previously described percent levels, in any combination, as well as including the specific percentages tailing within the ranges, such that increased half-life in a mammal can be expressed, in one embodiment, as a range of about 30% to about 40%, and it will be understood that such a described range includes percent values of 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, and 39%.
- the bioavailability of the compound of the invention is measured by AUC.
- the compound of the invention can provide about a 20% or greater increase in bioavailability over the corresponding non-deuterated compound.
- the compound of the invention can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound.
- the compound of the invention can provide about a 70% or greater increase in bioavailability over the corresponding non-deuterated compound.
- the compound of the invention can provide about a 80% or greater increase in bioavailability over the corresponding non- deuterated compound.
- the compound of the invention can provide about a 90% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 95% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 100% increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the percentage increase in bioavailability of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 100% between 40% and 100%; between 70% and 100%; between 40% and 45%; between 45% and 75%; between 45% and 70%; or, between 70% and 100%.
- the percentage increase in bioavailability of a pharmaceutical composition including the compound of the invention over the pharmaceutical composition comprising the corresponding non-deuterated compound is from about 0.01 % to about 10%, or from about 0.01% to about 7.5%, or from about 0.01% to about 5%, or from about 0.01% to about 2.5%, from about 0.05% to about 10%, from about 0.05% to about 5%, from about 0.5% to about 10%, from about 1 .0% to about 10%, from about 2.5% to about 10%, from about 5.0% to about 10%, from about 1.0% to about 7.5%, from about 1.0% to about 5.0%, from about 10% to about 100%; from about 10% to about 90%; from about 10% to about 80%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 70%; from about 20% to
- the bioavailability of the compound of the invention is measured by ( max.
- the compound of the invention can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of the invention can provide about a 50% or greater increase in bioavai lability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of the invention can provide about a 80% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of the invention can provide about a 100% or greater increase in bioavailability’ over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 125% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 150% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of the invention can provide about a 200% increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the percentage increase in bioavailability' of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 200% between 40% and 200%; between 70% and 200%; between 40% and 100%; between 45% and 125%; between 45% and 150%; or, between 70% and 200%, [00147]
- the bioavailability of the compound of the invention is measured by Crnax.
- the compound of formula (I) can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 50% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 80% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of formula (I) can provide about a 100% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 125% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 150% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the compound of formula (I) can provide about a 200% increase in bioavailability' over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol.
- the percentage increase in bioavailability of the compound of formula (I) over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 200% between 40% and 200%; between 70% and 200%; between 40% and 100%; between 45% and 125%; between 45% and 150%; or, between 70% and 200%.
- the percentage increase in bioavailability of a pharmaceutical composition including the compound of the invention over the pharmaceutical composition comprising the corresponding non-deuterated compound is from about 0.01% to about 10%, or from about 0.01% to about 7.5%, or from about 0.01% to about 5%, or from about 0.01% to about 2.5%, from about 0.05% to about 10%, from about 0.05% to about 5%, from about 0.5% to about 10%, from about 1.0% to about 10%, from about 2.5% to about 10%, from about 5.0% to about 10%, from about 1.0% to about 7.5%, from about 1.0% to about 5.0%, from about 10% to about 200%; from about 10% to about 150%; from about 10% to about 100%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to about 200%; from about 20% to about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 20% to about
- Plasma levels of the compound of the invention as described herein, or metabolites thereof may be measured using the methods described by Li et al. Rapid Communications in Mass Spectrometry 2005, 19, 1943-1950; De Francia et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(18+19), 1721-1726; Parise et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(20+21), 1894-1900; Pursche et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2007, 852(1-2), 208-216; Haouala et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(22), 1982-1996; and any references cited therein and any modifications made thereof.
- Examples of cytochrome P450 isofonns in a mammalian subject include, but are not limited to, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S 1, CYP3A4, CYP3A5, CYP3A5P1 , CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F1 1, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1 , CYP7B1, CYP8A1, CYP5A
- Examples of monoamine oxidase isofonns in a mammalian subject include, but are not limited to, MAO A, and MAOB.
- the inhibition of the cytochrome P450 isoform is measured by the method of Ko et al, British Journal of Clinical Pharmacology 2000, 49, 343-351.
- the inhibition of the MAOA isofonn is measured by the method of Weyler eZ al, J. Biol Chem. 1985, 260, 13199-13207.
- the inhibition of the MAOB isoform is measured by the method of Uebelhack et al, Pharmacopsychiatry 1998, 31, 187-192.
- Examples of polymorphically-expressed cytochrome P450 isoforms in a mammalian subject include, but are not limited to, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
- liver microsomes cytochrome P450 isoforms
- monoamine oxidase isoforms are measured by the methods described herein.
- improved disorder-control and/or disorder-eradication endpoints include, but are not limited to, major cytogenetic response, complete cytogenetic response, complete hematologic response, complete molecular remission, improved progression-free survival, increase in overall survival rate, tumor shrinkage, increased median overall survival time, improved overall response rate, and improved disease control rate.
- ALT alanine aminotransferase
- SGPT serum glutamic-pyruvic transaminase
- AST aspartate aminotransferase
- ALTZAST ratios serum aldolase, alkaline phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl transpeptidase ("GGTP,” “y-GTP,” or “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5 '-nucleotidase, and blood protein.
- Hepatobiliary endpoints are compared to the stated normal levels as given in "Diagnostic and Laboratory Test Reference", 4 th edition, Mosby, 1999.
- the present invention provides methods for treating cancer in a subject.
- the subject is a mammal.
- the subject is a human. These methods can be achieved by administering to the subject a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.
- the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung tumors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma.
- the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+- ( ML).
- the present invention provides methods for treating a neurodegenerative disease or disorder in a subject.
- the subject is a mammal.
- the subject is an animal.
- the subject is a human. These methods include administering to the mammal a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.
- the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, or progressive muscular atrophy.
- AD Alzheimer's disease
- PD Parkinson's disease
- PD-related disorders prion disease
- SCA spinocerebellar ataxia
- SMA spinal muscular atrophy
- ALS amyotrophic lateral sclerosis
- progressive bulbar palsy primary lateral sclerosis
- primary lateral sclerosis multiple sclerosis
- tardive or progressive muscular atrophy.
- the described methods of treatment can additionally include administering to the subject one or more additional therapeutic agents.
- additional therapeutic agents may be administered, by a route and in an amoun t commonly used therefore, simultaneously or sequentially with a compound or composition of the present invention.
- the compounds disclosed herein can be combined with one or more alkylating agents, antimetabolite agents, mitotic inhibitors, tyrosine kinase inhibitors, topoisomerase inhibitors, cancer immunotherapy monoclonal antibodies, anti-tumor agents, and anti-cancer agents.
- the compounds of the invention as described herein can be combined with one or more alkydating agents, including, but not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
- alkydating agents including, but not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA
- the compounds of the invention as described herein can be combined with one or more anti -metabolite agents, including, but not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafor, camiofur, capecitabine and gemcitabine.
- anti -metabolite agents including, but not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafor, camiofur, capecitabine and gemcitabine.
- the compounds of the invention as described herein can be combined with one or more mitotic inhibitors, including, but not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
- mitotic inhibitors including, but not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
- the compounds of the invention as described herein can be combined with one or more tyrosine kinase inhibitors, including, but not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
- the compounds of the invention as described herein can be combined with one or more topoisomerase inhibitors, including, but not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan,
- the compounds of the invention as described herein can be combined with one or more cancer immunotherapy monoclonal antibodies, including, but not limited to, rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, and trastuzumab.
- cancer immunotherapy monoclonal antibodies including, but not limited to, rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, and trastuzumab.
- the compounds of the invention as described herein can be combined with one or more anti-tumor agents, including, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
- anti-tumor agents including, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
- the compounds disclosed herein can be combined with one or more anti-cancer agents, including, but not limited to, amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
- anti-cancer agents including, but not limited to, amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, t
- norepinephrine reuptake inhibitors such as atomoxetine
- dopamine reuptake inhibitors D A R Is
- D A R Is dopamine reuptake inhibitors
- SNRIs serotonin-norepinephrine reuptake inhibitors
- NDRIs norepinephrine-dopamine reuptake inhibitor
- SNDRls serotoninmorepinephrine-dopamine-reuptake-inhibit.ors
- SNDRls such as venlafaxine
- monoamine oxidase inhibitors such as selegiline
- ECE endothelin converting enzyme
- opioids such as tramado
- squalene synthetase inhibitors include fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tric
- metformin glucosidase inhibitors
- acarbose glucosidase inhibitors
- insulins meglitinides (e.g., repaglinide)
- meglitinides e.g., repaglinide
- sulfonylureas e.g., glimepiride, glyburide, and glipizide
- thiozolidinediones e.g.
- troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; farnesyl-protein transferase inhibitors; hormonal agents, such as glucocor
- the present invention provides a method of treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is a mammal.
- the present invention provides a method of treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, 11-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, 11-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (I), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation,
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety’, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (II), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation,
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a combination of the compound of formula (I) and the compound of formula (II), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity', Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, U-4, II-6, 11-7, 11-14, 11-15, or 11-16, wherein said disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety' disorder, or separation anxiety' in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, U-4, II
- the subject is an animal. In some embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a horse. In some embodiments, the subject is a dog. In some embodiments, the subject is a cat. In some embodiments, the subject is a ferret.
- the present invention provides a method of treating or preventing a subject suffering from a disease or disorder selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity', type 2 diabetes, and testosterone insufficiency, wherein said method comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1- 14, 1-20, 1- 24, 1
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity’ disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- a compound of formula (A) or (B), formula (I) or (II) or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
- a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
- the pain is chronic pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
- a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
- disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis.
- the disease or disorder is musculoskeletal disorders.
- the disease or disorder is anorexia.
- the disease or disorder is emesis.
- the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity.
- the disease or disorder is a metabolic syndrome-related disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, II-4, IT-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is a non-human animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the pain or inflammation is associated with osteoarthritis.
- the pain or inflammation is a postoperative pain or postoperative inflammation.
- the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the postoperative inflammation is associated with orthopedic surgeiy, soft-tissue surgery, or dental surgery.
- the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, IT-6, II-7, 11-14, II- 15, or II- 16, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is a non-human animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, IT-6, TI-7, 11-14, 11-15, or IT-16, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is a non-human animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient.
- the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is a non-human animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, , e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, II-4, II-6, IT-7, 11-14, 11-15, or 11-16, or any combination thereof, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
- the subject is a dog.
- the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the causes of anorexia include, but are not limited to, secondary to chemo, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, and iatrogenic problems. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the aggression is dominance aggression, tear aggression, intraspecific aggression, or territorial aggression.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, , e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any combination thereof wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
- the subject is a cat.
- the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourete's syndrome, or emesis, or any combination thereof.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and Al H-A22, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and Al H-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegen erative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, or Rett syndrome.
- the invention further provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of fomulauAJd; wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal
- the disease or disorder is anxiety, infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety' disorder, seasonal affective disorder, attention deficit hyperactivity' disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary' insomnia circadian rhythm -related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity’ disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. hi some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- the pain is chronic pain.
- the pain is acute pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds 8, 13, and 18-22, or any combination thereof.
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A 13, and A18-A22, or any combination thereof.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering io said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22,
- the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. Tn some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. Tn some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma.
- the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. Tn some embodiments, the disease or disorder is cancer. Tn some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the subject in the method of the invention is a mammal. Tn other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and Al 8-A22, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and Al 8-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, AI3, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, AI3, and A18-A22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog. In other
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds 8, 13, and 18-22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds 8, 13, and 18-22, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula OVA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula OVA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures.
- a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof wherein said disease or disorder is anorexia,
- the subject is a dog.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia.
- the anorexia is a primary anorexia.
- the anorexia is a secondary anorexia, e.g., secondary to chemo.
- the anxiety is separation anxiety or generalized anxiety.
- the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
- the subject is a cat.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia.
- the anorexia is a primary anorexia.
- the anorexia is a secondary' anorexia, e.g., secondary’ to chemo.
- the anorexia is associated with chronic renal insufficiency.
- the method of the invention further comprises the administration of an additional therapeutic agent.
- the additional therapeutic agent is antiemetics or analgesics.
- the analgesic is carprofen, meloxicam, carbamazepine, gabapentin, pregabalin, acetaminophen, acetylsalicyclic acid, ibuprofen, or naproxen.
- the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, and palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, or Rett syndrome.
- the invention further provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (AAI), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- AAI Alzheimer's disease
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, wherein said disease or disorder is aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
- the subject is an animal.
- the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a horse. In some embodiments, the subject is a dog. In some embodiments, the subject is a cat. In some embodiments, the subject is a ferret.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity,
- a compound of the invention as
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary' insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivitydisorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g. , a compound of formula (AAI), or a compound of formula (AAA), or any one of compound A.A7, A.A1 1, AA16, and A.A20-A.A24, or any combination thereof.
- a compound of the invention as described herein, e.g. , a compound of formula (AAI), or a compound of formula (AAA), or any one of compound A.A7, A.A1 1, AA16, and A.A20-A.A24, or any combination thereof.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AA 16, and AA20- AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AA 16, and AA20- AA24, or any combination thereof.
- the pain is chronic pain.
- the pain is acute pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity', and metabolic syndrome -related disorders.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound
- the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington’s disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma.
- the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AAI 6, and AA20-AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AAI 6, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperati ve pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery , soft-tissue surgery', or dental surgery 1 .
- the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1 , AA16, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferre
- the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1 , AA16, and AA20-AA24, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1, AA16, and AA20-AA24, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1, AA16, and AA20-AA24, or any combination thereof.
- the subject is a human.
- the subject is an animal.
- the subject is a dog.
- the subject is a horse or a cat.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures.
- a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11 , AA16, and AA20
- the subject is an animal. In some embodiments, the subject is a dog. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
- the subject is an animal.
- the subject is a cat.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
- the method of the invention further comprises the administration of an additional therapeutic agent.
- the additional therapeutic agent is antiemetics or analgesics.
- the analgesic is meloxicam, carprofen, carbamazepine, gabapentin, pregabalin, acetaminophen, acetylsalicyclic acid, ibuprofen, or naproxen.
- the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, and palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
- the method of the invention further comprises the administration of an additional therapeutic agent.
- the additional therapeutic agent is carprofen, meloxicam, fluoxetine hydrochloride, comipramine hydrochloride, or phenobarbital
- the present invention further provides a combination therapy.
- combination therapy means the administration of two or more therapeutic agents to treat a therapeutic disorder described in the present invention. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. Tn addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drag combination in treating the disorders described herein.
- the present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administering a compound of formula (A) or a compound of formula (B) in combination with the therapeutic agent.
- a combination therapy that includes a deuterated compound of formula (A) or formula (B) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect.
- the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (A) or formula (B).
- a combination of a deuterated tetrahydrocannabinol compound of formula (A) or a deuterated tetrahydrocannabivarm compound of formula (B) with at least one additional therapeutic agent as described herein may minimizing toxicity during treatments and result in a decrease in the onset of resistance development.
- the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) and at least one additional therapeutic agent,
- R 1 -R30 are each independently H or D
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia nervosa, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
- the disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency .
- the disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia.
- the disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
- the compound of formula (A) is a deuterated compound of (6aR, 10aR)-delta-9-Tetrahydrocannabinol (THC), or a derivative thereof,
- R 15 is D or OH. In some embodiments, when R3 is H, R 15 is OH. In some embodiments, R 15 is D or OH; provided that when Rs is H, R 15 is OH. In some embodiments, Ri and R2 are D. In some embodiments, Ri is D. In some embodiments, R4 and Rs are D. In some embodiments, R4-R14 are D. In some embodiments, Rs -Ri4 are D. [00243] In some embodiments, the compound of formula (A) is represented by a compound of formula (I): wherein
- Rj ⁇ Ri4 are each independently H or D;
- Ri 5 is D or OH; provided that when Rs is H, Ri s is OH.
- Ri and R2 are D.
- Rs is D.
- R4 and Rs are D.
- R4-Ri4 are D.
- Rs -RM are D.
- the compound of formula (A) or (I) is represented by compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26:
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) and at least one additional therapeutic agent.
- R 1 -R9 and R 15 -Rn are each independently H or D; and R 15 is D or OH,
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourete's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia nervosa, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
- the disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smifh-Magenis syndrome, major depressive disorder, primary' insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency .
- the disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia.
- the disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia, anxiety', epilepsy, osteoarthritis, or glaucoma.
- the compound of formula (B) is a deuterated compound of delta- 9-tetrahydrocannabivarin (THCV), or a derivative thereof.
- R 15 is D. In some embodiments, R 15 is OH. In some embodiments, Rs is D. In some embodiments, Ri and Re are D. In some embodiments, R4 and R5 are D. In some embodiments, R4- R9 and R 31 are D. In some embodiments, Ri and R2 are D; and R 15 is D. In some embodiments, R4 and Rs are D; and R 15 is D. In some embodiments, Rt- R9 are D; and R 15 is D. [00255] In some embodiments, the compound of formula (B) is represented by a compound of formula (II): wherein R 1 -R9 and Rs; are each independently H or D; and R 15 is D or OH.
- R 15 is D. In some embodiments, R 15 is OH. In some embodiments, R3 is D. In some embodiments, Ri and R2 are D.
- R4 and R5 are D. In some embodiments, R ⁇ - R9 and R 31 are D. In some embodiments, Ri and R? are D; and R 15 is D. In some embodiments, R4 and Rs are D; and R 15 is
- R+- R9 are D; and R 15 is D.
- the compound of formula (B) or (II) is represented by compound
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) or formula (B) and at least one additional therapeutic agent.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A) as described herein and at least an additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (A) is the compound of formula (I), or any one of compounds 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, and I- 26, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (B) as described herein and at least an additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (B) is the compound of formula (II), or compound 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non- human animal.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A) as described herein and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any' combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment andprevention of the disease or disorder.
- the compound of formula (A) is the compound of formula (I), or any' one of compounds 1-4, 1-6, 1- 7, 1-14, 1-20, 1-24, 1-25, and 1-26, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (B) as described herein and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any' combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (B) is the compound of formula (II), or compound IT-4, II-6, TI-7, IT-14, U-15, or 11-16, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A), or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1- 24, 1-25, 1-26, 11-4, II-6, TI-7, IT- 14, IT- 15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affect
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivitydisorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a nonhuman animal.
- the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, chemo-related nausea, vomiting, and anorexiain a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11- 7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent.
- the pain is chronic pain.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent.
- the pain is chronic pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (1), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, IT-6, II-7, IT-14, 11-15, or II- 16, or any compound as descried herein, and at least one additional therapeutic agent.
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (1), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1- 26, 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, II-6, IT-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
- the disease or disorder is anorexia.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia.
- the anorexia is a primary anorexia.
- the anorexia is a secondary anorexia, e.g., secondary to chemo.
- the causes of anorexia include, but are not limited to, secondary to chemo, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, and iatrogenic problems.
- the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the disease or disorder is a compulsive disorder. In some embodiments, the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
- the disease or disorder is anorexia. In some embodiments, the disease or disorder is anxiety. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is glaucoma.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In certain embodiments, the subject is a cat.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson’s disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is osteoarthritis.
- the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, I- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia.
- the disease or disorder is pain. In some embodiments, the pain is chronic pain. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is chemo-related nausea, vomiting, and anorexia.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non- human animal.
- the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, I- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used tor the treatment or prevention of pain or inflammation.
- the additional therapeutic agent is as described anywhere herein tor the treatment and prevention of pain or inflammation.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In other embodiments, the subject is a horse or a cat. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the ‘‘therapeutic agent” as used herein refers to an agent or a drug that is capable of providing a local or systemic biological, physiological, or therapeutic effect in the biological system to which it is applied.
- the “therapeutic agent” can be any agent or drug as known in the art or being currently developed.
- the terms “therapeutic agent” and “therapeutic drug” are used interchangeably.
- the “therapeutic agent” refers to the “additional therapeutic agent” as used herein.
- the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
- the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an analgesic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent.
- the disease or disorder is pain, e.g., acute pain or chronic pain.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an analgesic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent.
- the disease or disorder is pain, e.g., acute pain or chronic pain.
- the compound of formula (B) is the compound of (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent.
- the non-opioid analgesic agent is meloxicam, acetaminophen, aspirin, ibuprofen, carprofen, fenbuprofen, flubiproten, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin.
- the analgesic agent is naproxen sodium or magnesium.
- the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, or naproxen.
- the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol.
- the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride.
- the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppry.
- the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder.
- the disease or disorder is a neurodegenerative disease or disorder.
- the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy.
- the neurodegenerative disease or disorder is Parkinson’s disease, Alzheimer's disease, or Huntington's disease.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder.
- the disease or disorder is a neurodegenerative disease or disorder.
- the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy.
- the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease.
- the compound of formula (B) is the compound of formula (II), or compound II-4, IT-6, TI-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERMAXTM), ephenedrine sulfate (EPHEDRINETM), pemoline CYLERTTM), mazindol (SANOREXTM), d,l-a-methylphenethylamine (ADDERALLTM) methylphenydate (RITALINTM), pramipexole (MIRAPEXTM), modafinil (PROVIGILTM), or ropinirole (REQUIPTM).
- anthocyanins e.g., anthocyanin cyanidin-3-O-glucoside
- levodopa e.g., pergolide (PERMAXTM), ephenedrine sulfate (EPHEDRINETM), pemoline CYLERTTM), ma
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-dyskensia agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti- dyskensia agent.
- the disease or disorder is a movement disorder or Parkinson disease.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti -dyskensia agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti dyskensia agent.
- the disease or disorder is a movement disorder or Parkinson disease.
- the compound of formula (B) is the compound of formula (II), or compound 11-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the anti-dyskensia agent is selected from baclofen (LioresalTM), botulinum toxin (BotoxTM), clonazepam (KlonopinTM), and diazepam (ValiumTM).
- an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an immunosuppressive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent.
- the disease or disorder is an autoimmune disease.
- the autoimmune disease is lupus or rheumatoid arthritis.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an immunosuppressive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent.
- the disease or disorder is an autoimmune disease.
- the autoimmune disease is lupus or rheumatoid arthritis.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, prednisolone, methylprednisone, dexamethasone, heterologous anti-lymphocyte globulin, deoxyspergualin, or rapamycin.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-spasmodic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti- spasmodic agent.
- the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-spasmodic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antispasmodic agent.
- the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction.
- the compound of formula (B) is the compound of formula (II), or compound 11-4. 11-6. 11- 7. 11-14, 11-15, or 11-16, or any compounds as described herein.
- the anti-spasmodic agent is carbamatepine, oxcarbazepine, ferbocate, fiirboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinamide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-diabetic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent.
- the disease or disorder is diabetes.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, I- 20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-diabetic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent.
- the disease or disorder is diabetes.
- the compound of formula (B) is the compound of formula (II), or compound II-4, 11-6. II-7, 11-14, II- 15, or 11-16, or any compounds as described herein.
- the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glimepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is seizure, neuropathic pain, or epilepsy.
- the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is seizure, neuropathic pain, or epilepsy.
- the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- the compound of formula (B) is the compound of formula (II), or compound 11-4, II-6, II--7, 11-14, 11- 15, or 11-16, or any compounds as described herein.
- the anti-convulsant agent or anti-epileptic agent is phenobarbital, pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbamatepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, tibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin.
- the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide.
- the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide.
- the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-psychotic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antipsychotic agent.
- the disease or disorder is schizophrenia, psychosis, or bipolar disorder.
- the compound of formula (A) is the compound of formula
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-psychotic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antipsychotic agent.
- the disease or disorder is schizophrenia, psychosis, or bipolar disorder.
- the compound of formula (B) is the compound of formula
- the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an cholesterol/lipid lowering agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent.
- the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an cholesterol/lipid lowering agent.
- the disease or disorder is any? one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent.
- the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II- 7, II- 14, 11-15, or 11-16, or any compounds as described herein.
- the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenofibrate, benzafibrate, rosiglitazone, or ezetimibe.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-inflammatory agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent.
- the disease or disorder is an inflammatory disease.
- the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-inflammatory agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent.
- the disease or disorder is an inflammatory’ disease.
- the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, IT-7, 11- 14. 11-15, or 11-16, or any compounds as described herein.
- the anti-inflammatory agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, naproxen, ketoprofen, ceiecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, ciidanac, oxpinac, niefena
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-bacterial agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent.
- the disease or disorder is a bacterial infection.
- the disease or disorder is a skin or eye infection, tuberculosis, or a urinary tract infection.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-bacterial agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent.
- the disease or disorder is a bacterial infection.
- the disease or disorder is a skin or eye infection, tuberculosis, or a urinary' tract infection.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, IT-7, II- 14, II- 15, or 11-16, or any compounds as described herein.
- the anti-bacterial agent is selected from the group consisting of erythromycin, aji azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, Piperacillin, azlocillin, ternocillin, cepalothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefmetazole, ceftazidime cefotaxime, cefizoxirne, ceftriaxone, cefoperazone, ceftazi
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-emetic.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics.
- the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and'or chemotherapy directed against cancer.
- the compound of formula (A) is the compound of formula
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-emetic.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics.
- the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer.
- the compound of formula (B) is the compound of formula
- the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidoi, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-depressant.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant.
- the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, postraumatic stress disorder (PTSD), phobias, or social anxiety disorder.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or I- 26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-depressant.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant.
- the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, posttraumatic stress disorder (PTSD), or social anxiety disorder.
- the compound of formula (B) is the compound of formula (II), or compound II-4, IT-6, II-7, 11-14, 11-15, or IT-16, or any compounds as described herein.
- the anti-depressants is selected from the group consisting of adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, apelinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, eianopramine, cinioxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprin
- the anti-depressant agent is a selective serotonin reuptake inhibitor (SSRI). In some embodiments, the anti-depressant agent is fluoxetine.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-anxiety agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent.
- the disease or disorder is generalized anxiety disorder, social phobia, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-anxiety agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent.
- the disease or disorder is generalized anxiety disorder, social phobia, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, II- 15, or 11-16, or any compounds as described herein.
- the anti-anxiety agent is comipramine hydrochloride, fluoxetine hydrochloride, salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a sleeping agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent.
- the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and a sleeping agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent.
- the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder.
- the compound of formula (B) is the compound of formula (11), or compound 11-4, II-6, 11-7, 11-14, 11- 15, or 11-16, or any compounds as described herein.
- the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an orexigenic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent.
- the disease or disorder is anorexia .
- a compound of formula (A) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an orexigenic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent.
- the disease or disorder is anorexia.
- a compound of formula (A) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the orexigenic agent is megestrol or oxandrolone.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an ocular hypotensive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent.
- the disease or disorder is glaucoma.
- a compound of formula (A) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP).
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an ocular hypotensive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent.
- the disease or disorder is glaucoma.
- a compound of formula (A) as described herein and an ocular hypotensive agent can lower intraocular pressure (TOP).
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
- the present invention provides a method tor treating or preventing osteoporosis in a subject in need thereof, comprising administering io the subject a compound of formula (A) as described herein and an anti-osteoporosis agent.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1- 24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-osteoporosis agent.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, 11-7, 11-14, II- 15, or II- 16, or any compounds as described herein.
- the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, apeledoxifene, teriparatide, abaloparatide, and denosumab.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-migraine agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent.
- the disease or disorder is migraine headache or migraine pain.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-migraine agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent.
- the disease or disorder is migraine headache or migraine pain.
- the compound of formula (B) is the compound of formula (II), or compound 11-4, IT-6, II-7, 11-14, IT-15, or 11-16, or any compounds as described herein.
- the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a cardiovascular agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent.
- the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and a cardiovascular agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent.
- the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery’ disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the term “cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory’ system (blood vessels).
- the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, methykiofu, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine
- the present invention provides a method tor treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (A) as described herein and an anti-cancer agent.
- the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
- the present invention provides a method tor treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (B) as described herein and an anti-cancer agent.
- the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
- the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung minors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma.
- the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).
- the anti-cancer agent is a chemotherapeutic agent.
- the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
- the anti-cancer agent is a cytostatic drug.
- the cytostatic drag is busulfan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
- the anti-cancer agent is an alkylating agent.
- the alkylating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
- the anti-cancer agent is a cancer immunotherapy monoclonal antibody.
- the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
- the anti-cancer agent is an anti-tumor agent.
- the anti-tumor antibiotic agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
- the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
- the anti-cancer agent is an anti-metabolite agent.
- the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine, and gemcitabine.
- the anti-cancer agent is a mitotic inhibitor.
- the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
- the anti-cancer agent is a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
- the anti-cancer agent is a topoisomerase inhibitor.
- the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
- the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, anti atherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti -infective agents, antiviral agents, antibacterial agents, antiviral agents
- the additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atornoxetine; dopamine reuptake inhibitors (DARIs), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRIs), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such
- NRIs norepinephrine reuptake
- squalene synthetase inhibitors include fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tric
- metformin glucosidase inhibitors
- glucosidase inhibitors e.g., acarbose
- insulins meglitinides (e.g., repaglinide)
- meglitinides e.g., repaglinide
- sulfonylureas e.g., glimepiride, glyburide, and glipizide
- thiozolidinediones e.g.
- troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl-protein transferase inhibitors; hormonal agents, such as glucocor
- the present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administration a deuterated cannabigerol compound of formula (AA) in combination with the therapeutic agent.
- a combination therapy that includes a deuterated cannabigerol compound of formula (AA) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect.
- the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA).
- a combination of a deuterated cannabigerol compound of formula (AA) with at least one additional therapeutic agent as described herein may allow for an improved safety profile of the additional therapeutic agent during treatments and result in a decrease in the onset of resistance development.
- the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA) in the treatment.
- Such combination therapy may allow for at least the same efficacy as, or a higher efficacy than, the treatment using the therapeutic agent alone, with an improved safety profile of the therapeutic agent.
- the therapeutically effective amount of the therapeutic agent administered to the subject is the same as the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA) in the treatment.
- Such combination therapy may allow for an increased efficacy with the same safety' profile of the therapeutic agent.
- the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent, wherein R 1 -R32 are each independently H or D, provided that at least one of R.-R 17 is D, wherein said disease or disorder is seiected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder
- the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent,
- R 1 -R32 are each independently H or D, provided that at least one of R 1 -R 17 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, or any combination thereof; or wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work
- the compound of formula (AA) is a deuterated compound of cannabigerol (CBG), or a derivative thereof.
- R 1 -Re are D.
- R 1 -Ro, RB, and RM are D.
- R 1 -R 17 are D.
- R? and Rs are D.
- R9-R1 ? are D.
- the compound of formula (AA) is represented by the compound of formula (Al) wherein R 1 -R20 are each independently H or D, provided that at least one of R 1 -Rn is D.
- R 1 -Re are D.
- R 1 -R0, RB, and R14 are D.
- R 1 -R 17 are D.
- R? and Rs are D.
- R9-R 17 are D.
- the compound of formula (AA) or (Al) is represented by compound A8, A13, A18, Al 9, A20, or A21:
- the invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein and at least an additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. Tn some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA), or a compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- AA non-24-hour sleep wake disorder
- the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula ( AA) as described herein, or a compound of formula (Al), or any one of compounds A8, AI3, and A18- A22, or any combination thereof, and at least one additional therapeutic agent.
- the pain is chronic pain. In other embodiments, the pain is acute pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A 13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent.
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the disease or disorder is seizures.
- the disease or disorder is epilepsy.
- the disease or disorder is aggression. In some embodiments, the disease or disorder is fear. In some embodiments, the disease or disorder is phobias, e.g., noise phobias. In some embodiments, the disease or disorder is generalized anxiety disorder. In some embodiments, the disease or disorder is separation anxiety. In some embodiments, the subject is an animal. In other embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
- AA compound of formula
- Al compound of formula
- the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the disease or disorder is a neoplastic disease. In some embodiments, the disease or disorder is a degenerative disorder. In some embodiments, the disease or disorder is an auto-immune disease. In other embodiments, the disease or disorder is allergies. In other embodiments, the disease or disorder is a metabolic disorder. In some embodiments, the disease or disorder is infection.
- the disease or disorder is inflammation. In some embodiments, the disease or disorder is trauma. In other embodiments, the disease or disorder is toxicity. In some embodiments, the disease or disorder is nutritional imbalance. In some embodiments, the disease or disorder is an idiopathic condition. In some embodiments, the disease or disorder is an iatrogenic problem. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression. In some embodiments, the disease or disorder is a compulsive disorder.
- the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is seizures. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any’ one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
- the disease or disorder is anorexia.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia.
- the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
- the disease or disorder is anxiety. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject is an animal. In certain embodiments, the subject is a cat. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds A8, A 13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds A8, A 13, and A18-A22, or any
- the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington’s disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. Tn some embodiments, the disease or disorder is glaucoma.
- the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. Tn some embodiments, the disease or disorder is cancer. Tn some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment andprevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds 8, 13, and 18-22, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia,.
- the disease or disorder is pain.
- the pain is chronic pain.
- the disease or disorder is multiple sclerosis.
- the disease or disorder is epilepsy.
- the disease or disorder is chemo-related nausea, vomiting, and anorexia.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the additional therapeutic agent is the one as know' n in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds A8, A13, and AI8-A22, or any combination thereof, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of pain or inflammation.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of pain or inflammation.
- the subject in the method of the invention is a mammal.
- the subject is a human patient.
- the subject is an animal.
- the subject is a companion animal, an exotic animal, or a farm animal.
- the subject is a horse, a dog, a cat, or a ferret.
- the subject is a dog.
- the pain or inflammation is associated with osteoarthritis.
- the pain or inflammation is a postoperative pain or postoperative inflammation.
- the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
- the postoperative inflammation is associated with orthopedic surgery', soft-tissue surgery, or dental surgery.
- the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds 8, 13, and 18-22, or any' compounds as described herein, and at least one additional therapeutic agent.
- the therapeutic agent in the method of the invention is an analgesic agent including drugs and agents that provide pain relief.
- the therapeutic agent is a non-steroidal anti-inflammatory’ drug (NSAID).
- the non-steroidal antiinflammatory drug is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefena
- NSAID non-ster
- the non-steroidal antiinflammatory drug is meloxicam, carprofen, deracoxib, or firocoxib. In certain embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam. In other embodiments, the non-steroidal anti-inflammatory drug (NSAID) is carprofen.
- the subject is a human. In other embodiments, the subject is an animal. In certain embodiments, the subject is a dog. In some embodiments, the subject is a cat.
- the additional therapeutic agent is an analgesic agent, an anti-anxiety' agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
- an analgesic agent an anti-anxiety' agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an anti
- the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent tor treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
- the deuterated compound as described herein can be used to treat the adverse effects resulting from the treatment with the additional therapeutic agent as described herein.
- adverse effects include, but are not limited to, vomiting, dizziness, drowsiness, dry mouth, swollen tongue, loss of balance or coordination, and unsteadiness.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an analgesic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent.
- the disease or disorder is pain such as acute pain or chronic pain.
- the compound of formula ( AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
- the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent.
- the non-opioid analgesic agent is acetaminophen, aspirin, ibuprofen, meloxicam, carprofen, fenbuprofen, flubiprofen, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin.
- the analgesic agent is naproxen sodium or magnesium.
- the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, meloxicam, or naproxen.
- the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol.
- the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride.
- the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppy.
- the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder.
- the disease or disorder is a neurodegenerative disease or disorder.
- the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy.
- the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERMAXTM), ephenedrine sulfate (EPHEDRINETM), pemoline CYLERTTM), mazindol (SANOREXTM), d,l-a-methylphenethylamine (ADDERALLTM) methylphenydate (RITALINTM), pramipexole (MIRAPEXTM), modafinil (PROVIGILTM), or ropinirole (REQUIPTM).
- anthocyanins e.g., anthocyanin cyanidin-3-O-glucoside
- levodopa e.g., pergolide (PERMAXTM), ephenedrine sulfate (EPHEDRINETM), pemoline CYLERTTM), ma
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A A) as described herein and an anti-dyskensia agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-dyskensia agent.
- the disease or disorder is a movement disorder or Parkinson disease.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
- the anti-dyskensia agent is selected from baclofen (LIORESAL TM), botulinum toxin (BOTOXTM), clonazepam (KLONOPINTM), and diazepam (VALRJMTM).
- an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an immunosuppressive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent.
- the disease or disorder is an autoimmune disease.
- the autoimmune disease is lupus or rheumatoid arthritis.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, methylprednisone, dexamethasone, heterologous anti -lymphocyte globulin, deoxy spergualin, or rapamycin.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-spasmodic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-spasmodic agent.
- the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction.
- the compound of formula (AA) is the compound of formula (AT), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein.
- the anti-spasmodic agent is carbamatepine, oxcarbazepine, terbocate, furboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinamide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-diabetic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent.
- the disease or disorder is diabetes.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
- the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glimepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is seizure, neuropathic pain, or epilepsy.
- the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- the compound of formula (AA) is the compound of formula ( AT), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-convulsant agent or anti-epileptic agent is pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbarn atepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, fibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin.
- the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide.
- the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide.
- the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-psychotic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-psychotic agent.
- the disease or disorder is schizophrenia, psychosis, or bipolar disorder.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an cholesterol/lipid lowering agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent.
- the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
- the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenotibrate, benzatibrate, rosiglitazone, or ezetimibe.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-inflammatory agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent.
- the disease or disorder is an inflammatory disease.
- the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
- the anti-inflammatory agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, prarnoprofen, rnuroprofen, trioxaprofen, suprofen, arninoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac,
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-bacterial agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent.
- the disease or disorder is a bacterial infection.
- the disease or disorder is a skin or eye infection, tuberculosis, or a urinary tract infection.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
- the anti-bacterial agent is selected from the group consisting of erytliromycin, aji azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, Piperacillin, azlocillin, temocillin, cepalothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefinetazole, ceftazidime cefotaxime, cefizoxime, ceftriaxone, cefoperazone, cef
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula ( AA) as described herein and an anti-emetic.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics.
- the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein,
- the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-depressant.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant.
- the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, posttraumatic stress disorder (PTSD), phobias, or social anxiety disorder.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-depressant is selected from the group consisting of adinazolam, alaproclate, amineptine, aniitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, apelinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprin
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-anxiety agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent.
- the disease or disorder is generalized anxiety disorder, social and other phobias, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression.
- the compound of formula (AA) is the compound of formula (Al), or anyone of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-anxiety agent is salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, zolpidem; clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and a sleeping agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent.
- the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an orexigenic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent.
- the disease or disorder is anorexia .
- a compound of formula (AA) as described herein and an orexigenic agent can stimulate appetite andproduce weight gain in older persons.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and A18- A22, or any compounds as described herein.
- the orexigenic agent is megestrol or oxandrolone.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an ocular hypotensive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent.
- the disease or disorder is glaucoma.
- a compound of formula (AA) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP).
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and AI8-A22, or any compounds as described herein.
- the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
- the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-osteoporosis agent.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, apeledoxifene, teriparatide, abaloparatide, and denosumab.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-migraine agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent.
- the disease or disorder is migraine headache or migraine pain.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) or a compound of formula (Al) as described herein and a cardiovascular agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent.
- the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
- the term ‘cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory system (blood vessels).
- the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, methyldofu, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine,
- the present invention provides a method for treating or preven ting cancer, comprising administering to a subject in need thereof a compound of formula (AA) as described herein and an anti-cancer agent.
- the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
- the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, coion tumors, lung tumors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma.
- the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Pli+ CML).
- the anti-cancer agent is a chemotherapeutic agent.
- the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
- the anti-cancer agent is a cytostatic drug.
- the cytostatic drag is busulfan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
- the anti-cancer agent is an alkylating agent.
- the alkylating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
- the anti-cancer agent is a cancer immunotherapy monoclonal antibody.
- the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
- the anti-cancer agent is an anti-tumor agent.
- the anti-tumor agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
- the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxy carbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
- the anti-cancer agent is an anti-metabolite agent.
- the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine, and gemcitabine.
- the anti-cancer agent is a mitotic inhibitor.
- the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
- the anti-cancer agent is a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
- the anti-cancer agent is a topoisomerase inhibitor.
- the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
- the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, anti atherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents, antifungal agents,
- an additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atomoxetine; dopamine reuptake inhibitors (DARTs), such as methylphenidate; serotonin-norepmephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRIs), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such as ifetroban;
- NRIs norepine
- squalene synthetase inhibitors include fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tric
- metformin glucosidase inhibitors
- glucosidase inhibitors e.g., acarbose
- insulins meglitinides (e.g., repaglinide)
- meglitinides e.g., repaglinide
- sulfonylureas e.g., glimepiride, glyburide, and glipizide
- thiozolidinediones e.g.
- troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl -protein transferase inhibitors; hormonal agents, such as gluco
- the present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administration a deuterated cannabichromene compound of formula (AAA) in combination with the therapeutic agent.
- AAA cannabichromene compound of formula
- a combination therapy that includes a deuterated cannabichromene compound of formula (AAA) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect.
- the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA).
- a combination of a deuterated cannabichromene compound of formula (AAA) with at least one additional therapeutic agent as described herein may allow for an improved safety profile of the additional therapeutic agent during treatments and result in a decrease in the onset of resistance development.
- the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA) in the treatment.
- Such combination therapy may allow for at least the same efficacy as, or a higher efficacy than, the treatment using the therapeutic agent alone, with an improved safety profile of the therapeutic agent.
- the therapeutically effective amount of the therapeutic agent administered to the subject is the same as the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA) in the treatment.
- Such combination therapy may allow for an increased efficacy with the same safety profile of the therapeutic agent.
- the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent,
- R 1 -R30 are each independently H or D, provided that at least one of R 1 -R 25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity 1 , Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasi
- the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent, wherein R 1 -R30 are each independently H or D, provided that at least one of R 1 -R 25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, vomiting, and e
- the compound of formula (AAA) is a deuterated compound of cannabichromene (CBC), or a derivative thereof.
- R 1 -RB are D.
- RS-RB are D.
- RS-RB, Rao, and R21 are D.
- R8-R24 are D.
- R2.5 is D.
- the compound of formula (AAA) is represented by a compound of formula (AAI)
- R 1 -Rzs are each independently H or D, provided that at least one of R 1 -R2.5 is D.
- R 1 -RB are D.
- RS-RB are D.
- RS-RB, R20, and R21 are D.
- R 8 -R24 are D.
- R 25 is D.
- the compound of formula (AAA) or (AAI) is represented by any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24:
- the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein and at least an additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20- A A24, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- a compound of formula (AAA) as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy- induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
- the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA), or a compound of formula (AAI), or a compound of formula (AAI), or any one of compounds AA7, AA 11, AAI 6, and AA20- AA24.
- disease or disorder is selected from the group consisting of non-AA24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
- the disease or disorder is non- AA24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia.
- the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an atention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as d escribed herein, or a compound of formula (AAI), or any one of compound s AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- a compound of formula (AAA) as d escribed herein
- a compound of formula (AAI) or any one of compound s AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AA I I, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- AAA compound of formula
- AAI 6 compound of formula
- the pain is chronic pain.
- the pain is acute pain.
- the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- AAA compound of formula
- AAI AAI
- the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any combination thereof, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the disease or disorder is seizures.
- the disease or disorder is epilepsy. In some embodiments, the disease or disorder is aggression. In some embodiments, the disease or disorder is fear. In some embodiments, the disease or disorder is phobias, e.g., noise phobias. In some embodiments, the disease or disorder is generalized anxiety disorder. In some embodiments, the disease or disorder is separation anxiety. In some embodiments, the subject is an animal. In other embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety', aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
- the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary’ anorexia. In some embodiments, the anorexia is a secondary' anorexia, e.g., secondary' to chemo. In other embodiments, the disease or disorder is a neoplastic disease. In some embodiments, the disease or disorder is a degenerative disorder. In some embodiments, the disease or disorder is an auto-immune disease. In other embodiments, the disease or disorder is allergies. In other embodiments, the disease or disorder is a metabolic disorder.
- the disease or disorder is infection. In other embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is trauma. In other embodiments, the disease or disorder is toxicity'. In some embodiments, the disease or disorder is nutritional imbalance. In some embodiments, the disease or disorder is an idiopathic condition. In some embodiments, the disease or disorder is an iatrogenic problem. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the anxiety? is separation anxiety or generalized anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
- the disease or disorder is a compulsive disorder. In some embodiments, the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is seizures.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AA1 1, AA16, and AA20-AA24, or any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
- the disease or disorder is anorexia.
- the anorexia is acute anorexia.
- the anorexia is chronic anorexia.
- the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency. In some embodiments, the disease or disorder is anxiety'. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In certain embodiments, the subject is a cat. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AAI 1, AA 16, and AA20-AA24, or any combination thereof and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson’s disease, Huntington’s disease, Alzheimer’s disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
- the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntingtons disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma.
- the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo- related nausea, vomiting, and anorexia.
- the disease or disorder is pain.
- the pain is chronic pain.
- the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is chemo-related nausea, vomiting, and anorexia.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
- the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of pain or inflammation.
- the additional therapeutic agent is as described anywhere herein for the treatment and prevention of pain or inflammation.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery', or dental surgery’.
- the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent.
- the therapeutic agent in the method of the invention is an analgesic agent including drugs and agents that provide pain relief.
- the therapeutic agent is a non-steroidal anti-inflammatory drug (NSAID).
- the non-steroidal anti-inflammatory drug is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpina
- the non-steroidal anti-inflammatory drug is meloxicam, carprofen, deracoxib, or firocoxib. In certain embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam. In other embodiments, the non-steroidal anti-inflammatory drug (NSAID) is carprofen.
- the subject is a human. In other embodiments, the subject is an animal. In certain embodiments, the subject is a dog. In some embodiments, the subject is a cat.
- the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
- the additional therapeutic agent is an agent tor treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent tor treating Ret syndrome.
- the deuterated compound as described herein can be used to treat the adverse effects resulting from the treatment with the additional therapeutic agent as described herein.
- adverse effects include, but are not limited to, vomiting, dizziness, drowsiness, dry mouth, swollen tongue, loss of balance or coordination, and unsteadiness.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an analgesic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent.
- the disease or disorder is pain such as acute pain or chronic pain.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any compounds as described herein.
- the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent.
- the non-opioid analgesic agent is acetaminophen, aspirin, ibuprofen, meloxicam, carprofen, fenbuprofen, flubiprofen, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin.
- the analgesic agent is naproxen sodium or magnesium.
- the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, meloxicam, or naproxen.
- the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol.
- the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride.
- the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppy.
- the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder.
- the disease or disorder is a neurodegenerative disease or disorder.
- the neurodegenerative disease or disorder is Alzheimer’s disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette’s syndrome, or progressive muscular atrophy.
- the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERM AXTM), ephenedrine sulfate (EPHEDRINETM), pemoline CYLERTTM), mazindol (SANOREX rM ), dj-a-methylphenethylamine (ADDERALLTM) methylphenydate (RITALINTM), pramipexole (MIRAPEXTM), modafinil (PROVIGILTM), or ropinirole (REQUIPTM).
- anthocyanins e.g., anthocyanin cyanidin-3-O-glu
- the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-dyskensia agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-dyskensia agent.
- the disease or disorder is a movement disorder or Parkinson disease.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, A A 16, and AA20-AA24, or any compounds as described herein.
- the anti-dyskensia agent is selected from baclofen (LIORESALTM), botulinum toxin (BOTOXTM), clonazepam (KLONOPINTM), and diazepam (VALIUMTM).
- an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an immunosuppressive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent.
- the disease or disorder is an autoimmune disease.
- the autoimmune disease is lupus or rheumatoid arthritis.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AA16, and AA20-AA24, or any compounds as described herein.
- the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, methylprednisone, dexamethasone, heterologous anti -lymphocyte globulin, deoxy spergualin, or rapamycin.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-spasmodic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-spasmodic agent.
- the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA 16, and AA20-AA24, or any compounds as described herein.
- the anti-spasmodic agent is carbamatepine, oxcarbazepine, ferbocate, furboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinarnide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-diabetic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-diabetic agent.
- the disease or disorder is diabetes.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
- the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glinepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent.
- the disease or disorder is seizure, neuropathic pain, or epilepsy.
- the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
- the anti-convulsant agent or anti-epileptic agent is pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbarn atepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, fibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin.
- the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide.
- the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide.
- the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-psychotic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-psychotic agent.
- the disease or disorder is schizophrenia, psychosis, or bipolar disorder.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
- the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an cholesterol/lipid lowering agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent.
- the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI I, AA16, and AA20-AA24, or any compounds as described herein.
- the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenofibrate, benzafibrate, rosiglitazone, or ezetimibe.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-inflammatory' agent.
- the disease or disorder is any? one that can be treated or prevented as known in the art by an anti-inflammatory agent.
- the disease or disorder is an inflammatory disease.
- the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein,
- the anti-inflammatory’ agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac,
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-bacterial agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-bacterial agent.
- the disease or disorder is a bacterial infection.
- the disease or disorder is a skin or eye infection, tuberculosis, or a urinary tract infection.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-.AA24, or any compounds as described herein.
- the anti-bacterial agent is selected from the group consisting of erythromycin, azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarciilin, mezlocillin, Piperacillin, azlociilin, temociliin, cepaiothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefinetazole, ceftazidime cefotaxime, cefizoxime, ceftriaxone, cefoperazone, ceftazidime
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-emetic.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics.
- the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds A.A7, AA11, AAI 6, and AA20-.AA24, or any compounds as described herein.
- the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-depressant.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant.
- the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety' disorder, bipolar disorder, posttraumatic stress disorder (PTSD), phobias, or social anxiety' disorder.
- the compound of formula (AAA) is the compound of formula (AAT), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the anti-depressants is selected from the group consisting of adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, apelinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, i
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-anxiety agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent.
- the disease or disorder is generalized anxiety disorder, social and other phobias, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the anti-anxiety agent is salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, zolpidem; clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and a sleeping agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent.
- the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
- the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an orexigenic agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent.
- the disease or disorder is anorexia.
- a compound of formula (AAA) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AA16, and AA20-AA24, or any compounds as described herein.
- the orexigenic agent is megestrol or oxandrolone.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an ocular hypotensive agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent.
- the disease or disorder is glaucoma.
- a compound of formula (AAA) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP).
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
- the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
- the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti -osteoporosis agent.
- the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any compounds as described herein.
- the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, apeledoxifene, teriparatide, abaloparatide, and denosumab.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-migraine agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an anti-migraine agent.
- the disease or disorder is migraine headache or migraine pain.
- the compound of formula ( AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
- the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
- the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) or a compound of formula (AAI) as described herein and a cardiovascular agent.
- the disease or disorder is any one that can be treated or prevented as known in the art by an cardiovascular agent.
- the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
- the term “cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory system (blood vessels).
- the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, niethyldofo, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine
- the present invention provides a method for treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (AAA) as described herein and an anti-cancer agent.
- the compound of formula (AAA) is the compound of formula (AV), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
- the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung humors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma.
- the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).
- the anti-cancer agent is a chemotherapeutic agent.
- the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinoreibine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
- the anti-cancer agent is a cytostatic dmg.
- the cytostatic drug is busuifan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
- the anti-cancer agent is an alkylating agent.
- the alkydating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busuifan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
- the anti-cancer agent is a cancer immunotherapy monoclonal antibody.
- the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
- the anti-cancer agent is an anti-tumor agent.
- the anti-tumor agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea,
- the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
- the anti-cancer agent is an anti-metabolite agent.
- the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafor, carmofor, capecitabine, and gemcitabine.
- the anti-cancer agent is a mitotic inhibitor.
- the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
- the anti-cancer agent is a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
- the anti-cancer agent is a topoisomerase inhibitor.
- the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
- the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, antiatheroscl erotic agents, anticoagulants, antithrombotic agents, protlirombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents
- an additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atomoxetine; dopamine reuptake inhibitors ( D ARIs), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRls), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such as ifetroban
- NRIs norepine
- squalene synthetase inhibitors include fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethiazide, polythiazide, benzothiazide, ethacrynic acid,
- metformin glucosidase inhibitors
- glucosidase inhibitors e.g., acarbose
- insulins meglitinides (e.g., repaglinide)
- meglitinides e.g., repaglinide
- sulfonylureas e.g., glimepiride, glyburide, and glipizide
- thiozolidinediones e.g.
- troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl-protein transferase inhibitors; hormonal agents, such as glucocortic
- a daily dosage may be about 0.1 to about 1 milligrams of the compound of the invention per kilogram of patient body weight and, in the case of the additional therapeutic agent, the usual dosage of the therapeutic agent when administered alone may be reduced by about 10-90% when administered with a compound of the invention as described herein.
- the compound of the invention any compounds as described herein.
- the therapeutically effective amount of the additional therapeutic agent administered to the subject is less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention as described herein. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is 10% to 90% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is 20% to 80% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention.
- the therapeutically effective amount of the therapeutic agent administered to the subject is 20% to 70% less than the therapeutically effective amount of the therapeutic agent wiien administered in the absence of the compound of the invention.
- the compound of the invention is any compounds as described herein.
- the therapeutically effective amount of the therapeutic agent administered to the subject is at least 10% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention as described herein. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 20% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 30% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 40% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention.
- the therapeutically effective amount of the therapeutic agent administered to the subject is at least 50% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 5%, or 15%, or 25%, or 35%, or 45%, or 55% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the compound of the invention is any compounds as described herein.
- the additional therapeutic agent and a compound of the invention as described herein are administered in combination administered concurrently. In other embodiments, the additional therapeutic agent and the compound of the invention are administered concurrently.
- the present invention further provides a combination therapy.
- administered in combination or “combination therapy” means the administration of the compound of the invention as described herein, and one or more additional therapeutic agents to treat a therapeutic disorder described in the present invention.
- Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient.
- administration also encompasses use of each type of active ingredient in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the diseases or disorders described herein.
- the therapeutic agent and the compound of the invention are formulated in the same pharmaceutical composition. Accordingly, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention, at least one additional therapeutic agent, and a pharmaceutically acceptable earner. In some embodiments, the compound of the invention is any compounds as described herein.
- the additional therapeutic agent is formulated in a first pharmaceutical composition and the compound of the invention as described herein is formulated in a second pharmaceutical composition.
- the present invention provides a kit comprising a first compartment containing a first pharmaceutical composition comprising a therapeutic agent as described herein and a second compartment containing a second pharmaceutical composition comprising a compound of the invention.
- the compound of the invention as described herein and the additional therapeutic agents are combined in a single dosage unit they may be formulated such that the physical contact between the active ingredients is minimized to reduce a potential chemical interaction between the combined active ingredients.
- one or both active ingredients may be enteric coated.
- the active ingredient(s) may be coated with a material that affects a sustained release throughout the gastrointestinal tract.
- the compound of the invention may not be coated.
- the term “deuterium enrichment” is used to describe an above -natural amount of deuterium contained at any position of the compounds of the invention as described herein, designated by the letter “D” (or by the designation “2H”).
- the deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
- an approximate percentage is used to quantitatively define the amount of deuterium enrichment at a certain position of the described chemical structure, such as, for example, "deuterium enrichment is no less than about 10%.” Where such quantitative approximations are used in this invention, they are meant to describe a percentage of the described compounds in an aggregate composition of like compounds that contain deuterium at the identified position D instead of protium. [00522] In each of the foregoing and each of the following embodiments, it is to be understood that the formulas also include any and all hydrates and/or solvates of the compound formulas.
- solvate refers to compounds that further include a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. If the sol vent is water, the solvate is referred to as "hydrate.” Pharmaceutically acceptable solvates and hydrates are complexes that, for example, may include from 1 to about 100, or from 1 to about 10, or from one to about 2.3 or 4 molecules of water or a solvent. In some embodiments, the hydrate may be a channel hydrate. It should be understood that the term “compound” in this application covers the compound and solvates of the compound, as well as mixtures thereof.
- hydrate includes, but is not limited to, hemihydrate, monohydrate, dihydrate, trihydrate and the like.
- Subject refers to an animal, including, but not limited to, a primate (e.g., human, monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, and hamsters), lagomorphs (e.g., rabbit), swine (e.g., pig and miniature pig), equine, ferrets, parrots, canine, feline, bovine, ovine, caprine, and camelids.
- a primate e.g., human, monkey, chimpanzee, gorilla, and the like
- rodents e.g., rats, mice, gerbils, and hamsters
- lagomorphs e.g., rabbit
- swine e.g., pig and miniature pig
- equine ferrets
- parrots canine, feline, bovine, ovine, caprine, and camelids.
- the compounds of the invention and formulations comprising the same as disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals.
- the animals include horses, dogs, and cats.
- the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog.
- treatment refers to the administering of a therapeutic effective amount of the composition of the present invention which is effective to ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
- the phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the present invention also includes “pharmaceutically' acceptable salts” of the compounds described herein.
- “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds -wherein the parent compound is modified by converting an existing acid or base moiety' to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the compound of the invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the compound of the invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; for example, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile.
- the pharmaceutically acceptable salts of the compound of the invention can be formed by conventional means, such as by reacting the free base or free acid form of the product with one or more equivalents of the appropriate acid or base in a solvent or medium in which the salt is insoluble or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the ions of a existing salt for another ion or suitable ion-exchange resin.
- Possible pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19, 1977; incorporated herein by reference.
- a pharmaceutically acceptable salt form of a compound can be prepared in situ during the final isolation and purification of the compound, or separately by reacting the free base functionality with a suitable organic or inorganic acid.
- Suitable acids for preparation of the pharmaceutically acceptable salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
- Other pharmaceutically acceptable salts can include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pa
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and quaternary ammonium salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- Suitable bases for use in the preparation of pharmaceutically acceptable salts including, but not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, or sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, N-methyl-glucamine, hydrabamine, IH-imidazole, L-lysine, morpholine, 4-(2- hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, l
- the invention further includes derivatives of the compound of the invention.
- derivatives includes but is not limited to ether derivatives, acid derivatives, amide derivatives, ester derivatives and the like.
- the invention further includes metabolites of the compound of the invention.
- metabolite means any substance produced from another substance by metabolism or a metabolic process.
- the invention further includes pharmaceutical products of the compound of the invention.
- pharmaceutical product means a composition suitable for pharmaceutical use (pharmaceutical composition), as defined herein.
- the invention further includes prodrugs of the compound of the invention.
- ⁇ prodrug means a substance which can be converted in vivo into a biologically active agent by such reactions as hydrolysis, esterification, de-esterification, activation, salt formation and the like.
- compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any combination.
- the invention further provides processes for the preparation of compounds of the invention as described herein.
- the compound of the invention can be prepared using methods known in the art, including, for example, by referring to the following Schemes.
- Schemes 1 - 6 provide processes for the preparation of compounds (1-4), (1-6), (1-7),
- Schemes 7- 11 provide processes for the preparation of compounds (II--4), (II-6), (II-7), and (II- 16):
- Scheme 12 provides processes for the preparation of compound (1-24):
- the invention further provides the processes for the preparation of compounds of the present invention.
- Schemes Al -A3 provide processes for the preparation of compounds (A8), (Al 3), and (Al 8).
- the invention further provides the processes for the preparation of compounds of the present invention.
- Schemes AA1- AA4 provide processes for the preparation of compounds (AA7), (AA11), (AA16) and (AA20).
- Liver microsomal stability’ assays are conducted at 1 mg per mL liver microsome protein with an NADPH-generating system in 2% sodium bicarbonate (2.2 mM NADPH, 25.6 mM glucose 6-phosphate, 6 units per mL glucose 6-phosphate dehydrogenase and 3.3 mM magnesium chloride).
- Test compounds are prepared as solutions in 20% acetonitrile-water and added to the assay? mixture (final assay concentration 5 microgram per mL) and incubated at 37° C. Final concentration of acetonitrile in the assay? should be ⁇ 1%.
- the cytochrome P450 enzymes are expressed from the corresponding human cDNA using a baculovirus expression system (BD Biosciences, San Jose, Calif.).
- reaction is stopped by the addition of an appropriate solvent (e.g., acetonitrile, 20% trichloroacetic acid, 94% acetonitrile/6% glacial acetic acid, 70% perchloric acid, 94% acetonitrile/6% glacial acetic acid) and centrifuged (10,000 g) for 3 minutes. The supernatant is analyzed by HPLC/MS/MS.
- an appropriate solvent e.g., acetonitrile, 20% trichloroacetic acid, 94% acetonitrile/6% glacial acetic acid, 70% perchloric acid, 94% acetonitrile/6% glacial acetic acid
- PK Pharmacokinetics
- Rats or mice receive a single intravenous dose of THC or deuterated compounds at a dose of 1 mg/kg body weight, or a single oral dose of THC or deuterated compounds at a dose of 10-50 mg/kg body weight
- Plasma samples are collected at different times following dosing and the plasma concentrations of THC or deuterated compounds is determined by HPLC-MS/MS analysis using standards methods. Clearance, half-life, volume of distribution and oral bioavailability' are calculated from the plasma concentration-time course data using established methods.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds, methods for preparation thereof, compositions comprising the same, and uses thereof for the treatment or prevention of numerous diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
Description
DEUTERATED CANNABINOID COMPOUNDS
FIELD OF THE INVENTION
[001] This invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds, methods for preparation thereof, compositions comprising the same, and uses thereof for the treatment or prevention of numerous diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome- related disorders.
BACKGROUND OF THE INVENTION
[002] ((6a R,10aR)-delta-9-Tetrahydrocannabinol (THC) is metabolized in the liver by enzymes of the cytochrome P450 (CYP) hepatic mixed-function oxidase family. THC is oxidized by CYP to active, equipotent 11-OH-THC metabolite, which is then rapidly metabolized to the inactive THC-COOH metabolite, resulting in low concentrations of THC and 11-OH-THC in blood and much higher concentrations of THC-COOH, The presence of the carboxyl group of THC-COOH resu lts in a loss of biological activity, since THC-COOH can no longer bind tightly to cannabinoid receptors. Because THC is subject to extensive CYP-mediated first pass hepatic metabolism following oral administration, its oral bioavailability is low.
(THC)
[003] EPIDIOLEX (cannabidiol) has been approved for relief of spasticity in patients with multiple sclerosis. It is formulated in anhydrous ethanol, peppermint oil, and propylene glycol for buccal application. To date, no break-through in improving the bioavailability of THC has been reported. Current FDA approved THC product Dronabinol (Trade names: Marinol and Syndros),
used as an appetite stimulant, is a synthetic form of THC dissolved in sesame oil that has an oral bioavailability of 10-20%.
[004] Cannabigerol (CBG) is one of cannabinoid compounds found in the plant genus cannabis. It acts on specific physiological systems and the results for medicinal use are promising. Endocannabinoid receptors are prevalent in eye structures. Cannabigerol is considered to be particularly effective in treating glaucoma because it reduces intraocular pressure. It is also effective in decreasing the inflammation characteristic of inflammatory bowel disease in animal experiments involving mice.
(CBG)
[005] Cannabigerol has shown to protect neurons in mice with Huntington’s disease, which is characterized by nerve cell degeneration in the brain. Further, it is shown to block receptors that cause cancer cell growth. For example, it inhibits the gro wth of colorectal cancer cells in mice and also inhibits tumors and chemically-induced colon carcinogenesis.
[006] Cannabichromene (CBC), also known as cannabichrome, pentylcannabichromene, or cannabinochromene, is one of major cannabinoids in Cannabis sativa L. and the second abundant cannabinoid in drug-type cannabis. Cannabichromene (CBC) outperforms other major cannabinoids in terms of anti-bacterial and anti-fungal activity. CBC also shows potent antiinflammatory activity in the carrageenan-induced rat paw edema assay.
(CBC)
[007] Deuterium has twice the mass of protium. A C-D bond is stronger than the corresponding C-’H bond. If a C-kH bond is broken during a rate-determining step in a chemical reaction (i.e., the step with the highest transition state energy), substituting a deuterium for that protium may lead
to a decrease in the reaction rate. However, while deuteration of pharmaceuticals to improve pharmacokinetics (PK), pharmacodynamics (PD), and toxicity profiles has been investigated, deuteration is inherently unpredictable. Deuterium incorporation can only produce an effect if the incorporated deuterium is broken during a rate -determining metabolic step. As a result, deuterium incorporation may produce no improvement in PK, PD, or toxicity profile. In addition, deuterium incorporation can lead to metabolic switching. Metabolic switching occurs when xenogens, sequestered by Phase I enzymes, bind transiently and re-bind in a variety of conformations prior to the chemical reaction (e.g., oxidation). Metabolic switching can lead to different proportions of known metabolites as well as production of new metabolites. This new metabolic profile may impart more or less toxicity, or it may produce negative effects on PD and/or PD (Miwa et al., BioEssays 1987; 7(5), 215-19). Unsuccessful deuteration attempts have been reported. For example, nevirapine deuteration resulted in increased metabolism, rather than decreased metabolism (Harbeson and Tung, 2011, 46, Annu. Rep. Med. Chern, 403-417). Deuterated versions of tramadol were not found to be superior to the parent compound. (Id,, at 409-410). Because of the unpredictable outcomes of deuteration, the pharmacokinetic and metabolic behaviors of a particular compound after deuteration can be very different, and PK / PD outcomes cannot be predicted before the compound is synthesized and tested in a series of in vitro and in vivo PK / PD experiments.
[008] The present invention provides deuterated cannabinoid compounds or derivatives thereof. Such deuterated cannabinoid compounds will maintain the beneficial aspects of the corresponding non-isotopically enriched cannabinoids while substantially slowing metabolism and improving half-life and bioavailability’ (via oral or other routes of administration). A combination of deuterated cannabinoid compounds with additional therapeutic agents may exhibit a therapeutic synergistic or additive effect and allow for an improved safety profile of said therapeutic agents. The required therapeutically effective amount of the therapeutic agents may also be less than current recommended and approved dosages, thus minimizing the toxicity during treatments. Such a combination therapy may also prevent or delay the onset of drug resistance and reduce potentially the side effects that arise from the use of the therapeutic agents alone.
SUMMARY OF THE INVENTION
[009] In one aspect, the invention provides a deuterated compound of (6aR,10a/?)-delta-9- tetrahydrocannabinol (THC), or a derivative thereof, represented by the compound of formula (A)
wherein R1-R30 are each independently H or D.
[0010] In another aspect, the invention provides a deuterated compound of (6aR,10aR)-delta-9- tetrahydrocannabinol (THC) represented by the compound of formula (I) wherein R1-R14 are each independently H or D; and R15 is D or OH; provided that when R3 is H, R15 is OH.
[0011] In another aspect, the invention provides a deuterated compound of delta-9- tetrahydrocannabivarin (THCV) represented by the compound of formula (B)
wherein
R1-R9 and R16-R31 are each independently H or D; and R15 is D or OH.
[0012] In some embodiments, the invention provides a deuterated compound of delta-9- tetrahydrocannabivarin (THCV) represented by the compound of formula (II): wherein
R1-R9 and R31 are each independently H or D; and R15 iS D or OH.
[ 0013] In one aspect, the invention provides a deuterated compound of cannabigerol (CBG), or a derivative thereof, represented by a compound of formula (AA) wherein R1-R32 are each independently H or D, provided that at least one of R1-R17 is D.
[0014] In another aspect, the invention provides a deuterated compound of cannabigerol (CBG) represented by a compound of formula (Al) wherein R1-R20 are each independently H or D, provided that at least one of R1 to R17 is D.
[0015] In one aspect, the invention provides a deuterated compound of cannabi chromene (CBC), or a derivative thereof, represented by a compound of formula (AAA)
wherein R1-R30 are each independently H or D, provided that at least one of R1-R25 is D.
[0016] In another aspect, the invention provides a deuterated compound of cannabichromene
(CBC) represented by a compound of formula (AA1) wherein R1-R2.5 are each independently H or D, provided that at least one of R1-R2.5 is D.
[0017] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain,
musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[0018] In a further aspect, the present invention provides a method of treating or preventing seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal.
[0019] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency.
[0020] In another aspect, the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising adminis tering to said subject a therapeutically effective amount of a compound of the invention as described herein.
[0021] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome- related disorders.
[0022] In another aspect, the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
[0023] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures. In some embodiments, the subject is a dog.
[0024] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the subject is a dog.
[0025] In another aspect, the present invention provides a method of heating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma. In some embodiments, the subject is a cat.
[0026] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) and at least one additional therapeutic agent,
wherein R1-R30 are each independently H or D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary' insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity', type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington’s disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[0027] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) and at least one additional therapeutic agent.
(B) wherein R1-R9 and R16-R31 are each independently H or D; and R15 is D or OH. wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson’s disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[0028] In some embodiments, the compound of formula (B) is represented by a compound of formula (II) wherein
R1-R9 and R31 are each independently H or D; and R15 is D or OH.
[0029] In some embodiments of the method of the invention comprising administering a compound of formula (A) or a compound of formula (B) and at least one additional therapeutic agent, the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an anti-emetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti-dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an anti-osteoporosis agent, or a cardiovascular agent.
[0030] In some embodiments, the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
[0031] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent, wherein R1-R32 are each independently H or D, provided that at least one of R1-R17 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, atention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[0032] In some embodiments, the compound of formula (AA) is represented by a compound of formula (Al) wherein R1-R20 are each independently H or D, provided that at least one of Ri to R17 is D.
[0033] In some embodiments, said additional therapeutic agent is an analgesic agent, an antianxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti-convulsive agent, antiepileptics, an anti-inflammatory agent, an anti -depressant agent, an anti-emetic agent, an anti- ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodeeenerative diseases or disorders, an anti-dvskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an anti-osteoporosis agent, or a cardiovascular agent.
[0034] In some embodiments, the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent tor treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
[0035] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent,
(AAA) wherein R1-Rso are each independently H or D, provided that at least one of R1-R25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[0036] In some embodiments, the compound of formula (AAA) is represented by a compound of formula (AAI)
OH
(AAT) wherein R1-R25 are each independently H or D, provided that at least one of R1-R25 is D.
[0037] In some embodiments of the method of the invention, the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti -depressant agent, an antiemetic agent, an anti -ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
[0038] In some embodiments, the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent tor treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
[0039] The details of one or more embodiments of the invention are set forth in the accompanying the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
[ 0040] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure the present invention.
[0041] The present invention relates to deuterated cannabinoid compounds. In some embodiments, the present invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds. The deuterated compounds of the invention maintain the beneficial aspects of the corresponding non-isotopically enriched compounds while substantially increasing the maximum tolerated dose, decreasing toxicity, increasing the half-life (T1/2.), lowering the maximum plasma concentration (Cmax) of the therapeutically efficacious dose or the minimum efficacious dose (MED), lowering the efficacious dose, prevent or slow metabolism, and improving oral bioavailability and bioavailability following other routes of administration.
[0042] In one aspect, the invention provides a deuterated compound of (6aR,10a/?)-delta-9~ Tetrahydrocannabinol (THC), or a derivative thereof, represented by a compound of formula (A): wherein R1-R30 are each independently H or D.
[0043] In some embodiments of the compound of formula (A), R15 is D or OH. In some embodiments, when R3 is H, R15 is OH. In some embodiments, Ri 5 is D or OH; provided that when R? is H, R15 is OH. In some embodiments, Ri and R2 are D, In some embodiments, R3 is D. In some embodiments, R4 and Rs are D. In some embodiments, R4-R14 are D. In some embodiments, Rs -R14 are D.
[0044] In another aspect, the invention provides a deuterated compound of (6aA’,10aR)-delta-9- Tetrahydrocannabinol (THC) represented by a compound of formula (I): wherein R1-R14 are each independently H or D; and R15 is D or OH: provided that when R3 is H, R15 is OH.
[ 0045] In some embodiments of the compound of the invention of formula (I), Ri and R?, are D. In some embodiments, R3 is D. In some embodiments, Ri and Rs are D. In some embodiments,
R4-R14 are D. In some embodiments, Re -R14 are D.
[0046] In some embodiments, the compound of formula (I) is represented by compound 1-4, 1-6,
1-7, 1-14, 1-20, 1-24, 1-25, or 1-26:
[0047] In some embodiments, the compound of formula (I) or the compound of formula (A) is represented by any one of the following compounds:
[0048] In another aspect, the invention provides a deuterated compound of delta-9- tetrahydroeannabivarm (THCV) represented by a compound of formula (B):
(B) wherein R1-R9 and Rie-Rsi are each independently H or D; and R15 is D or OH.
[0049] In some embodiments of the compound of formula (B), R15 is D. In some embodiments, R15 is OH. In some embodiments, R3 is D. In some embodiments, Ri and R2 are D. In some embodiments, R4 and R5 are D. In some embodiments, R4- Rs and Rsi are D. In some embodiments, R and R2 are D; and R15 is D. In some embodiments, R4 and Rs are D; and R15 is D. In some embodiments, R+- R9 are D; and R15 is D.
[0050] In some embodiments, the invention provides a deuterated compound of delta-9- tetrahydroeannabivarm (THCV) represented by a compound of formula (II):
wherein R1-R9 and R31 are each independently H or D; and R15 IS D or OH.
[0051] In some embodiments of the compound of formula (II), R15 is D. In some embodiments, R15 is OH. In some embodiments, R3 is D. In some embodiments, Ri and R2 are D. In some embodiments, R4 and R5 are D. In some embodiments, Ra- Rs and R3i are D. In some embodiments, R and R2 are D; and R15 is D. In some embodiments, R4 and Rs are D; and R15 is D. In some embodiments, R4- R9 are D; and R15 is D.
[ 0052] In some embodiments, the compound of formula (II) is represented by compound II-4, II-
6, 11-7, 11-14, 11-15, or 11-16:
[0053] In some embodiments, the compound of formula (B) or the compound of formula (II) is represented by any one of the following compounds:
[0054] In one aspect, the invention provides a deuterated compound of cannabigerol (CBG), or a derivative thereof, represented by the compound of formula (AA) wherein R1-R32 are each independently H or D, provided that at least one of R.-R17 is D.
[0055] In some embodiments of the compound of formula (AA), R.-Rs are D. In some embodiments, R1-Rs, R13, and R14 are D. In some embodiments, R1-R17 are D. In some embodiments, R? and Rg are D. In some embodiments, R9-R17 are D.
[0056] In another aspect, the invention provides a deuterated compound of cannabigerol (CBG) represented by the compound of formula (Al) wherein R1-Rzo are each independently H or D, provided that at least one of R1-Rn is D.
[0057] In some embodiments of the compound of formula (Al), Rt-Rs are D. In some embodiments, R1-Ro, RB, and RM are D. In some embodiments, R1-R17 are D. In some embodiments, R? and Rs are D. In some embodiments, R9-R1 ? are D.
[0058] In some embodiments, the compound of formula (Al) is represented by compound A8, A13, Al 8, A19, A20, or A21 :
[0059] In some embodiments, the compound of formula (Al) or the compound of formula (AA) is represented by any one of the following compounds:
[0060] In one aspect, the invention provides a deuterated compound of cannabichromene (CBC), or a derivative thereof, represented by a compound of formula (AAA)
wherein R1-R30 are each independently H or D, provided that at least one of R1-R25 is D.
[0061] In some embodiments of the compound of formula (AAA), R1-R13 are D. In some embodiments, R8-Ru are D. In some embodiments, Rs~Ri3, R20, and R21 are D. In some embodiments, Rg-R?,4 are D. In other embodiments, R25 is D.
[0062] In another aspect, the invention provides a deuterated compound of cannabichromene
(CBC), or a deri vative thereof, represented by a compound of formula ( AAI)
OH
(AAI) wherein R1-R25 are each independently H or D, provided that at least one of R1-R25 is D.
[0063] In some embodiments of the compound of formula (AAI), R1-Ri 3 are D. In some embodiments, Rs~Ri3 are D. In some embodiments, RS-RB, R20, and R21 are D. In some embodiments, R8-R?4 are D. In other embodiments, R2.5 is D.
[0064] In some embodiments, the compound of formula (AAI) is represented by compound AA7,
AA 11 , AA 16, AA20, AA21 , AA22, AA23, or AA24:
(AA11)
(AA16),
(AA21),
[0065] In some embodiments, the compound of formula (AAI) or the compound of formula (AAA) is represented by any one of the following compounds:
[0066] In some embodiments, when a particular atomic position is designated as having deuterium or "D," it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%.
[0067] In some embodiments, the compound of the invention as described herein is deuterium- enriched at every position represented D. In some embodiments, deuterium enrichment at any position represented as D in the compound of formula (II) or in the compound of formula (B) is at least about 1%; at least about 5%; at least about 10%; at least about 15%; at least about 20%; at least about 25%; at least about 30%; at least about 35%; at least about 40%; at least about 45%; at least about 50%; at least about 55%; at least about 60%; at least about 65%; at least about 70%; at least about 75%; at least about 80%; at least about 85%; at least about 90%; at least about 95%; at least about 98%; at least about 99%; or at least about 100%.
[0068] In some embodiments, deuterium enrichment at any position represented as D in the compound of the invention is from about 1% to about 100%; from about 1% to about 98%; from about 1% to about 90%; from about 1% to about 75%; from about 1% to about 50%; from about 1% to about 25%; from about 1% to about 20%; from about 1% to about 10%; from about 1% to about 5%; from about 5% to about 100%; from about 5% to about 99%; from about 5% to about 98%; from about 5% to about 90%; from about 5% to about 75%; from about 5% to about 50%; from about 5% to about 25%; from about 5% to about 20%; from about 5% to about 10%; from about 10% to about 100%; from about 10% to about 99%; from about 10% to about 98%; from about 10% to about 90%; from about 10% to about 75%; from about 10% to about 50%; from about 10% to about 25%; from about 10% to about 20%; from about 20% to about 100%; from about 20% to about 99%; from about 20% to about 98%; from about 20% to about 90%; from about 20% to about 75%; from about 20% to about 50%; from about 20% to about 25%; from about 25% to about 100’%; from about 25% to about 99%; from about 25% to about 98%; from
about 25% to about 90%; from about 25% to about 75%; from about 25% to about 50%; from about 50% to about 100%; from about 50% to about 99%; from about 50% to about 98%; from about 50% to about 90%; from about 50% to about 75%; from about 75% to about 100%; from about 75% to about 99%; from about 75% to about 98%; from about 75% to about 90%; from about 90% to about 100%; from about 90% to about 99%; from about 90% to about 98%; from about 98% to about 100%; from about 98% to about 99%; or from about 99% to about 100%.
[0069] In some embodiments, the positions that are specifically deuterated as shown in the compounds of the invention as described herein are deuterium- enriched at about the same percentage. In other embodiments, the positions that are specifically deuterated as shown in the compounds of the invention as described herein are differentially deuterium enriched.
[0070] In some embodiments, the overall deuterium enrichment of the compounds of the invention as described herein is no less than 1%; no less than 5%; no less than 10%; no less than 15%; no less than 20%; no less than 25%; no less than 30%; no less than 35%; no less than 40%; no less than 45%; no less than 50%; no less than 55%; no less than 60%; no less than 65%; no less than 70%; no less than 75%; no less than 80%; no less than 85%; no less than 90%; no less than 95%; no less than 98%; no less than 99%; or no less than 100 %. Overall deuterium enrichment of the compounds of the invention can be determined using mass spectroscopy, according to methods known in the art.
[0071] As used herein, delta-9-tetrahydrocannabivarin (THCV or THV) is a homologue of (6a/?,10a/?)-delta-9-tetrahydrocannabinol (THC) having a propyl (3-carbon) side chain instead of a pentyl (5-carbon) group on the molecule.
[0072] The present invention further provides a pharmaceutical composition comprising a compound the invention as described herein and a pharmaceutically acceptable carrier.
[0073] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula (A) of the invention as described herein and a pharmaceutically acceptable earner. In some embodiments, the invention provides a pharmaceutical composition comprising a compound of formula (B) of the invention as described herein and a pharmaceutically acceptable carrier. In certain embodiments, the invention provides a pharmaceutical composition comprising a mixture of a compound of formula (A) and a compound of formula (B) and a pharmaceutically acceptable carrier.
[0074] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula (I) of the invention as described herein and a pharmaceutically acceptable earner. In some embodiments, the invention provides a pharmaceutical composition comprising a compound of formula (II) of the invention as described herein and a pharmaceutically acceptable carrier. In certain embodiments, the invention provides a pharmaceutical composition comprising a mixture of a compound of formula (I) and a compound of formula (II) and a pharmaceutically acceptable carrier.
[0075] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula (AA) of the invention and a pharmaceutically acceptable carrier. In some embodiments, the invention provides a pharmaceutical composition comprising a compound of formula (Al) of the invention and a pharmaceutically acceptable carrier.
[0076] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula (AAA) of the invention as described herein and a pharmaceutically acceptable carrier. In some embodiments, the invention provides a pharmaceutical composition comprising a compound of formula (A Al) of the invention as described herein and a pharmaceutically acceptable carrier.
[ 0077] As used herein, "pharmaceutical composition" refers to a therapeutically effective amount of a compound of the present invention, together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or earners. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g.; Tris-HCL, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzy l alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
[0078] A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given indication and administration regimen.
[0079] Numerous standard references are available that describe procedures for preparing various compositions or formulations suitable for administration of the compounds of the invention. Examples of methods of making formulations and preparations can be found in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Rachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
[0080] The mode of administration and dosage form are closely related to the therapeutic amounts of the compounds or compositions which are desirable and efficacious for the given treatment application.
[0081] The pharmaceutical compositions of the invention can be administered to a subject by any method known to a person skilled in the art. These methods include, but are not limited to, orally, parenterally, intravascularly, paracancerally, transmucosally, transderm ally, intramuscularly, intranasally, intravenously, intradermally, subcutaneously, sublingually, intraperitoneally, intra ventricularly, intracranially, intravaginally, by inhalation, rectally, or intratumorally. These methods include any means in which the composition can be delivered to tissue (e.g., needle or catheter). Alternatively, a topical administration may be desired for application to dermal, ocular, or mucosal surfaces. Another method of administration is via aerosol formulation. The pharmaceutical compositions may be administered topically to body surfaces and are thus formulated in a form suitable for topical administration. Suitable topical formulations include gels, ointments, creams, lotions, drops and the like. For topical administrations, the compositions are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical earner.
[0082] Suitable dosage forms include, but are not limited to, oral, rectal, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdennal, spinal, intrathecal, intraarticular, intra-arterial, sub-arachinoid, bronchial, lymphatic, and intra-uterile administration, and other dosage forms for systemic delivery of active ingredients. Depending on the indication, in some embodiments, the formulations are suitable for oral or topical administration.
[0083] As used herein "pharmaceutically acceptable carriers or diluents" are well known to those skilled in the art. The carrier or diluent may be a solid earner or diluent for solid formulations, a liquid carrier or diluent for liquid formulations, or mixtures thereof.
[0084] Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
[0085] In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as, suspensions, elixirs, and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. For solid oral preparations such as, chewable, soft-chew, gummy, powders, capsules, and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like. Due to their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form. If desired, tablets may be sugar coated or enteric coated by standard techniques.
[0086] For parenteral formulations, the carrier will usually comprise sterile water, though other ingredients may be included, such as ingredients that aid solubility or for preservation. Injectable solutions may also be prepared in which case appropriate stabilizing agents may be employed.
[0087] In some applications, it may be advantageous to utilize the active agent in a "vectorized" form, such as by encapsulation of the active agent in a liposome or other encapsulant medium, or by fixation of the active agent, e.g., by covalent bonding, chelation, or associative coordination, on a suitable biomolecule, such as those selected from proteins, lipoproteins, glycoproteins, and polysaccharides.
[0088] Methods of treatment using formulations suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, orally disintegrating tablets or films, or lozenges, each containing a predetermined amount of the active ingredient. Optionally, a suspension in an aqueous liquor or a non-aqueous liquid may be employed, such as a syrup, an elixir, an emulsion, or a draught.
[0089] A tablet may be made by compression or molding, or wet granulation, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules
which optionally is mixed with, for example, a binder, disintegrant, lubricant, inert diluent, surface active agent, or discharging agent. Molded tablets comprised of a mixture of the powdered active compound with a suitable earner may be made by molding in a suitable machine.
[0090] A syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient/ s). Such accessory ingredients) may include flavorings, suitable preservative, agents to retard crystallization of the sugar, and agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.
[0091] As used herein, flavorings can be added to all dosage forms when needed, including, but not limited to, solid oral forms and liquid oral forms.
[0092] Formulations suitable for parenteral administration may comprise a sterile aqueous preparation of the active compound, which in some embodiments is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may include suspending agents and thickening agents and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose form.
[0093] Parenteral administration may comprise any suitable form of systemic delivery. Administration may for example be intravenous, intra-arterial, intrathecal, intramuscular, subcutaneous, intramuscular, intra-abdominal (e.g., intraperitoneal), etc., and may be affected by infusion pumps (external or implantable) or any other suitable means appropriate to the desired admini stration modality.
[0094] Nasal and other mucosal spray formulations (e.g. inhalable forms) can comprise purified aqueous solutions of the active compounds with preservative agents and isotonic agents. Such formulations are in some embodiments adjusted to a pH and isotonic state compatible with the nasal or other mucous membranes. Alternatively, they can be in the form of finely divided solid powders suspended in a gas carrier. Such formulations may be delivered by any suitable means or method, e.g., by nebulizer, atomizer, metered dose inhaler, or the like.
[0095] Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acids.
[0096] Transdermal formulations may be prepared by incorporating the active agent in a thixotropic or gelatinous carrier such as a cellulosic medium, e.g., methyl cellulose or hydroxyethyl cellulose, with the resulting formulation then being packed in a transdermal device adapted to be secured in dermal contact with the skin of a wearer.
[0097] In addition to the aforementioned ingredients, compositions of this invention may farther include one or more ingredient selected from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
[0098] The formulations may be of immediate release, sustained release, delayed-onset release or any other release profile known to one skilled in the art.
[0099] For administration to mammals, it is expected that the physician will determine the actual dosage and duration of treatment, which will be most suitable for an individual and can vary with the age, weight, genetics and/or response of the particular individual.
[ 00100] The methods of the invention comprise administration of a compound at a therapeutically effective amount. The therapeutically effective amount may include various dosages.
[00101] A dosage unit of the compounds used in the present invention may comprise a single compound or mixtures thereof with additional therapeutic agents. A "‘dose'’ or "‘dosage unit” or “unit dosage” of a compound of the in vention as measured in milligrams refers to the milligrams of the compound of the invention, present in a preparation, regardless of the form of the preparation. A dosage unit may comprise a single compound or mixtures of compounds thereof.
[00102] In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.025-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.05-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.075-1.0 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01 -0.075 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01-0.05 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.01- 0.025 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 0.025-0.05 mg per day. In some embodiments, a compound of the
invention as described herein is administered at a dosage of 0.05-0.075 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1- 3000 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1-1000 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 1-500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 10- 500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 50-500 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 5- 250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 10-250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 20-250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25- 250 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-200 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-150 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25- 125 mg per day. In some embodiments, a compound of the invention as described herein is administered at a dosage of 25-100 mg per day.
[00103] In other embodiments, a compound of the invention as described herein is administered at a dose of 1-10 mg per day, 3-26 mg per day, 3-60 mg per day, 3-16 mg per day, 3-30 mg per day, 10-26 mg per day, 10-100 mg per day, 15-60 mg per day, 15-100 mg per day, 25-100 mg per day, 50-100 mg per day, 50-200 mg per day, 100-200 mg per day, 100-250 mg per day, 125-300 mg per day, 20-50 mg per day, 5-50 mg per day, 200-500 mg per day, 125-500 mg per day, 500- 1000 mg per day, 200-1000 mg per day, 1000-2000 mg per day, 1000-3000 mg per day, 125-3000 mg per day, 2000-3000 mg per day, 300-1500 mg per day or 100-1000 mg per day.
[00104] In some embodiments, a compound of the invention as described herein is administered at a dosage of 25 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 40 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 50 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 67.5 mg per day. In one
embodiment, a compound of the invention as described herein is administered at a dosage of 75 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 80 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 100 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 125 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 250 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 300 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 500 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 600 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 1000 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 1500 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 2000 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 2500 mg per day. In one embodiment, a compound of the invention as described herein is administered at a dosage of 3000 mg per day.
[00105] The methods may comprise administering a compound at various dosages. For exampie, the compound may be administered at a dosage of 3 mg, 10 mg, 30 mg, 40 mg, 50 mg, 80 mg, 100 mg, 120 mg, 125 mg, 200 mg, 250 nig, 300 mg, 450 mg, 500 mg, 600 mg, 900 mg, 1000 mg, 1500 mg, 2000 mg, 2500 mg or 3000 mg.
[00106] Alternatively, the compound may be administered at a dosage of 0.1 mg/kg/day. The compound may be administered at a dosage between 0.2 to 30 mg/kg/day, or 0.2 mg/kg/day, 0.3 mg/kg/day, 1 mg/kg/day, 3 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, 50 mg/kg/day or 100 mg/kg/day.
[00107] In some embodiments, a dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, liquid suspensions, and granules.
[00108] In some embodiments, the pharmaceutical composition of the invention comprises from about 0.01 mg to about 250 mg compound of the invention as described herein. In some embodiments, the pharmaceutical composition of the invention comprises from about 0.05 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 0. 1 mg to about 250 mg compound of the invention. In
some embodiments, the pharmaceutical composition of the invention comprises from about 0.5 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 1.0 mg to about 250 mg compound of the invention. In some embodiments, the pharmaceutical composition of the invention comprises from about 5 mg to about 250 mg compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 0.1 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 0,5 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 1.0 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 5.0 mg of compound of the invention. In some embodiment, the pharmaceutical composition of the invention comprises about 10 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 25 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 50 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 75 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 100 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 150 mg of compound of the invention. In another embodiment, the pharmaceutical composition of the invention comprises about 200 mg of compound of the invention.
[00109] The invention further provides a pharmaceutical composition comprising a compound of formula (1) or formula (II) for use in the treatment or prevention of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00110] The invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof,
comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal.
[00111] The invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00112] The invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (IT) for use in the treatment or prevention of a disease or disorder selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm -related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelnian syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity
disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
[00113] The invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
[001 14] The present invention further provides a pharmaceutical composition comprising a compound of formula (I) or formula (II) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or
disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In other embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
[00115] In some embodiments, the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti-convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory agent. In some embodiments, the compound of the invention is an anti-depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some embodiments, the compound of the invention is an anti-ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent. In some embodiments, the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an ocular hypotensive agent. In some embodiments, the compound of the invention is an immunosuppressive agent.
[00116] The invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00117] The invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any’ combination thereof.
[00118] The invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of aggression, fear, phobias, generalized anxiety- disorder, or separation anxiety’ in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal.
[001 19] The present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep -wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In
some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary’ insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
[ 00120] The present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (Al) tor use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically' effective amount of a compound of the invention as described herein. In some embodiments, the pain is chronic pain. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of multiple sclerosis
ill a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (AT) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
[00121] The present invention further provides a pharmaceutical composition comprising a compound of formula (Al) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, tor example, Parkinson's disease, Huntington's disease, and/or Alzheimer’s disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
[00122] In some embodiments, the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the
compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti -convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory’ agent. In some embodiments, the compound of the invention is an anti- depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some embodiments, the compound of the invention is an anti-ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent. In some embodiments, the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an immunosuppressi ve agent.
[00123] The invention further provides a pharmaceutical composition comprising a compound of formula (AAA) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00124] The invention further provides a pharmaceutical composition comprising a compound of formula (AAA) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00125] The invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain,
musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00126] The invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal.
[00127] The invention further provides a pharmaceutical composition comprising a compound of formula ( AAI) for use in the treatment of a disease or disorder, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00128] The present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety’ disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease
or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety' disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency.
[00129] The present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiment, the pain is chronic pain. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of multiple sclerosis in a subject in need thereof) comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the present invention provides a
pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein.
[00130] The present invention further provides a pharmaceutical composition comprising a compound of formula (AAI) for use in the treatment or prevention of a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. Tn some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson’s disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder.
[00131] In some embodiments, the compound of the invention is an analgesic agent. In some embodiments, the compound of the invention is an anti-anxiety agent. In some embodiments, the compound of the invention is an anti-cancer agent. In some embodiments, the compound of the invention is an anti-bacterial agent. In some embodiments, the compound of the invention is an anti-convulsive agent. In some embodiments, the compound of the invention is an antiinflammatory agent. In some embodiments, the compound of the invention is an anti-depressant agent. In some embodiments, the compound of the invention is an anti-emetic agent. In some
embodiments, the compound of the invention is an anti -ischemic agent. In some embodiments, the compound of the invention is an anti-psychotic agent. In some embodiments, the compound of the invention is an anti-spasmodic agent. In some embodiments, the compound of the invention is a bone-stimulant agent. In some embodiments, the compound of the invention is an immunosuppressive agent.
[00132] In some embodiments, the pharmaceutical composition of the invention is in the form of a capsule, a tablet, or a liquid suspension. In other embodiments, the pharmaceutical composition of the invention is in an oral dosage unit form.
[00133] The exact dose and regimen of administration of the composition will necessarily be dependent upon the therapeutic or nutritional effect to be achieved and may vary with the particular formula, the route of administration, and the age and condition of the individual subject to whom the composition is to be administered.
[00134] In another embodiment, a pharmaceutical composition is prepared for once daily administration. In another embodiment, a pharmaceutical composition is prepared for more than once daily administration, for example, twice daily, three times daily, four times daily, etc.
[00135] In some embodiments, the compounds of the invention as described herein, or pharmaceutical compositions containing either or both, can provide an increased half-life in a mammal over the corresponding non-deuterated compound e.g., tetrahydrocannabinol or tetrahydrocannabivarin, as measured using an in vitro liver microsomal assay.
[00136] In some embodiments, the concentration of the compound of the invention as d escribed herein, in the pharmaceutical compositions of the present invention is about 100%, 90%, 80%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 22.5%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 1 1%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01 %, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001%. It should be appreciated that the concentration of the compound of the invention in the pharmaceutical compositions described herein can also be expressed as range defined by any two of the concentrations as described here. It should be further appreciated that the concentration percentages as described herein can be on a weigh (/weight, weighVvolume, or a volume/volume basis.
[00137] In some embodiments, the amount of the compound of the invention as described herein in the pharmaceutical compositions of the present invention is about 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 nig, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, 100 mg, 090 mg, 80 mg, 70 mg, 60 mg, 50 mg, 40 mg, 30 mg, 20 mg, 10 mg, 9 mg, 8 mg, 7 mg, 6 mg, 5 mg, 4 mg, 3 mg, 2 mg, 1 mg, 0.9 mg, 0.8 mg, 0,7 mg, 0.6 mg, 0.5 mg, 0.4 mg, 0.3 mg, 0,2 mg, or 0,1 mg. It should be appreciated that the amount of the compound of the invention in the pharmaceutical compositions described herein can also be expressed as range defined by any two of the amounts as described here.
[00138] In some aspects, the administration of a compound of the invention provides one or more of the following: (1) a decrease in inter-individual variation in plasma levels of the compound or a metabolite thereof; (2) an increase in average plasma levels of the compound or a decrease in average plasma levels of at least one metabolite of the compound per dosage unit; (3) a decrease in the inhibition of, and/or metabolism by at least one cytochrome P450 or monoamine oxidase isoform in the subject; (4) a decrease in metabolism via at least one polymorphically- expressed cytochrome P450 isoform in the subject; (5) at least one statistically-significant improvement in disorder-control and/or disorder-eradication endpoint; (6) an improvement in clinical effect during the treatment of the disorder, (7) prevention of recurrence, or delay of decline or appearance, of abnormal alimentary' or hepatic parameters as the primary clinical benefit, or (8) reduction or elimination of deleterious changes in any adverse event, including diagnostic hepatobiliary function endpoints, as compared to the corresponding non-deuterated compound, e.g., tetrahydrocannabinol or tetrahydrocannabivarin.
[00139] In certain embodiments, inter-individual variation in plasma levels of the compounds as disclosed herein, or metabolites thereof, decreases; average plasma levels of the compound as disclosed herein increase; average plasma levels of a metabolite of the compound as disclosed herein decrease; inhibition of a cytochrome P450 or monoamine oxidase isoform by a compound as disclosed herein decrease; or metabolism of the compound as disclosed herein by at least one polymorphically-expressed cytochrome P450 isoform decrease; by greater than about 5%, greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, or by greater than about 50% as compared to the corresponding non-deuterated compound. In some embodiments, the compound of the invention can provide about a 40% or greater increase in halflife in a mammal over the corresponding non-deuterated compound. In certain embodiments, the
compound of the invention can provide about a 45% or greater increase in halt-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 70% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 75% or greater increase in half-life in a mammal over the corresponding non- deuterated compound. In certain embodiments, the percentage increase in half-life of the compound of the invention over the corresponding non-deuterated compoundcan be expressed as a range, such as between 40% and 75%; between 40% and 70%; between 40% and 45%; between 45% and 75%; between 45’% and 70%; or, between 70% and 75%.
[00140] In some embodiments, the compound of the invention can provide about a 30% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 35% or greater increase in halflife in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 100% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 105% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the percentage increase in halflife of the compound of the invention over the corresponding non-deuterated compoundcan be expressed as a range, such as between 30% and 105%: between 30% and 100%: between 30% and 35%; between 35% and 105%; between 35% and 100%.
[00141] In certain embodiments, a pharmaceutical composition including the compound of the invention can provide about a 10% or greater increase in half- life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 20% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 30% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 40% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 50% or greater increase half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 60% or greater increase in half-life in a mammal over the
corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 70% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about an 80% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 90% or greater increase in half-life in a mammal over the corresponding non-deuterated compound. In certain embodiments, the pharmaceutical composition can provide about a 100% increase in half-life in a mammal over the corresponding non-deuterated compound.
[00142] In some embodiments, the percentage increase in half-life of a pharmaceutical composition including the compound of the invention over the corresponding non-deuterated compound is from about 10% to about 105%: from about 10% to about 100%; from about 10% to about 90%; from about 10% to about 80%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to about 105%; from about 20% to about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 70%; from about 20% to about 60%; from about 20% to about 50%; from about 20% to about 40%; from about 20% to about 30%; from about 30% to about 105%; from about 30% to about 100%; from about 30% to about 90%; from about 30% to about 80%; from about 30% to about 70%; from about 30% to about 60%; from about 30% to about 50%; from about 30% to about 40%; from about 40% to about 105%; from about 40% to about 100%; from about 40% to about 90%; from about 40% to about 80%; from about 40% to about 70%; from about 40% to about 60%; from about 40% to about 50%; from about 50% to about 105%; from about 50% to about 100%; from about 50% to about 90%; from about 50% to about 80%; from about 50% to about 70%; from about 50% to about 60%; from about 60% to about 105%; from about 60% to about 100%; from about 60% to about 90%; from about 60% to about 80%; from about 60% to about 70%; from about 70% to about 105%; from about 70% to about 100%; from about 70% to about 90%; from about 70% to about 80%; from about 80% to about 105%; from about 80% to about 100%; from about 80% to about 90%; from about 90% to about 105%; or from about 90% to about 100%.
[00143] It should be appreciated that the disclosed percent increase in measured half-life in a mammal can also be expressed as a range including any of the previously described percent levels,
in any combination, as well as including the specific percentages tailing within the ranges, such that increased half-life in a mammal can be expressed, in one embodiment, as a range of about 30% to about 40%, and it will be understood that such a described range includes percent values of 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, and 39%.
[00144] In some embodiments, the bioavailability of the compound of the invention is measured by AUC. In some embodiments, the compound of the invention can provide about a 20% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 70% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 80% or greater increase in bioavailability over the corresponding non- deuterated compound. In certain embodiments, the compound of the invention can provide about a 90% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 95% or greater increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the compound of the invention can provide about a 100% increase in bioavailability over the corresponding non-deuterated compound. In certain embodiments, the percentage increase in bioavailability of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 100% between 40% and 100%; between 70% and 100%; between 40% and 45%; between 45% and 75%; between 45% and 70%; or, between 70% and 100%.
[00145] In some embodiments, the percentage increase in bioavailability of a pharmaceutical composition including the compound of the invention over the pharmaceutical composition comprising the corresponding non-deuterated compoundis from about 0.01 % to about 10%, or from about 0.01% to about 7.5%, or from about 0.01% to about 5%, or from about 0.01% to about 2.5%, from about 0.05% to about 10%, from about 0.05% to about 5%, from about 0.5% to about 10%, from about 1 .0% to about 10%, from about 2.5% to about 10%, from about 5.0% to about 10%, from about 1.0% to about 7.5%, from about 1.0% to about 5.0%, from about 10% to about 100%; from about 10% to about 90%; from about 10% to about 80%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to
about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 70%; from about 20% to about 60%; from about 20% to about 50%; from about 20% to about 40%; from about 20% to about 30%; from about 30% to about 100%; from about 30% to about 90%; from about 30% to about 80%; from about 30% to about 70%; from about 30% to about 60%; from about 30% to about 50%; from about 30% to about 40%; from about 40% to about 100%; from about 40% to about 90%; from about 40% to about 80%; from about 40% to about 70%; from about 40% to about 60%; from about 40% to about 50%; from about 50% to about 100%; from about 50% to about 90%; from about 50% to about 80%; from about 50% to about 70%; from about 50% to about 60%; from about 60% to about 90%; from about 60% to about 80%; from about 60% to about 70%; from about 70% to about 100%; from about 70% to about 90%; from about 70% to about 80%; from about 80% to about 100%; from about 80% to about 90%; or from about 90% to about 100%.
[00146] In some embodiments, the bioavailability of the compound of the invention is measured by ( max. In some embodiments, the compound of the invention can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 50% or greater increase in bioavai lability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 80% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 100% or greater increase in bioavailability’ over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 125% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 150% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of the invention can provide about a 200% increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the percentage increase in bioavailability' of the compound of the invention over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 200% between 40% and 200%; between 70% and 200%; between 40% and 100%; between 45% and 125%; between 45% and 150%; or, between 70% and 200%,
[00147] In some embodiments, the bioavailability of the compound of the invention is measured by Crnax. In some embodiments, the compound of formula (I) can provide about a 40% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 50% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 80% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 100% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 125% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 150% or greater increase in bioavailability over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the compound of formula (I) can provide about a 200% increase in bioavailability' over the corresponding non-deuterated compound, e.g., tetrahydrocannabinol. In certain embodiments, the percentage increase in bioavailability of the compound of formula (I) over the corresponding non-deuterated compound can be expressed as a range, such as between 20 and 200% between 40% and 200%; between 70% and 200%; between 40% and 100%; between 45% and 125%; between 45% and 150%; or, between 70% and 200%.
[00148] In some embodiments, the percentage increase in bioavailability of a pharmaceutical composition including the compound of the invention over the pharmaceutical composition comprising the corresponding non-deuterated compoundis from about 0.01% to about 10%, or from about 0.01% to about 7.5%, or from about 0.01% to about 5%, or from about 0.01% to about 2.5%, from about 0.05% to about 10%, from about 0.05% to about 5%, from about 0.5% to about 10%, from about 1.0% to about 10%, from about 2.5% to about 10%, from about 5.0% to about 10%, from about 1.0% to about 7.5%, from about 1.0% to about 5.0%, from about 10% to about 200%; from about 10% to about 150%; from about 10% to about 100%; from about 10% to about 70%; from about 10% to about 60%; from about 10% to about 50%; from about 10% to about 40%; from about 10% to about 30%; from about 10% to about 20%; from about 20% to about 200%; from about 20% to about 100%; from about 20% to about 90%; from about 20% to about 80%; from about 20% to about 70%; from about 20% to about 60%; from about 20% to about 50%; from about 20% to about 40%; from about 20% to about 30%; from about 30% to
about 200%; from about 30% to about 150%; from about 30% to about 100%; from about 30% to about 80%; from about 30% to about 70%; from about 30% to about 60%; from about 30% to about 50%; from about 30% to about 40%; from about 40% to about 200%; from about 40% to about 150%; from about 40% to about 100%; from about 40% to about 80%; from about 40% to about 70%; from about 40% to about 60%; from about 40% to about 50%; from about 50% to about 200%; from about 50% to about 150%; from about 50% to about 100%; from about 50% to about 80%; from about 50% to about 70%; from about 50% to about 60%; from about 60% to about 200%; from about 60% to about 150%; from about 60% to about 100%; from about 60% to about 80%; from about 60% to about 70%; from about 70% to about 100%; from about 70% to about 90%; from about 70% to about 80%; from about 80% to about 200%; from about 80% to about 150%; or from about 90% to about 100%.
[00149] Plasma levels of the compound of the invention as described herein, or metabolites thereof, may be measured using the methods described by Li et al. Rapid Communications in Mass Spectrometry 2005, 19, 1943-1950; De Francia et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(18+19), 1721-1726; Parise et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(20+21), 1894-1900; Pursche et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2007, 852(1-2), 208-216; Haouala et al, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877(22), 1982-1996; and any references cited therein and any modifications made thereof.
[00150] Examples of cytochrome P450 isofonns in a mammalian subject include, but are not limited to, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S 1, CYP3A4, CYP3A5, CYP3A5P1 , CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F1 1, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1 , CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1 , CYP27B1, CYP39, CYP46, and CYP51.
[00151] Examples of monoamine oxidase isofonns in a mammalian subject include, but are not limited to, MAO A, and MAOB.
[00152] The inhibition of the cytochrome P450 isoform is measured by the method of Ko et al, British Journal of Clinical Pharmacology 2000, 49, 343-351. The inhibition of the MAOA isofonn
is measured by the method of Weyler eZ al, J. Biol Chem. 1985, 260, 13199-13207. The inhibition of the MAOB isoform is measured by the method of Uebelhack et al, Pharmacopsychiatry 1998, 31, 187-192.
[00153] Examples of polymorphically-expressed cytochrome P450 isoforms in a mammalian subject include, but are not limited to, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
[00154] The metabolic activities of liver microsomes, cytochrome P450 isoforms, and monoamine oxidase isoforms are measured by the methods described herein.
[00155] Examples of improved disorder-control and/or disorder-eradication endpoints, or improved clinical effects include, but are not limited to, major cytogenetic response, complete cytogenetic response, complete hematologic response, complete molecular remission, improved progression-free survival, increase in overall survival rate, tumor shrinkage, increased median overall survival time, improved overall response rate, and improved disease control rate.
[00156] Examples of diagnostic hepatobiliary function endpoints include, but are not limited to, alanine aminotransferase ("ALT”), serum glutamic-pyruvic transaminase ("SGPT”), aspartate aminotransferase ("AST" or "SGOT"), ALTZAST ratios, serum aldolase, alkaline phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl transpeptidase ("GGTP," "y-GTP," or "GGT"), leucine aminopeptidase ("LAP"), liver biopsy, liver ultrasonography, liver nuclear scan, 5 '-nucleotidase, and blood protein. Hepatobiliary endpoints are compared to the stated normal levels as given in "Diagnostic and Laboratory Test Reference", 4th edition, Mosby, 1999.
[00157] In some embodiments, the present invention provides methods for treating cancer in a subject. In some embodiments, the subject is a mammal. In other embodiments, the subject is a human. These methods can be achieved by administering to the subject a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention. In one embodiment, the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung tumors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma. In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+- ( ML).
[00158] In some embodiments, the present invention provides methods for treating a neurodegenerative disease or disorder in a subject. In some embodiments, the subject is a mammal.
In some embodiments, the subject is an animal. In other embodiments, the subject is a human. These methods include administering to the mammal a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention. In one embodiment, the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, or progressive muscular atrophy.
[00159] In some embodiments, the described methods of treatment can additionally include administering to the subject one or more additional therapeutic agents. Such other therapeutic agents may be administered, by a route and in an amoun t commonly used therefore, simultaneously or sequentially with a compound or composition of the present invention. In certain embodiments, the compounds disclosed herein can be combined with one or more alkylating agents, antimetabolite agents, mitotic inhibitors, tyrosine kinase inhibitors, topoisomerase inhibitors, cancer immunotherapy monoclonal antibodies, anti-tumor agents, and anti-cancer agents.
[00160] In some embodiments related to the methods of treating cancer in a subject, the compounds of the invention as described herein can be combined with one or more alkydating agents, including, but not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
[00161] In some embodiments, the compounds of the invention as described herein can be combined with one or more anti -metabolite agents, including, but not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafor, camiofur, capecitabine and gemcitabine.
[00162] In some embodiments, the compounds of the invention as described herein can be combined with one or more mitotic inhibitors, including, but not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
[00163] In some embodiments, the compounds of the invention as described herein can be combined with one or more tyrosine kinase inhibitors, including, but not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
[00164] In some embodiments, the compounds of the invention as described herein can be combined with one or more topoisomerase inhibitors, including, but not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan,
[00165] In some embodiments, the compounds of the invention as described herein can be combined with one or more cancer immunotherapy monoclonal antibodies, including, but not limited to, rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, and trastuzumab.
[00166] In some embodiments, the compounds of the invention as described herein can be combined with one or more anti-tumor agents, including, but not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea. [0096] In certain embodiments, the compounds disclosed herein can be combined with one or more anti-cancer agents, including, but not limited to, amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
[00167] The compounds of the invention as descried herein can also be administered in combination with other classes of compounds, including, but not limited to, norepinephrine reuptake inhibitors (NRIs) such as atomoxetine; dopamine reuptake inhibitors ( D A R Is ), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotoninmorepinephrine-dopamine-reuptake-inhibit.ors (SNDRls), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such as ifetroban; potassium channel openers; thrombin inhibitors, such as hirudin; hypothalamic phospholipids; growth factor inhibitors, such as modulators of PDGF activity; platelet activating factor (PAF) antagonists; anti-platelet agents, such as GPIIb/IIIa blockers (e.g., abdximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and CS-747), and aspirin; anticoagulants, such as warfarin; low molecular weight heparins, such as enoxaparin; Factor Vila Inhibitors and Factor Xa Inhibitors; renin inhibitors; neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP- ACE
inhibitors), such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride, and spironolactone; thrombolytic agents, such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC); anti-diabetic agents, such as biguanides (e.g. metformin), glucosidase inhibitors (e.g,, acarbose), insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists; mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; farnesyl-protein transferase inhibitors; hormonal agents, such as glucocorticoids (e.g., cortisone), estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate; micro tubule-disruptor agents, such as ecteinascidins; microtubule-stabilizing agents, such as paclitaxel, docetaxel, and epothilones A-F; plant-derived products, such as vinca alkaloids, epipodophyllotoxins, and taxanes; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and cyclosporins; steroids, such as prednisone and dexamethasone; cytotoxic drugs, such as azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as tenidap; anti-TNF antibodies or soluble TNF receptor, such as etanercept, rapamycin, and leflunimide; and cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; and miscellaneous agents such as, hydroxyurea,
procarbazine, mitotane, hexamethylmelamine, gold compounds, platinum coordination complexes, such as cisplatin, satraplatin, and carboplatin.
[00168] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00169] hi a further aspect, the present invention provides a method of treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, 11-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof In some embodiments, the subject in the method of the invention is a
mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00170] The invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (I), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety’, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00171] The invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (II), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00172] The invention further provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a combination of the compound of formula (I) and the compound of formula (II), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity', Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00173] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, U-4, II-6, 11-7, 11-14, 11-15, or 11-16, wherein said disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety' disorder, or separation anxiety' in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal. In some embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a horse. In some embodiments, the subject is a dog. In some embodiments, the subject is a cat. In some embodiments, the subject is a ferret.
[00174] In a further aspect, the present invention provides a method of treating or preventing a subject suffering from a disease or disorder selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders,
neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity', type 2 diabetes, and testosterone insufficiency, wherein said method comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1- 14, 1-20, 1- 24, 1-25, 1-26, 11-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity’ disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00175] In another aspect, the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
25. 1-26, II-4, 11-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the pain is chronic pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-
6. 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, 11-4, JI-6, TI-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00176] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
25, 1-26, II-4, 11-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof, wherein said disease or
disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In other embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00177] In another aspect, the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, II-4, IT-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the
postoperative inflammation is associated with orthopedic surgeiy, soft-tissue surgery, or dental surgery.
[00178] In another aspect, the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, IT-6, II-7, 11-14, II- 15, or II- 16, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00179] In yet another aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, IT-6, TI-7, 11-14, 11-15, or IT-16, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00180] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic
animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00181] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00182] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, , e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1- 25, 1-26, II-4, II-6, IT-7, 11-14, 11-15, or 11-16, or any combination thereof, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the subject is a dog. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the causes of anorexia include, but are not limited to, secondary to chemo, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, and iatrogenic problems. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the aggression is dominance aggression, tear aggression, intraspecific aggression, or territorial aggression.
[00183] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, , e.g., a compound of formula (A) or (B), formula (I) or (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-
25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any combination thereof wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma. In some embodiments, the subject is a cat. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
[00184] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourete's syndrome, or emesis, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an ani-ma-h
[00185] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00186] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a
compound of formula (AA), or any one of compounds A8, Al 3, and Al H-A22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00187] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegen erative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00188] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00189] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, or Rett syndrome.
[00190] The invention further provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of fomulauAJd; wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is anxiety, infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the subject in the method of the invention is a
mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00191] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety' disorder, seasonal affective disorder, attention deficit hyperactivity' disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary' insomnia circadian rhythm -related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity’ disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments,
the disease or disorder is epilepsy. hi some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00192] In another aspect, the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof. In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds 8, 13, and 18-22, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A 13, and A18-A22, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00193] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering io said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. Tn some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. Tn some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. Tn some embodiments, the disease or disorder is cancer. Tn some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the subject in the method of the invention is a mammal. Tn other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00194] In another aspect, the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and Al 8-A22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or
a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
[00195] In another aspect, the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00196] In yet another aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00197] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, AI3, and A18-A22, or any combination thereof. In some
embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00198] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds 8, 13, and 18-22, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00199] In another aspect, the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula OVA), or any one of compounds A8, A13, and A18-A22, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00200] In yet another aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00201] hi a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof,
comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00202] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as descried herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00203] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, A13, and A18-A22, or any combination thereof wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures. In some embodiments, the subject is a dog. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
[00204] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (Al), or a compound of formula (AA), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof wherein said disease or disorder is anorexia, anxiety,
epilepsy, or glaucoma. In some embodiments, the subject is a cat. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary' anorexia, e.g., secondary’ to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
[00205] In some embodiments, the method of the invention further comprises the administration of an additional therapeutic agent. In some embodiments, the additional therapeutic agent is antiemetics or analgesics. In some embodiments, the analgesic is carprofen, meloxicam, carbamazepine, gabapentin, pregabalin, acetaminophen, acetylsalicyclic acid, ibuprofen, or naproxen. In some embodiments, the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, and palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
[00206] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00207] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer,
depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00208] In a further aspect, the present invention provides a method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof
[00209] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof.
[00210] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[0021 1] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, or Rett syndrome.
[00212] The invention further provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject a compound of formula (AAI), wherein the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments,
the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof.
[00213] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, wherein said disease or disorder is aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein. In some embodiments, the subject is an animal. In some embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a horse. In some embodiments, the subject is a dog. In some embodiments, the subject is a cat. In some embodiments, the subject is a ferret.
[00214] In a further aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary' insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or
disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivitydisorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[ 00215 ] In another aspect, the present invention provides a method of treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g. , a compound of formula (AAI), or a compound of formula (AAA), or any one of compound A.A7, A.A1 1, AA16, and A.A20-A.A24, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AA 16, and AA20- AA24, or any combination thereof. In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as
described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof. Tn some embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1, AAI 6, and AA20-AA24, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00216] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity', and metabolic syndrome -related disorders. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington’s disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a
cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00217] In another aspect, the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AAI 1 , AAI 6, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperati ve pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery , soft-tissue surgery', or dental surgery1.
[00218] In another aspect, the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1 , AA16, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00219] In yet another aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need
thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AA16, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00220] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00221] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00222] In another aspect, the present invention provides a method of treating or preventing pain or inflammation associated with osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as
described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1 , AA16, and AA20-AA24, or any combination thereof. Tn some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00223] In yet another aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with orthopedic surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11, AAI 6, and AA20-AA24, or any combination thereof. In some embodiments, the subject is a human. Tn some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00224] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with soft-tissue surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1, AA16, and AA20-AA24, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00225] In a further aspect, the present invention provides a method of treating or preventing a postoperative pain or inflammation associated with dental surgery in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA1 1, AA16, and AA20-AA24, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse or a cat.
[00226] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a
compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, phobias, epilepsy, or seizures. IN some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
[00227] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of the invention as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compound AA7, AA11 , AA16, and AA20-AA24, or any combination thereof, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma. In some embodiments, the subject is an animal. In some embodiments, the subject is a cat. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency.
[ 00228] In some embodiments, the method of the invention further comprises the administration of an additional therapeutic agent. In some embodiments, the additional therapeutic agent is antiemetics or analgesics. In some embodiments, the analgesic is meloxicam, carprofen, carbamazepine, gabapentin, pregabalin, acetaminophen, acetylsalicyclic acid, ibuprofen, or naproxen. In some embodiments, the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, and palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine,
dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
[00229] In some embodiments, the method of the invention further comprises the administration of an additional therapeutic agent. In some embodiments, the additional therapeutic agent is carprofen, meloxicam, fluoxetine hydrochloride, comipramine hydrochloride, or phenobarbital
[00230] The present invention further provides a combination therapy. The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic disorder described in the present invention. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. Tn addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drag combination in treating the disorders described herein.
[00231 ] The present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administering a compound of formula (A) or a compound of formula (B) in combination with the therapeutic agent.
[00232] It is one aspect of the invention that a combination therapy that includes a deuterated compound of formula (A) or formula (B) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (A) or formula (B).
[00233] It is another aspect of the invention that a combination of a deuterated tetrahydrocannabinol compound of formula (A) or a deuterated tetrahydrocannabivarm compound of formula (B) with at least one additional therapeutic agent as described herein may minimizing toxicity during treatments and result in a decrease in the onset of resistance development.
[00234] In one aspect, the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) and at least one additional therapeutic agent,
wherein R1-R30 are each independently H or D,
[00235] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[00236] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia,
psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia nervosa, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
[00237] In some embodiments, the disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency .
[00238] In some embodiments, the disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
[00239] In some embodiments, the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia.
[00240] In some embodiments, the disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
[00241] In some embodiments, the compound of formula (A) is a deuterated compound of (6aR, 10aR)-delta-9-Tetrahydrocannabinol (THC), or a derivative thereof,
[00242] In some embodiments of the compound of formula (A), R15 is D or OH. In some embodiments, when R3 is H, R15 is OH. In some embodiments, R15 is D or OH; provided that when Rs is H, R15 is OH. In some embodiments, Ri and R2 are D. In some embodiments, Ri is D. In some embodiments, R4 and Rs are D. In some embodiments, R4-R14 are D. In some embodiments, Rs -Ri4 are D.
[00243] In some embodiments, the compound of formula (A) is represented by a compound of formula (I): wherein
Rj~Ri4 are each independently H or D; and
Ri 5 is D or OH; provided that when Rs is H, Ri s is OH.
[00244] In some embodiments of the compound of formula (A) or (I), Ri and R2 are D. In some embodiments, Rs is D. In some embodiments, R4 and Rs are D. In some embodiments, R4-Ri4 are D. In some embodiments, Rs -RM are D.
[00245] In some embodiments, the compound of formula (A) or (I) is represented by compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26:
[00246] In another aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) and at least one additional therapeutic agent.
(B) wherein R1-R9 and R15-Rn are each independently H or D; and R15 is D or OH,
[00247] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourete's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jetlag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington’s disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[00248] In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia,
psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia nervosa, dementia, cachexia, HIV wasting syndrome, Tourette’s syndrome, or emesis, or any combination thereof.
[00249] In some embodiments, the disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smifh-Magenis syndrome, major depressive disorder, primary' insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency .
[00250] In some embodiments, the disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
[00251] In some embodiments, the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia.
[00252] In some embodiments, the disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia, anxiety', epilepsy, osteoarthritis, or glaucoma.
[00253] In some embodiments, the compound of formula (B) is a deuterated compound of delta- 9-tetrahydrocannabivarin (THCV), or a derivative thereof.
[00254] In some embodiments of the compound of formula (B), R15 is D. In some embodiments, R15 is OH. In some embodiments, Rs is D. In some embodiments, Ri and Re are D. In some embodiments, R4 and R5 are D. In some embodiments, R4- R9 and R31 are D. In some embodiments, Ri and R2 are D; and R15 is D. In some embodiments, R4 and Rs are D; and R15 is D. In some embodiments, Rt- R9 are D; and R15 is D.
[00255] In some embodiments, the compound of formula (B) is represented by a compound of formula (II): wherein R1-R9 and Rs; are each independently H or D; and R15 is D or OH.
[00256] In some embodiments of the compound of formula (B) or (II), R15 is D. In some embodiments, R15 is OH. In some embodiments, R3 is D. In some embodiments, Ri and R2 are D.
In some embodiments, R4 and R5 are D. In some embodiments, R<- R9 and R31 are D. In some embodiments, Ri and R? are D; and R15 is D. In some embodiments, R4 and Rs are D; and R15 is
D. In some embodiments, R+- R9 are D; and R15 is D.
[00257] In some embodiments, the compound of formula (B) or (II) is represented by compound
II-4, 11 -6, II-7, II- 14, 11- I 5 , or 11-16:
(IT- 16).
[00258] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) or formula (B) and at least one additional therapeutic agent.
[00259] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A) as described herein and at least an additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (A) is the compound of formula (I), or any one of compounds 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, and I- 26, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00260] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (B) as described herein and at least an additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that
can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non- human animal.
[00261] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A) as described herein and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any' combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment andprevention of the disease or disorder. In some embodiments, the compound of formula (A) is the compound of formula (I), or any' one of compounds 1-4, 1-6, 1- 7, 1-14, 1-20, 1-24, 1-25, and 1-26, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00262] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (B) as described herein and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any' combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described
anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound IT-4, II-6, TI-7, IT-14, U-15, or 11-16, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00263] In a farther aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A), or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1- 24, 1-25, 1-26, 11-4, II-6, TI-7, IT- 14, IT- 15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivitydisorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective
disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivitydisorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a nonhuman animal.
[00264] In another aspect, the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, chemo-related nausea, vomiting, and anorexiain a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11- 7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent. In some embodiments, the pain is chronic pain. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent. In some embodiments, the pain is chronic pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (1), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, IT-6, II-7, IT-14, 11-15, or II- 16, or any compound as descried herein, and at least one additional therapeutic agent. In some
embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (1), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1- 26, 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, IT-4, II-6, IT-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00265] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, 11-4, 11-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In some embodiments, the causes of anorexia include, but are not limited to, secondary to chemo, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, and iatrogenic problems.
[00266] In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the disease or disorder is a compulsive disorder. In some embodiments, the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog.
[00267] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is anxiety. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In certain embodiments, the subject is a cat.
[00268] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson’s disease, Huntington's
disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington's disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal.
[00269] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, I- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia. In some embodiments, the disease or disorder is pain. In some embodiments, the pain is chronic pain. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is chemo-related nausea, vomiting, and anorexia. In some embodiments, the additional therapeutic agent is the one as
known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non- human animal.
[00270] In another aspect, the present invention provides a method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (A) as described herein, or a compound of formula (B), or a compound of formula (I), or a compound of formula (II), or compound 1-4, I- 6, 1-7, 1-14, 1-20, 1-24, 1-25, 1-26, II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compound as descried herein, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used tor the treatment or prevention of pain or inflammation. In some embodiments, the additional therapeutic agent is as described anywhere herein tor the treatment and prevention of pain or inflammation. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In other embodiments, the subject is a horse or a cat. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
[00271] In some embodiments, the ‘‘therapeutic agent” as used herein refers to an agent or a drug that is capable of providing a local or systemic biological, physiological, or therapeutic effect in
the biological system to which it is applied. The “therapeutic agent” can be any agent or drug as known in the art or being currently developed. In some embodiments, the terms “therapeutic agent” and “therapeutic drug” are used interchangeably. In some embodiments, the “therapeutic agent” refers to the “additional therapeutic agent” as used herein.
[00272] In some embodiments of the method of the invention, the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
[00273] In some embodiments, the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
[00274] In one aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an analgesic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent. In some embodiments, the disease or disorder is pain, e.g., acute pain or chronic pain. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00275] In one aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an analgesic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent. In some embodiments, the disease or disorder is pain, e.g., acute pain or chronic pain. In some
embodiments, the compound of formula (B) is the compound of (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00276] In some embodiments, the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent. In some embodiments, the non-opioid analgesic agent is meloxicam, acetaminophen, aspirin, ibuprofen, carprofen, fenbuprofen, flubiproten, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin. In certain embodiments, the analgesic agent is naproxen sodium or magnesium. In some embodiments, the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, or naproxen.
[00277] In some embodiments, the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol. In some embodiments, the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride. In some embodiments, the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppry. In certain embodiments, the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
[00278] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder. In some embodiments, the disease or disorder is a neurodegenerative disease or disorder. In some embodiments, the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy. In some embodiments, the neurodegenerative disease or disorder is Parkinson’s disease, Alzheimer's disease, or Huntington's disease. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00279] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a
compound of formula (B) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder. In some embodiments, the disease or disorder is a neurodegenerative disease or disorder. In some embodiments, the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy. In some embodiments, the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, IT-6, TI-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00280] In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERMAX™), ephenedrine sulfate (EPHEDRINE™), pemoline CYLERT™), mazindol (SANOREX™), d,l-a-methylphenethylamine (ADDERALL™) methylphenydate (RITALIN™), pramipexole (MIRAPEX™), modafinil (PROVIGIL™), or ropinirole (REQUIP™). In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
[00281 ] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-dyskensia agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti- dyskensia agent. In some embodiments, the disease or disorder is a movement disorder or Parkinson disease. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00282] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti -dyskensia agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti
dyskensia agent. In some embodiments, the disease or disorder is a movement disorder or Parkinson disease. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound 11-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00283] In some embodiments, the anti-dyskensia agent is selected from baclofen (Lioresal™), botulinum toxin (Botox™), clonazepam (Klonopin™), and diazepam (Valium™). In other embodiments, an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
[00284] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an immunosuppressive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent. In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease is lupus or rheumatoid arthritis. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00285] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an immunosuppressive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent. In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease is lupus or rheumatoid arthritis. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, 11-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00286] In some embodiments, the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, prednisolone, methylprednisone, dexamethasone, heterologous anti-lymphocyte globulin, deoxyspergualin, or rapamycin.
[00287] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-spasmodic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-
spasmodic agent. In some embodiments, the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00288] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-spasmodic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antispasmodic agent. In some embodiments, the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound 11-4. 11-6. 11- 7. 11-14, 11-15, or 11-16, or any compounds as described herein.
[00289] In some embodiments, the anti-spasmodic agent is carbamatepine, oxcarbazepine, ferbocate, fiirboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinamide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
[00290] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-diabetic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent. In some embodiments, the disease or disorder is diabetes. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, I- 20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00291 ] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-diabetic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent. In some embodiments, the disease or disorder is diabetes. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, 11-6. II-7, 11-14, II- 15, or 11-16, or any compounds as described herein.
[00292] In some embodiments, the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glimepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
[00293] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is seizure, neuropathic pain, or epilepsy. In some embodiments, the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00294] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is seizure, neuropathic pain, or epilepsy. In some embodiments, the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound 11-4, II-6, II--7, 11-14, 11- 15, or 11-16, or any compounds as described herein.
[00295] In some embodiments, the anti-convulsant agent or anti-epileptic agent is phenobarbital, pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbamatepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, tibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin. In some embodiments, the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine,
topiramate, sodium valproate, vigabatrin, or zonisamide. In some embodiments, the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide. In some embodiments, the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
[ 00296] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-psychotic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antipsychotic agent. In some embodiments, the disease or disorder is schizophrenia, psychosis, or bipolar disorder. In some embodiments, the compound of formula (A) is the compound of formula
(I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00297] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-psychotic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antipsychotic agent. In some embodiments, the disease or disorder is schizophrenia, psychosis, or bipolar disorder. In some embodiments, the compound of formula (B) is the compound of formula
(II), or compound TI-4, 11-6, II-7, 11-14, 11-15, or II- 16, or any compounds as described herein.
[00298] In some embodiments, the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
[ 00299] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[ 00300] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is any? one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II- 7, II- 14, 11-15, or 11-16, or any compounds as described herein.
[00301] In some embodiments, the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenofibrate, benzafibrate, rosiglitazone, or ezetimibe.
[00302] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-inflammatory agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent. In some embodiments, the disease or disorder is an inflammatory disease. In some embodiments, the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00303] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-inflammatory agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent. Tn some embodiments, the disease or disorder is an inflammatory’ disease. In some embodiments, the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, IT-7, 11- 14. 11-15, or 11-16, or any compounds as described herein.
[00304] In some embodiments, the anti-inflammatory agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, naproxen, ketoprofen, ceiecoxib, rofecoxib, diclofenac,
benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, ciidanac, oxpinac, niefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen.
[00305] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-bacterial agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent. In some embodiments, the disease or disorder is a bacterial infection. In some embodiments, the disease or disorder is a skin or eye infection, tuberculosis, or a urinary tract infection. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00306] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-bacterial agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent. In some embodiments, the disease or disorder is a bacterial infection. In some embodiments, the disease or disorder is a skin or eye infection, tuberculosis, or a urinary' tract infection. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, IT-7, II- 14, II- 15, or 11-16, or any compounds as described herein.
[00307] In some embodiments, the anti-bacterial agent is selected from the group consisting of erythromycin, aji azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, Piperacillin, azlocillin, ternocillin, cepalothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefmetazole, ceftazidime cefotaxime, cefizoxirne, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, cetazide, ceftibuten, cefdinir, cefpirome, cefepime, aztreonam, imipenem, meropenem, meropenem penicillin (ertapenem), doricane (doripenem), cephalosporin ceftobiprole and ceftaroline, citric acid, porphyrin, norfloxacin, pelloxacin, enoxacin, oufumycin, levofloxacin, ciprofloxacin,
tiproxoxacin temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, and rafosa trovafloxacin), clinafloxacin, gatifloxacin, moxifloxacin, sitar Sitafloxacin, garenoxacin, gemifloxacin, pazufloxacin, p-aminobenzoic acid, sulfadiazine, sulfonamide azole, sulfamethine oxazole and sulfonamide, streptomycin, neomycin, kenmycin, baromycin, gentamicin, tobramycin, butyl Amine kanamycin, netilmicin, spectinomycin, perillamycin, dardamycin and ezeparin, tetracycline, chlortetracycline, chlorotetracycline, go Mechlorin, minocycline, oxy tetracycline, methicillin, tigcycline, doxycycline, rifampicin, rifampin, rifapentine, rifabutin, bezoxazinorifamycin and rifaximin, lincomycin, kesendamycin, telavancin, vancomycin, ticlosin, daptomycin, quinupristin and darfapolis Daflopristin, linoleide, polymyxin, colistin, colin, trimethoprim, and bacitracin.
[00308] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-emetic. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics. In some embodiments, the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and'or chemotherapy directed against cancer. In some embodiments, the compound of formula (A) is the compound of formula
(I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00309] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-emetic. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics. In some embodiments, the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer. In some embodiments, the compound of formula (B) is the compound of formula
(II), or compound 11-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00310] In some embodiments, the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidoi, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
[ 00311] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-depressant. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant. In some embodiments, the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, postraumatic stress disorder (PTSD), phobias, or social anxiety disorder. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or I- 26, or any compounds as described herein.
[00312] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-depressant. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant. In some embodiments, the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, posttraumatic stress disorder (PTSD), or social anxiety disorder. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, IT-6, II-7, 11-14, 11-15, or IT-16, or any compounds as described herein.
[00313] In some embodiments, the anti-depressants is selected from the group consisting of adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, eianopramine, cinioxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, Htoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, fluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine, and zometapine. In some embodiments, the anti-depressant agent is a selective serotonin reuptake inhibitor (SSRI). In some embodiments, the anti-depressant agent is fluoxetine.
[00314] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-anxiety agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent. In some embodiments, the disease or disorder is generalized anxiety disorder, social phobia, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1- 6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00315] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-anxiety agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent. In some embodiments, the disease or disorder is generalized anxiety disorder, social phobia, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, II- 15, or 11-16, or any compounds as described herein.
[00316] In some embodiments, the anti-anxiety agent is comipramine hydrochloride, fluoxetine hydrochloride, salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
[00317] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a sleeping agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent. In some embodiments, the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00318] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and a sleeping agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent. In some embodiments, the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder. In some embodiments, the compound of formula (B) is the compound of formula (11), or compound 11-4, II-6, 11-7, 11-14, 11- 15, or 11-16, or any compounds as described herein.
[00319] In some embodiments, the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
[00320] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an orexigenic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent. In some embodiments, the disease or disorder is anorexia . In some embodiments, a compound of formula (A) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[ 00321 ] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an orexigenic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent. In some embodiments, the disease or disorder is anorexia. In some embodiments, a compound of formula (A) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00322] In some embodiments, the orexigenic agent is megestrol or oxandrolone.
[00323] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a
compound of formula (A) as described herein and an ocular hypotensive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent. In some embodiments, the disease or disorder is glaucoma. In some embodiments, a compound of formula (A) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP). In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00324] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an ocular hypotensive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent. In some embodiments, the disease or disorder is glaucoma. In some embodiments, a compound of formula (A) as described herein and an ocular hypotensive agent can lower intraocular pressure (TOP). In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00325] In some embodiments, the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
[ 00326] In some embodiments, the present invention provides a method tor treating or preventing osteoporosis in a subject in need thereof, comprising administering io the subject a compound of formula (A) as described herein and an anti-osteoporosis agent. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1- 24, 1-25, or 1-26, or any compounds as described herein.
[00327] In some embodiments, the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-osteoporosis agent. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, 11-7, 11-14, II- 15, or II- 16, or any compounds as described herein.
[00328] In some embodiments, the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, bazedoxifene, teriparatide, abaloparatide, and denosumab.
[00329] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and an anti-migraine agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent. In some embodiments, the disease or disorder is migraine headache or migraine pain. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00330] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and an anti-migraine agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent. In some embodiments, the disease or disorder is migraine headache or migraine pain. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound 11-4, IT-6, II-7, 11-14, IT-15, or 11-16, or any compounds as described herein.
[00331] In some embodiments, the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
[00332] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A) as described herein and a cardiovascular agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent. In some embodiments, the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00333] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (B) as described herein and a cardiovascular agent. In some embodiments,
the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent. Tn some embodiments, the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery’ disease, high or low blood pressure, high cholesterol, heart failure, and stroke. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00334] As used herein, in some embodiments, the term “cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory’ system (blood vessels). In some embodiments, the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, methykiofu, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine, mexiletine, procainamide, quinidine gluconate, propafenone hydrochloride, or tocainide.
[00335] In some embodiments, the present invention provides a method tor treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (A) as described herein and an anti-cancer agent. In some embodiments, the compound of formula (A) is the compound of formula (I), or compound 1-4, 1-6, 1-7, 1-14, 1-20, 1-24, 1-25, or 1-26, or any compounds as described herein.
[00336] In some embodiments, the present invention provides a method tor treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (B) as described herein and an anti-cancer agent. In some embodiments, the compound of formula (B) is the compound of formula (II), or compound II-4, II-6, II-7, 11-14, 11-15, or 11-16, or any compounds as described herein.
[00337] In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung minors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma. In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).
[00338] In some embodiments, the anti-cancer agent is a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
[00339] In some embodiments, the anti-cancer agent is a cytostatic drug. In some embodiments, the cytostatic drag is busulfan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
[00340] In some embodiments, the anti-cancer agent is an alkylating agent. In some embodiments, the alkylating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
[ 00341] In some embodiments, the anti-cancer agent is a cancer immunotherapy monoclonal antibody. In some embodiments, the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
[00342] In some embodiments, the anti-cancer agent is an anti-tumor agent. In some embodiments, the anti-tumor antibiotic agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
[00343] In certain embodiments, the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
[00344] In some embodiments, the anti-cancer agent is an anti-metabolite agent. In some embodiments, the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate,
pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine, and gemcitabine.
[00345] In some embodiments, the anti-cancer agent is a mitotic inhibitor. In some embodiments, the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
[00346] In some embodiments, the anti-cancer agent is a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
[00347] In some embodiments, the anti-cancer agent is a topoisomerase inhibitor. In some embodiments, the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
[00348] In some embodiments of the method of the invention, the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, anti atherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti -infective agents, antiviral agents, antibacterial agents, antiviral agents, antifungal agents, cholesterol/lipid lowering agents and lipid profile therapies, and agents that mimic ischemic preconditioning and/or myocardial stunning, or a combination thereof.
[ 00349] In some embodiments of the method of the invention, the additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atornoxetine; dopamine reuptake inhibitors (DARIs), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRIs), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids,
such as tramadol; thromboxane receptor antagonists, such as itetroban; potassium channel openers; thrombin inhibitors, such as hirudin; hypothalamic phospholipids; growth factor inhibitors, such as modulators of PDGF activity; platelet activating factor (PAF) antagonists; anti -platelet agents, such as GPIIb/IIIa blockers (e.g., abdximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and CS-747), and aspirin; anticoagulants, such as warfarin; low molecular weight heparins, such as enoxaparin; Factor Vila Inhibitors and Factor Xa Inhibitors; renin inhibitors; neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tricrynafen, chlorthalidone, furosenilde, musolimine, bumetanide, triamterene, amiloride, and spironolactone; thrombolytic agents, such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC); anti-diabetic agents, such as biguanides (e.g. metformin), glucosidase inhibitors (e.g., acarbose), insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists; mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl-protein transferase inhibitors; hormonal agents, such as glucocorticoids (e.g., cortisone), estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate; microtubule-disruptor agents, such as ecteinascidins; microtubule-stabilizing agents, such as paclitaxel, docetaxel, and
epothilones A-F; plant-derived products, such as vinca alkaloids, epipodophyllotoxins, and taxanes; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and cyclosporins; steroids, such as prednisone and dexamethasone; cytotoxic drugs, such as azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as tenidap; anti-TNF antibodies or soluble TNF receptor, such as etanercept, rapamycin, and leflunimide; and cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; and miscellaneous agents such as, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, gold compounds, platinum coordination complexes, such as cisplatin, satraplalin, and carboplatin.
[00350] The present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administration a deuterated cannabigerol compound of formula (AA) in combination with the therapeutic agent.
[00351] It is one aspect of the invention that a combination therapy that includes a deuterated cannabigerol compound of formula (AA) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA). It is another aspect of the invention that a combination of a deuterated cannabigerol compound of formula (AA) with at least one additional therapeutic agent as described herein may allow for an improved safety profile of the additional therapeutic agent during treatments and result in a decrease in the onset of resistance development. In another aspect, the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA) in the treatment. Such combination therapy may allow for at least the same efficacy as, or a higher efficacy than, the treatment using the therapeutic agent alone, with an improved safety profile of the therapeutic agent. In another aspect, the therapeutically effective amount of the therapeutic agent administered to the subject is the same as the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AA) in the treatment. Such combination therapy may allow for an increased efficacy with the same safety' profile of the therapeutic agent.
[00352] In one aspect, the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent, wherein R1-R32 are each independently H or D, provided that at least one of R.-R17 is D, wherein said disease or disorder is seiected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith- Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm -related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome -related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[00353] In one aspect, the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent,
wherein R1-R32 are each independently H or D, provided that at least one of R1-R17 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, or any combination thereof; or wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; or wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders; or
wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia, or wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety; or wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, autoimmune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety’, aggression, compulsive disorders, noise phobias, epilepsy, or seizures; or wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
[00354] In some embodiments, the compound of formula (AA) is a deuterated compound of cannabigerol (CBG), or a derivative thereof.
[00355] In some embodiments of the compound of formula (AA), R1-Re are D. In some embodiments, R1-Ro, RB, and RM are D. In some embodiments, R1-R17 are D. In some embodiments, R? and Rs are D. In some embodiments, R9-R1 ? are D.
[00356] In some embodiments, the compound of formula (AA) is represented by the compound of formula (Al) wherein R1-R20 are each independently H or D, provided that at least one of R1-Rn is D.
[00357] In some embodiments of the compound of formula (Al), R1-Re are D. In some embodiments, R1-R0, RB, and R14 are D. In some embodiments, R1-R17 are D. In some embodiments, R? and Rs are D. Tn some embodiments, R9-R17 are D.
[00358] In some embodiments, the compound of formula (AA) or (Al) is represented by compound A8, A13, A18, Al 9, A20, or A21:
[00359] In one aspect, the invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) and at least one additional therapeutic agent.
[00360] In another aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein and at least an additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. Tn some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00361] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00362] In a further aspect, the present invention provides a method for treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as
described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00363] In a farther aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA), or a compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non-24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an attention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments,
the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00364] In another aspect, the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any combination thereof. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula ( AA) as described herein, or a compound of formula (Al), or any one of compounds A8, AI3, and A18- A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the pain is chronic pain. In other embodiments, the pain is acute pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A 13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia, in a subject in need thereof, comprising administering to said subject a therapeutically
effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. Tn some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00365] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is aggression. In some embodiments, the disease or disorder is fear. In some embodiments, the disease or disorder is phobias, e.g., noise phobias. In some embodiments, the disease or disorder is generalized anxiety disorder. In some embodiments, the disease or disorder is separation anxiety. In some embodiments, the subject is an animal. In other embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00366] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures. Tn some embodiments, the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other
embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the disease or disorder is a neoplastic disease. In some embodiments, the disease or disorder is a degenerative disorder. In some embodiments, the disease or disorder is an auto-immune disease. In other embodiments, the disease or disorder is allergies. In other embodiments, the disease or disorder is a metabolic disorder. In some embodiments, the disease or disorder is infection. In other embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is trauma. In other embodiments, the disease or disorder is toxicity. In some embodiments, the disease or disorder is nutritional imbalance. In some embodiments, the disease or disorder is an idiopathic condition. In some embodiments, the disease or disorder is an iatrogenic problem. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the anxiety is separation anxiety or generalized anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression. In some embodiments, the disease or disorder is a compulsive disorder. In some embodiments, the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is seizures. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00367] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or any’ one of compounds A8, A13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma. In some embodiments, the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency. In some embodiments, the disease or disorder is
anxiety. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In certain embodiments, the subject is a cat. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00368] In another aspect, the present invention provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds A8, A 13, and A18-A22, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. Tn some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntington’s disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. Tn some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. Tn some embodiments, the disease or disorder is cancer. Tn some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment andprevention of the disease or disorder. In some embodiments,
the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00369] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds 8, 13, and 18-22, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia,. In some embodiments, the disease or disorder is pain. In some embodiments, the pain is chronic pain. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is chemo-related nausea, vomiting, and anorexia. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the additional therapeutic agent is the one as know' n in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00370] In another aspect, the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds A8, A13, and AI8-A22, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of pain or inflammation. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of pain or inflammation. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery', soft-tissue surgery, or dental surgery.
[00371 ] In another aspect, the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AA) as described herein, or a compound of formula (Al), or a compound of formula (Al), or any one of compounds 8, 13, and 18-22, or any' compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the therapeutic agent in the method of the invention is an analgesic agent including drugs and agents that provide pain relief. In some embodiments, the therapeutic agent is a non-steroidal anti-inflammatory’ drug (NSAID). In some embodiments, the non-steroidal antiinflammatory drug (NSAID) is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen. In some embodiments, the non-steroidal antiinflammatory drug (NSAID) is meloxicam, carprofen, deracoxib, or firocoxib. In certain embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam. In other embodiments, the non-steroidal anti-inflammatory drug (NSAID) is carprofen. In some embodiments, the subject is a human. In other embodiments, the subject is an animal. In certain embodiments, the subject is a dog. In some embodiments, the subject is a cat.
[00372] In some embodiments of the method of the invention, the additional therapeutic agent is an analgesic agent, an anti-anxiety' agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti-
dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
[00373] In some embodiments, the additional therapeutic agent is an agent for treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent tor treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent for treating Rett syndrome.
[00374] In one aspect, in the method of the invention, the deuterated compound as described herein can be used to treat the adverse effects resulting from the treatment with the additional therapeutic agent as described herein. Such adverse effects include, but are not limited to, vomiting, dizziness, drowsiness, dry mouth, swollen tongue, loss of balance or coordination, and unsteadiness.
[00375] In one aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an analgesic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent. In some embodiments, the disease or disorder is pain such as acute pain or chronic pain. In some embodiments, the compound of formula ( AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
[00376] In some embodiments, the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent. In some embodiments, the non-opioid analgesic agent is acetaminophen, aspirin, ibuprofen, meloxicam, carprofen, fenbuprofen, flubiprofen, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin. In certain embodiments, the analgesic agent is naproxen sodium or magnesium. In some embodiments, the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, meloxicam, or naproxen.
[00377] In some embodiments, the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone,
morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol. Tn some embodiments, the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride. In some embodiments, the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppy. In certain embodiments, the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
[00378] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder. In some embodiments, the disease or disorder is a neurodegenerative disease or disorder. In some embodiments, the neurodegenerative disease or disorder is Alzheimer's disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette's syndrome, or progressive muscular atrophy. In some embodiments, the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
[00379] In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERMAX™), ephenedrine sulfate (EPHEDRINE™), pemoline CYLERT™), mazindol (SANOREX™), d,l-a-methylphenethylamine (ADDERALL™) methylphenydate (RITALIN™), pramipexole (MIRAPEX™), modafinil (PROVIGIL™), or ropinirole (REQUIP™). In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
[ 00380] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (A A) as described herein and an anti-dyskensia agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-dyskensia agent. In some embodiments, the disease or disorder is a movement
disorder or Parkinson disease. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
[00381] In some embodiments, the anti-dyskensia agent is selected from baclofen (LIORESAL ™), botulinum toxin (BOTOX™), clonazepam (KLONOPIN™), and diazepam (VALRJM™). In other embodiments, an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
[00382] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an immunosuppressive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent. In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease is lupus or rheumatoid arthritis. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00383] In some embodiments, the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, methylprednisone, dexamethasone, heterologous anti -lymphocyte globulin, deoxy spergualin, or rapamycin.
[00384] In some embodimen is, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-spasmodic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-spasmodic agent. In some embodiments, the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction. In some embodiments, the compound of formula (AA) is the compound of formula (AT), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein.
[00385] In some embodiments, the anti-spasmodic agent is carbamatepine, oxcarbazepine, terbocate, furboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinamide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
[00386] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a
compound of formula (AA) as described herein and an anti-diabetic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidiabetic agent. In some embodiments, the disease or disorder is diabetes. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
[00387] In some embodiments, the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glimepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
[00388] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is seizure, neuropathic pain, or epilepsy. In some embodiments, the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. In some embodiments, the compound of formula (AA) is the compound of formula ( AT), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00389] In some embodiments, the anti-convulsant agent or anti-epileptic agent is pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbarn atepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, fibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin. In some embodiments, the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide. In some embodiments, the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide. In some embodiments, the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
[00390] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-psychotic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-psychotic agent. In some embodiments, the disease or disorder is schizophrenia, psychosis, or bipolar disorder. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00391] In some embodiments, the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
[00392] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
[00393] In some embodiments, the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenotibrate, benzatibrate, rosiglitazone, or ezetimibe.
[00394] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-inflammatory agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-inflammatory agent. In some embodiments, the disease or disorder is an inflammatory disease. In some embodiments, the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders,
or a fever. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and Al 8-A22, or any compounds as described herein.
[00395] In some embodiments, the anti-inflammatory agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, prarnoprofen, rnuroprofen, trioxaprofen, suprofen, arninoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen.
[00396] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-bacterial agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antibacterial agent. In some embodiments, the disease or disorder is a bacterial infection. In some embodiments, the disease or disorder is a skin or eye infection, tuberculosis, or a urinary tract infection. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and Al 8-A22, or any compounds as described herein.
[00397] In some embodiments, the anti-bacterial agent is selected from the group consisting of erytliromycin, aji azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, Piperacillin, azlocillin, temocillin, cepalothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefinetazole, ceftazidime cefotaxime, cefizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, cetazide, ceftibuten, cefdinir, cefpirome, cefepime, aztreonam, imipenern, meropenem, rneropenem penicillin (ertapenem), doricane (doripenem), cephalosporin ceftobiprole and ceftaroiine, citric acid, porphyrin, norfloxacin, pefloxacin, enoxacin, oufumycin, levofloxacin, ciprofloxacin, tiproxoxacin temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, and rufosa trovafloxacin), clinafloxacin, gatifloxacin, moxifloxacin, sitar Sitafloxacin, garenoxacin, gemifloxacin, pazufloxacin, p-aminobenzoic acid, sulfadiazine, sulfonamide azole, sulfamethine oxazole and sulfonamide, streptomycin, neomycin, kenmycin, baromycin,
gentamicin, tobramycin, butyl Amine kanamycin, netilmicin, spectinomycin, perillamycin, dardamycin and ezeparin, tetracycline, chlortetracycline, chlorotetracycline, go Mechlorin, minocycline, oxytetracycline, methicillin, tigcycline, doxycycline, rifampicin, rifampin, rifapentine, rifabutin, bezoxazinorifamycin and rifaximin, lincomycin, kesendamycin, telavancin, vancomycin, ticlosin, daptomycin, quinupristin and darfapolis Daflopristin, linoleide, polymyxin, colistin, colin, trimethoprim, and bacitracin.
[00398] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula ( AA) as described herein and an anti-emetic. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics. In some embodiments, the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and A18-A22, or any compounds as described herein,
[00399] In some embodiments, the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
[ 00400] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-depressant. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant. In some embodiments, the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety disorder, bipolar disorder, posttraumatic stress disorder (PTSD), phobias, or social anxiety disorder. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00401] In some embodiments, the anti-depressant is selected from the group consisting of adinazolam, alaproclate, amineptine, aniitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion,
caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, nietapramine, nietralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, fluorxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine, and zometapine. In some embodiments, the anti-depressant agent is a selective serotonin reuptake inhibitor (SSRI). In some embodiments, the anti-depressant agent is fluoxetine.
[00402] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-anxiety agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent. In some embodiments, the disease or disorder is generalized anxiety disorder, social and other phobias, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or anyone of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00403] In some embodiments, the anti-anxiety agent is salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, zolpidem; clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
[00404] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and a sleeping agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent. In some embodiments, the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder. In some embodiments, the compound of formula (AA) is the compound of
formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00405] In some embodiments, the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
[00406] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an orexigenic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent. In some embodiments, the disease or disorder is anorexia . In some embodiments, a compound of formula (AA) as described herein and an orexigenic agent can stimulate appetite andproduce weight gain in older persons. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A 13, and A18- A22, or any compounds as described herein.
[00407] In some embodiments, the orexigenic agent is megestrol or oxandrolone.
[00408] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an ocular hypotensive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent. In some embodiments, the disease or disorder is glaucoma. In some embodiments, a compound of formula (AA) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP). In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, A13, and AI8-A22, or any compounds as described herein.
[00409] In some embodiments, the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
[00410] In some embodiments, the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-osteoporosis agent. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00411] In some embodiments, the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, bazedoxifene, teriparatide, abaloparatide, and denosumab.
[00412] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) as described herein and an anti-migraine agent. Tn some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antimigraine agent. In some embodiments, the disease or disorder is migraine headache or migraine pain. In some embodiments, the compound of formula (AA) is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00413] In some embodiments, the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
[ 00414] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AA) or a compound of formula (Al) as described herein and a cardiovascular agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a cardiovascular agent. In some embodiments, the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
[00415] As used herein, in some embodiments, the term ‘"cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory system (blood vessels). In some embodiments, the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, methyldofu, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine, mexiletine, procainamide, quinidine gluconate, propafenone hydrochloride, or tocainide.
[ 00416] In some embodiments, the present invention provides a method for treating or preven ting cancer, comprising administering to a subject in need thereof a compound of formula (AA) as described herein and an anti-cancer agent. In some embodiments, the compound of formula (AA)
is the compound of formula (Al), or any one of compounds A8, Al 3, and A18-A22, or any compounds as described herein.
[00417] In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, coion tumors, lung tumors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma. In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Pli+ CML).
[00418] In some embodiments, the anti-cancer agent is a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
[00419] In some embodiments, the anti-cancer agent is a cytostatic drug. In some embodiments, the cytostatic drag is busulfan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
[00420] In some embodiments, the anti-cancer agent is an alkylating agent. In some embodiments, the alkylating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
[ 00421] In some embodiments, the anti-cancer agent is a cancer immunotherapy monoclonal antibody. In some embodiments, the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
[00422] In some embodiments, the anti-cancer agent is an anti-tumor agent. In some embodiments, the anti-tumor agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.
[00423] In certain embodiments, the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxy carbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
[00424] In some embodiments, the anti-cancer agent is an anti-metabolite agent. In some embodiments, the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine, and gemcitabine.
[00425] In some embodiments, the anti-cancer agent is a mitotic inhibitor. In some embodiments, the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
[00426] In some embodiments, the anti-cancer agent is a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
[00427] In some embodiments, the anti-cancer agent is a topoisomerase inhibitor. In some embodiments, the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
[00428] In some embodiments of the method of the invention, the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, anti atherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents, antifungal agents, cholesterol/lipid lowering agents and lipid profile therapies, and agents that mimic ischemic preconditioning and/or myocardial stunning, or a combination thereof.
[00429] In some embodiments, an additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atomoxetine; dopamine reuptake inhibitors (DARTs), such as methylphenidate; serotonin-norepmephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRIs), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such as ifetroban; potassium channel openers; thrombin inhibitors, such as hirudin; hypothalamic phospholipids; growth factor inhibitors, such as modulators of PDGF activity; platelet activating factor (PAF) antagonists; anti-platelet agents, such as GPIIb/IIIa blockers (e.g., abdximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and CS-747), and aspirin; anticoagulants, such as warfarin; low molecular weight heparins, such as enoxaparin; Factor Vila Inhibitors and Factor Xa Inhibitors; renin inhibitors; neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethi azide, polythiazide, benzothiazide, ethacrynic acid, tricrynafen, chlorthalidone, furosenilde, musolimine, bumetanide, triamterene, amiloride, and spironolactone; thrombolytic agents, such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC); anti-diabetic agents, such as biguanides (e.g. metformin), glucosidase inhibitors (e.g., acarbose), insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists; mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE HI inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil,
tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl -protein transferase inhibitors; hormonal agents, such as glucocorticoids (e.g., cortisone), estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate; microtubule-disruptor agents, such as ecteinascidins; microtubule-stabilizing agents, such as paclitaxel, docetaxel, and epothilones A-F; plant-derived products, such as vinca alkaloids, epipodophyllotoxins, and taxanes; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and cyclosporins; steroids, such as prednisone and dexamethasone; cytotoxic drugs, such as azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as tenidap; anti-TNF antibodies or soluble I'NF receptor, such as etanercept, rapamycin, and leflunimide; and cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; and miscellaneous agents such as, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, gold compounds, platinum coordination complexes, such as cisplatin, satraplatin, and carboplatin.
[00430] The present invention relates to a novel method for the treatment of a disease or disorder in a subject currently receiving a therapeutic agent by administration a deuterated cannabichromene compound of formula (AAA) in combination with the therapeutic agent.
[00431] It is one aspect of the invention that a combination therapy that includes a deuterated cannabichromene compound of formula (AAA) and at least one additional therapeutic agent as described herein exhibits a therapeutic synergistic or additive effect. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA). It is another aspect of the invention that a combination of a deuterated cannabichromene compound of formula (AAA) with at least one additional therapeutic agent as described herein may allow for an improved safety profile of the additional therapeutic agent during treatments and result in a decrease in the onset of resistance development. In another aspect, the therapeutically effective amount of the therapeutic agent administered to the subject is much less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA) in the
treatment. Such combination therapy may allow for at least the same efficacy as, or a higher efficacy than, the treatment using the therapeutic agent alone, with an improved safety profile of the therapeutic agent. In another aspect, the therapeutically effective amount of the therapeutic agent administered to the subject is the same as the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of formula (AAA) in the treatment. Such combination therapy may allow for an increased efficacy with the same safety profile of the therapeutic agent.
[00432] In one aspect, the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent,
(AAA) wherein R1-R30 are each independently H or D, provided that at least one of R1-R25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety', migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity1, Alzheimer’s disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders,
neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson’s disease, Huntingtoil’s disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
[00433] In one aspect, the invention provides a method for treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent, wherein R1-R30 are each independently H or D, provided that at least one of R1-R25 is D, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, vomiting, and emesis, or any combination thereof; or wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary' insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders,
neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity', type 2 diabetes, and testosterone insufficiency; or wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson’s disease, Huntington’s disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders; or wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia, or wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety; or wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures; or wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
[00434] In some embodiments, the compound of formula (AAA) is a deuterated compound of cannabichromene (CBC), or a derivative thereof.
[00435] In some embodiments of the compound of formula (AAA), R1-RB are D. In some embodiments, RS-RB are D. In some embodiments, RS-RB, Rao, and R21 are D. In some embodiments, R8-R24 are D. In other embodiments, R2.5 is D.
[00436] In some embodiments, the compound of formula (AAA) is represented by a compound of formula (AAI)
wherein R1-Rzs are each independently H or D, provided that at least one of R1-R2.5 is D.
[00437] In some embodiments of the compound of formula (AAA) or (AAI), R1-RB are D. In some embodiments, RS-RB are D. In some embodiments, RS-RB, R20, and R21 are D. In some embodiments, R8-R24 are D. In other embodiments, R25 is D.
[00438] In some embodiments, the compound of formula (AAA) or (AAI) is represented by any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24:
(AA22),
[00439] In one aspect, the invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) and at least one additional therapeutic agent.
[00440] In another aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein and at least an additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20- A A24, or any compounds as described herein. In some embodiments, the subject in the method
of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00441] In a further aspect, the present invention provides a method for treating or preventing a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00442] In a further aspect, the present invention provides a method for treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (AAA) as described herein, e.g., a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy- induced emesis, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof. In some embodiments, the disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder,
spasm, bone degradation, neurodegenerative disorder, pain, or convulsion, or any combination thereof. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00443] In a farther aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA), or a compound of formula (AAI), or a compound of formula (AAI), or any one of compounds AA7, AA 11, AAI 6, and AA20- AA24. or any compounds as described herein, and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of non-AA24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer's, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency. In some embodiments, the disease or disorder is non- AA24-hour sleep wake disorder. In other embodiments, the disease or disorder is Smith-Magenis syndrome. In some embodiments, the disease or disorder is major depressive disorder. In some embodiments, the disease or disorder is primary insomnia circadian rhythm-related disorders. In some embodiments, the disease or disorder is depression. In some embodiments, the disease or disorder is jet-lag. In some embodiments, the disease or disorder is work-shift syndrome. In some embodiments, the disease or disorder is a sleep disorder. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is a reproductive disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is benign prostatic hyperplasia. In some embodiments, the disease or disorder is an immune disorder. In some embodiments, the disease or disorder is a neuroendocrine disorder. In some embodiments, the disease or disorder is dysthymia. In some embodiments, the disease or disorder is bipolar disorder. In some embodiments, the disease or disorder is a delayed sleep phase
disorder. In some embodiments, the disease or disorder is a general anxiety disorder. In some embodiments, the disease or disorder is a seasonal affective disorder. In some embodiments, the disease or disorder is an atention deficit hyperactivity disorder. In some embodiments, the disease or disorder is Alzheimer's. In some embodiments, the disease or disorder is Angelman syndrome. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is autism. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is migraine. In some embodiments, the disease or disorder is night-time hypertension. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a type 2 diabetes. In some embodiments, the disease or disorder is testosterone insufficiency. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00444] In another aspect, the present invention provides a method for treating or preventing pain, multiple sclerosis, epilepsy, or chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as d escribed herein, or a compound of formula (AAI), or any one of compound s AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein. In some embodiments, the present invention provides a method of treating or preventing pain in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AA I I, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the present invention provides a method of treating or preventing multiple sclerosis in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the present invention provides a method of treating or preventing epilepsy in a subject in need thereof, comprising administering to said subject a
therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the present invention provides a method of treating or preventing chemo-related nausea, vomiting, and anorexia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any combination thereof, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00445] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is aggression. In some embodiments, the disease or disorder is fear. In some embodiments, the disease or disorder is phobias, e.g., noise phobias. In some embodiments, the disease or disorder is generalized anxiety disorder. In some embodiments, the disease or disorder is separation anxiety. In some embodiments, the subject is an animal. In other embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00446] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or
any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety', aggression, compulsive disorders, noise phobias, epilepsy, or seizures. In some embodiments, the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary’ anorexia. In some embodiments, the anorexia is a secondary' anorexia, e.g., secondary' to chemo. In other embodiments, the disease or disorder is a neoplastic disease. In some embodiments, the disease or disorder is a degenerative disorder. In some embodiments, the disease or disorder is an auto-immune disease. In other embodiments, the disease or disorder is allergies. In other embodiments, the disease or disorder is a metabolic disorder. In some embodiments, the disease or disorder is infection. In other embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is trauma. In other embodiments, the disease or disorder is toxicity'. In some embodiments, the disease or disorder is nutritional imbalance. In some embodiments, the disease or disorder is an idiopathic condition. In some embodiments, the disease or disorder is an iatrogenic problem. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the disease or disorder is anxiety. In some embodiments, the anxiety? is separation anxiety or generalized anxiety. In some embodiments, the disease or disorder is aggression. In some embodiments, the aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression. In some embodiments, the disease or disorder is a compulsive disorder. In some embodiments, the disease or disorder is noise phobias. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is seizures. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In some embodiments, the subject is a dog. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00447] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a
compound of formula (AAI), or any one of compounds AA7, AA1 1, AA16, and AA20-AA24, or any compounds as described herein, or any combination thereof, and at least one additional therapeutic agent, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma. In some embodiments, the disease or disorder is anorexia. In some embodiments, the anorexia is acute anorexia. In some embodiments, the anorexia is chronic anorexia. In other embodiments, the anorexia is a primary anorexia. In some embodiments, the anorexia is a secondary anorexia, e.g., secondary to chemo. In other embodiments, the anorexia is associated with chronic renal insufficiency. In some embodiments, the disease or disorder is anxiety'. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject is an animal. In certain embodiments, the subject is a cat. In other embodiments, the subject is a horse, a dog, a cat, or a ferret.
[00448] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AAI 1, AA 16, and AA20-AA24, or any combination thereof and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson’s disease, Huntington’s disease, Alzheimer’s disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders. In some embodiments, the disease or disorder is osteoarthritis. In some embodiments, the disease or disorder is musculoskeletal disorders. In some embodiments, the disease or disorder is anorexia. In some embodiments, the disease or disorder is emesis. In some embodiments, the disease or disorder is pain. In some embodiments, the disease or disorder is inflammation. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is neurodegenerative disorders, for example, Parkinson's disease, Huntingtons disease, and/or Alzheimer's disease. In some embodiments, the disease or disorder is seizures. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is glaucoma. In some embodiments, the
disease or disorder is osteoporosis. In some embodiments, the disease or disorder is schizophrenia. In some embodiments, the disease or disorder is a cardiovascular disorder. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is obesity. In some embodiments, the disease or disorder is a metabolic syndrome-related disorder. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00449] In another aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent, wherein the disease or disorder is pain, multiple sclerosis, epilepsy, or chemo- related nausea, vomiting, and anorexia. In some embodiments, the disease or disorder is pain. In some embodiments, the pain is chronic pain. In some embodiments, the disease or disorder is multiple sclerosis. In some embodiments, the disease or disorder is epilepsy. In some embodiments, the disease or disorder is chemo-related nausea, vomiting, and anorexia. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of the disease or disorder as described above. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of the disease or disorder. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal.
[00450] In another aspect, the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is the one as known in the art that can be used for the treatment or prevention of pain or inflammation. In some embodiments, the additional therapeutic agent is as described anywhere herein for the treatment and prevention of pain or inflammation. In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is an animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog. In some embodiments, the pain or inflammation is associated with osteoarthritis. In some embodiments, the pain or inflammation is a postoperative pain or postoperative inflammation. In certain embodiments, the postoperative pain is associated with orthopedic surgery, soft-tissue surgery, or dental surgery. In some embodiments, the postoperative inflammation is associated with orthopedic surgery, soft-tissue surgery', or dental surgery’.
[00451 ] In another aspect, the present invention provides a method for treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (AAA) as described herein, or a compound of formula (AAI), or a compound of formula (AAA), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein, and at least one additional therapeutic agent. In some embodiments, the therapeutic agent in the method of the invention is an analgesic agent including drugs and agents that provide pain relief. In some embodiments, the therapeutic agent is a non-steroidal anti-inflammatory drug (NSAID). In some embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid,
tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen. In some embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam, carprofen, deracoxib, or firocoxib. In certain embodiments, the non-steroidal anti-inflammatory drug (NSAID) is meloxicam. In other embodiments, the non-steroidal anti-inflammatory drug (NSAID) is carprofen. In some embodiments, the subject is a human. In other embodiments, the subject is an animal. In certain embodiments, the subject is a dog. In some embodiments, the subject is a cat.
[00452] In some embodiments of the method of the invention, the additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for neurodegenerative diseases or disorders, an anti- dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an anti-diabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an antiosteoporosis agent, or a cardiovascular agent.
[ 00453] In some embodiments, the additional therapeutic agent is an agent tor treating fragile X syndrome. In some embodiments, the additional therapeutic agent is an agent for treating autism spectrum disorder. In some embodiments, the additional therapeutic agent is an agent for treating lysosomal storage diseases. In some embodiments, the additional therapeutic agent is an agent for treating leukodystrophies. In some embodiments, the additional therapeutic agent is an agent tor treating Ret syndrome.
[00454] In one aspect, in the method of the invention, the deuterated compound as described herein can be used to treat the adverse effects resulting from the treatment with the additional therapeutic agent as described herein. Such adverse effects include, but are not limited to, vomiting, dizziness, drowsiness, dry mouth, swollen tongue, loss of balance or coordination, and unsteadiness.
[00455] In one aspect, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an analgesic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an analgesic agent. In some embodiments, the disease or disorder is pain such as acute pain or chronic pain. In some
embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any compounds as described herein.
[00456] In some embodiments, the analgesic agent is an opioid analgesic agent or a nonopioid analgesic agent. In some embodiments, the non-opioid analgesic agent is acetaminophen, aspirin, ibuprofen, meloxicam, carprofen, fenbuprofen, flubiprofen, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin. In certain embodiments, the analgesic agent is naproxen sodium or magnesium. In some embodiments, the analgesic is carbamazepine, gabapentin, pregabalin, acetaminophen, ibuprofen, meloxicam, or naproxen.
[00457] In some embodiments, the opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol. In some embodiments, the opioid analgesic agent is hydrocodone bitartrate or oxycodone hydrochloride. In some embodiments, the opioid analgesic agent is a naturally occurring opiate, such as an alkaloid occurring in the opium poppy. In certain embodiments, the naturally occurring opiate is morphine, codeine, narcotine, papaverine, narceine, or thebaine.
[00458] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and a therapeutic agent for treatment of a neurodegenerative disease or disorder. In some embodiments, the disease or disorder is a neurodegenerative disease or disorder. In some embodiments, the neurodegenerative disease or disorder is Alzheimer’s disease (AD), dementia, Parkinson's disease (PD), PD-related disorders, prion disease, Huntington's Disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, multiple sclerosis, tardive, Tourette’s syndrome, or progressive muscular atrophy. In some embodiments, the neurodegenerative disease or disorder is Parkinson's disease, Alzheimer's disease, or Huntington's disease. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
[00459] In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanins (e.g., anthocyanin cyanidin-3-O-glucoside), levodopa, pergolide (PERM AX™), ephenedrine sulfate (EPHEDRINE™), pemoline CYLERT™), mazindol (SANOREXrM), dj-a-methylphenethylamine (ADDERALL™) methylphenydate (RITALIN™), pramipexole (MIRAPEX™), modafinil (PROVIGIL™), or ropinirole (REQUIP™). In some embodiments, the therapeutic agent for treatment of a neurodegenerative disease or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
[00460] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-dyskensia agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-dyskensia agent. In some embodiments, the disease or disorder is a movement disorder or Parkinson disease. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, A A 16, and AA20-AA24, or any compounds as described herein.
[00461] In some embodiments, the anti-dyskensia agent is selected from baclofen (LIORESAL™), botulinum toxin (BOTOX™), clonazepam (KLONOPIN™), and diazepam (VALIUM™). In other embodiments, an anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
[00462] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an immunosuppressive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an immunosuppressive agent. In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease is lupus or rheumatoid arthritis. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AA16, and AA20-AA24, or any compounds as described herein.
[00463] In some embodiments, the immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, methylprednisone, dexamethasone, heterologous anti -lymphocyte globulin, deoxy spergualin, or rapamycin.
[00464] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-spasmodic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-spasmodic agent. In some embodiments, the disease or disorder is irritable bowel syndrome, abdominal pain, or bladder dysfunction. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA 16, and AA20-AA24, or any compounds as described herein.
[00465] In some embodiments, the anti-spasmodic agent is carbamatepine, oxcarbazepine, ferbocate, furboc acid, paroxamine, fibapramine, laxamide, talapanib, retigabine, levethiracetam, tobinarnide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
[00466] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-diabetic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-diabetic agent. In some embodiments, the disease or disorder is diabetes. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
[00467] In some embodiments, the anti-diabetic agent is mefluminine hydrochloride, acarbose, miglitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, gliniepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
[00468] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-convulsant agent or an anti-epileptic agent. In some embodiments, the disease or disorder is seizure, neuropathic pain, or epilepsy. In some embodiments, the disease or disorder is a seizure associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous
sclerosis complex. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
[00469] In some embodiments, the anti-convulsant agent or anti-epileptic agent is pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5- diphenylhydantoin, carbarn atepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, fibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin. In some embodiments, the anti-convulsant agent or anti-epileptic agent is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, non-ammonia ester, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide. In some embodiments, the anticonvulsant agent or anti-epileptic agent is arbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, topiramate, tiagabine, valproic acid, or zonisamide. In some embodiments, the anti-convulsant agent or anti-epileptic agent is Epidiolex®.
[00470] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-psychotic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-psychotic agent. In some embodiments, the disease or disorder is schizophrenia, psychosis, or bipolar disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AAI 6, and AA20-AA24, or any compounds as described herein.
[00471] In some embodiments, the anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
[00472] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an cholesterol/lipid lowering agent. In some
embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a cholesterol/lipid lowering agent. In some embodiments, the disease or disorder is high cholesterol, lipid abnormalities, obesity, or a metabolic syndrome-related disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI I, AA16, and AA20-AA24, or any compounds as described herein.
[00473] In some embodiments, the cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenofibrate, benzafibrate, rosiglitazone, or ezetimibe.
[00474] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-inflammatory' agent. In some embodiments, the disease or disorder is any? one that can be treated or prevented as known in the art by an anti-inflammatory agent. In some embodiments, the disease or disorder is an inflammatory disease. In some embodiments, the disease or disorder is severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, headaches, digestive disorders, or a fever. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein,
[00475] In some embodiments, the anti-inflammatory’ agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, meloxicam, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen.
[00476] In some embodimen ts, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-bacterial agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-bacterial agent. In some embodiments, the disease or disorder is a bacterial infection. In some embodiments, the disease or disorder is a skin or eye infection, tuberculosis, or a urinary
tract infection. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-.AA24, or any compounds as described herein.
[00477] In some embodiments, the anti-bacterial agent is selected from the group consisting of erythromycin, azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarciilin, mezlocillin, Piperacillin, azlociilin, temociliin, cepaiothin, cefepime, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefinetazole, ceftazidime cefotaxime, cefizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, cetazide, ceftibuten, cefdinir, cefpirome, cefepime, aztreonam, imipenem, meropenem, meropenem penicillin (ertapenem), doricane (doripenem), cephalosporin ceftobiprole and ceftaroline, citric acid, porphyrin, norfloxacin, petloxacin, enoxacin, oufumycin, levofloxacin, ciprofloxacin, tiproxoxacin temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, and rufosa trovafloxacin), clinailoxacin, gatifloxacin, moxifloxacin, sitar Sitafloxacin, garenoxacin, gemifloxacin, pazufloxacin, p-aminobenzoic acid, sulfadiazine, sulfonamide azole, sulfamethine oxazole and sulfonamide, streptomycin, neomycin, kenmycin, baromycin, gentamicin, tobramycin, butyl Amine kanamycin, netilmicin, spectinomycin, perillamycin, dardamycin and ezeparin, tetracycline, chlortetracycline, chlorotetracycline, go Mechlorin, minocycline, oxytetracycline, methicillin, tigcycline, doxycycline, rifampicin, rifampin, rifapentine, rifabutin, bezoxazinorifamycin and rifaximin, lincomycin, kesendamycin, telavancin, vancomycin, ticlosin, daptomycin, quinupristin and darfapolis Daflopristin, linoleide, polymyxin, colistin, colin, trimethoprim, and bacitracin.
[00478] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-emetic. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antiemetics. Tn some embodiments, the disease or disorder is vomiting, nausea, motion sickness, or the side effects of opioid analgesics, general anesthetics, and/or chemotherapy directed against cancer. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds A.A7, AA11, AAI 6, and AA20-.AA24, or any compounds as described herein.
[00479] In some embodiments, the anti-emetic is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
[00480] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-depressant. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an antidepressant. In some embodiments, the disease or disorder is an obsessive-compulsive disorder (OCD), depression, panic disorder, an anxiety' disorder, bipolar disorder, posttraumatic stress disorder (PTSD), phobias, or social anxiety' disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAT), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
[00481] In some embodiments, the anti-depressants is selected from the group consisting of adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflu carbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine, and zometapine. In some embodiments, the anti-depressant agent is a selective serotonin reuptake inhibitor (SSRI). In some embodiments, the anti-depressant agent is fluoxetine.
[00482] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-anxiety agent. In some embodiments,
the disease or disorder is any one that can be treated or prevented as known in the art by an antianxiety agent. In some embodiments, the disease or disorder is generalized anxiety disorder, social and other phobias, anxiety, obsessive-compulsive disorder (OCD), panic disorder, and depression. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
[00483] In some embodiments, the anti-anxiety agent is salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, zolpidem; clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
[00484] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and a sleeping agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by a sleeping agent. In some embodiments, the disease or disorder is insomnia, sleepwalking, night terrors, a movement disorder that interrupts sleep, such as restless legs syndrome (RLS) and periodic limb movement disorder. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
[00485] In some embodiments, the sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
[00486] In some embodiments, the present invention provides a method tor treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an orexigenic agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an orexigenic agent. In some embodiments, the disease or disorder is anorexia. In some embodiments, a compound of formula (AAA) as described herein and an orexigenic agent can stimulate appetite and produce weight gain in older persons. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1, AA16, and AA20-AA24, or any compounds as described herein.
[00487] In some embodiments, the orexigenic agent is megestrol or oxandrolone.
[00488] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an ocular hypotensive agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an ocular hypotensive agent. In some embodiments, the disease or disorder is glaucoma. In some embodiments, a compound of formula (AAA) as described herein and an ocular hypotensive agent can lower intraocular pressure (IOP). In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AA16, and AA20-AA24, or any compounds as described herein.
[00489] In some embodiments, the ocular hypotensive agent includes, but is not limited to, bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
[ 00490] In some embodiments, the present invention provides a method for treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti -osteoporosis agent. In some embodiments, the compound of formula (AAA) is the compound of formula (AAI), or any one of compounds AA7, AAI 1 , AAI 6, and AA20-AA24, or any compounds as described herein.
[00491] In some embodiments, the anti-osteoporosis agent includes, but is not limited to alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, bazedoxifene, teriparatide, abaloparatide, and denosumab.
[00492] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) as described herein and an anti-migraine agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an anti-migraine agent. In some embodiments, the disease or disorder is migraine headache or migraine pain. In some embodiments, the compound of formula ( AAA) is the compound of formula (AAI), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
[00493] In some embodiments, the anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or almotriptan.
[00494] In some embodiments, the present invention provides a method for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (AAA) or a compound of formula (AAI) as described herein and a cardiovascular agent. In some embodiments, the disease or disorder is any one that can be treated or prevented as known in the art by an cardiovascular agent. In some embodiments, the disease or disorder includes, but is not limited to, arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke.
[00495] As used herein, in some embodiments, the term “cardiovascular agents” refer to medicines that are used to treat medical conditions associated with the heart or the circulatory system (blood vessels). In some embodiments, the cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, niethyldofo, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine, mexiletine, procainamide, quinidine gluconate, propafenone hydrochloride, or tocainide.
[00496] In some embodiments, the present invention provides a method for treating or preventing cancer, comprising administering to a subject in need thereof a compound of formula (AAA) as described herein and an anti-cancer agent. In some embodiments, the compound of formula (AAA) is the compound of formula (AV), or any one of compounds AA7, AA11, AAI 6, and AA20-AA24, or any compounds as described herein.
[00497] In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia positive chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic diseases, myeloproliferative diseases, gliomas, ovarian tumors, prostate tumors, colon tumors, lung humors, small cell lung carcinoma, breast tumors, gynecological tumors, gastrointestinal stromal cancer, or melanoma. In some embodiments, the cancer is chronic phase or accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).
[00498] In some embodiments, the anti-cancer agent is a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is adrimycin, doxorubicin, 5-fluorouracil, cytosine arabinoside(“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C,
mitoxantrone, vincristine, vinoreibine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
[00499] In some embodiments, the anti-cancer agent is a cytostatic dmg. Tn some embodiments, the cytostatic drug is busuifan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, or oxaliplatin.
[00500] In some embodiments, the anti-cancer agent is an alkylating agent. In some embodiments, the alkydating agent includes, but is not limited to, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busuifan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.
[00501] In some embodiments, the anti-cancer agent is a cancer immunotherapy monoclonal antibody. In some embodiments, the cancer immunotherapy monoclonal antibody is rituximab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, or trastuzumab.
[00502] In some embodiments, the anti-cancer agent is an anti-tumor agent. In some embodiments, the anti-tumor agent includes, but is not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea,
[00503] In certain embodiments, the anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.
[00504] In some embodiments, the anti-cancer agent is an anti-metabolite agent. In some embodiments, the anti-metabolite agent includes, but is not limited to, aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafor, carmofor, capecitabine, and gemcitabine.
[ 00505] In some embodiments, the anti-cancer agent is a mitotic inhibitor. In some embodiments, the mitotic inhibitor includes, but is not limited to, docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.
[00506] In some embodiments, the anti-cancer agent is a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor includes, but is not limited to, imatinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, sorafenib, and sunitinib.
[00507] In some embodiments, the anti-cancer agent is a topoisomerase inhibitor. In some embodiments, the topoisomerase inhibitor includes, but is not limited to, etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.
[00508] In some embodiments of the method of the invention, the additional therapeutic agent is selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, antiatheroscl erotic agents, anticoagulants, antithrombotic agents, protlirombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phosphodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents, antifungal agents, cholesterol/lipid lowering agents and lipid profile therapies, and agents that mimic ischemic preconditioning and/or myocardial stunning, or a combination thereof.
[00509] In some embodiments, an additional therapeutic agent is selected from norepinephrine reuptake inhibitors (NRIs) such as atomoxetine; dopamine reuptake inhibitors ( D ARIs), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepham; norepinephrine-dopamine reuptake inhibitor (NDRIs), such as bupropion; serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRls), such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; opioids, such as tramadol; thromboxane receptor antagonists, such as ifetroban; potassium channel openers; thrombin inhibitors, such as hirudin; hypothalamic phospholipids; growth factor inhibitors, such
as modulators of PDGF activity; platelet activating factor (PAF) antagonists; anti-platelet agents, such as GPIIb/IIIa blockers (e.g., abdximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and CS-AA74AA7), and aspirin; anticoagulants, such as warfarin; low molecular weight heparins, such as enoxaparin; Factor Vila Inhibitors and Factor Xa Inhibitors; renin inhibitors; neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates; bile acid sequestrants, such as questran; niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP Inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinic agents; beta- muscarinic agents, such as carvedilol and metoprolol; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichioromethiazide, polythiazide, benzothiazide, ethacrynic acid, tricrynafen, chlorthalidone, furosenilde, musolimine, bumetanide, triamterene, amiloride, and spironolactone; thrombolytic agents, such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC); anti-diabetic agents, such as biguanides (e.g. metformin), glucosidase inhibitors (e.g., acarbose), insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists; mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, vardenafil); antiinflammatories; antiproliferatives, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic agents; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L- asparaginase; famesyl-protein transferase inhibitors; hormonal agents, such as glucocorticoids (e.g., cortisone), estrogens/antiestrogens, androgens/anti androgens, progestins, and luteinizing hormone -releasing hormone antagonists, and octreotide acetate; microtubule-disruptor agents, such as ecteinascidins; microtubule-stabilizing agents, such as paclitaxel, docetaxel, and epothilones A-F; plant-derived products, such as vinca alkaloids, epipodophyl lotoxins, and taxanes; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and cyclosporins;
steroids, such as prednisone and dexamethasone; cytotoxic drugs, such as azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as tenidap; anti-TNF antibodies or soluble TNF receptor, such as etanercept, rapamycin, and leflunimide; and cyclooxygenase-2 (COX- 2) inhibitors, such as celecoxib and rofecoxib; and miscellaneous agents such as, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, gold compounds, platinum coordination complexes, such as cisplatin, satraplatin, and carboplatin.
[00510] Where the compound of the invention as described herein is administered in combination with an additional therapeutic agent, typically a daily dosage may be about 0.1 to about 1 milligrams of the compound of the invention per kilogram of patient body weight and, in the case of the additional therapeutic agent, the usual dosage of the therapeutic agent when administered alone may be reduced by about 10-90% when administered with a compound of the invention as described herein. In some embodiments, the compound of the invention any compounds as described herein.
[0051 1] In some embodiments of the method of the invention, the therapeutically effective amount of the additional therapeutic agent administered to the subject is less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention as described herein. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is 10% to 90% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is 20% to 80% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is 20% to 70% less than the therapeutically effective amount of the therapeutic agent wiien administered in the absence of the compound of the invention. In some embodiments, the compound of the invention is any compounds as described herein.
[00512] In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 10% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention as described herein. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 20% less than the therapeutically effective amount of the
therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 30% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 40% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 50% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the therapeutically effective amount of the therapeutic agent administered to the subject is at least 5%, or 15%, or 25%, or 35%, or 45%, or 55% less than the therapeutically effective amount of the therapeutic agent when administered in the absence of the compound of the invention. In some embodiments, the compound of the invention is any compounds as described herein.
[00513] In some embodiments, the additional therapeutic agent and a compound of the invention as described herein are administered in combination administered concurrently. In other embodiments, the additional therapeutic agent and the compound of the invention are administered concurrently.
[00514] In some embodiments, the present invention further provides a combination therapy. The term “administered in combination” or “combination therapy” means the administration of the compound of the invention as described herein, and one or more additional therapeutic agents to treat a therapeutic disorder described in the present invention. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of active ingredient in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the diseases or disorders described herein.
[00515] It is another aspect of the invention that the therapeutic agent and the compound of the invention are formulated in the same pharmaceutical composition. Accordingly, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the
invention, at least one additional therapeutic agent, and a pharmaceutically acceptable earner. In some embodiments, the compound of the invention is any compounds as described herein.
[00516] In some embodiments, the additional therapeutic agent is formulated in a first pharmaceutical composition and the compound of the invention as described herein is formulated in a second pharmaceutical composition.
[00517] In another aspect, the present invention provides a kit comprising a first compartment containing a first pharmaceutical composition comprising a therapeutic agent as described herein and a second compartment containing a second pharmaceutical composition comprising a compound of the invention.
[00518] When the compound of the invention as described herein and the additional therapeutic agents are combined in a single dosage unit they may be formulated such that the physical contact between the active ingredients is minimized to reduce a potential chemical interaction between the combined active ingredients. For example, one or both active ingredients may be enteric coated. In some embodiments, the active ingredient(s) may be coated with a material that affects a sustained release throughout the gastrointestinal tract. In some embodiments, the compound of the invention may not be coated.
[ 00519] As used herein, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise.
[00520] As used herein, in some embodiments, the term "deuterium enrichment" is used to describe an above -natural amount of deuterium contained at any position of the compounds of the invention as described herein, designated by the letter "D" (or by the designation "2H"). The deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
[00521] In some embodiments, an approximate percentage is used to quantitatively define the amount of deuterium enrichment at a certain position of the described chemical structure, such as, for example, "deuterium enrichment is no less than about 10%." Where such quantitative approximations are used in this invention, they are meant to describe a percentage of the described compounds in an aggregate composition of like compounds that contain deuterium at the identified position D instead of protium.
[00522] In each of the foregoing and each of the following embodiments, it is to be understood that the formulas also include any and all hydrates and/or solvates of the compound formulas. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulas are to be understood to include and represent those various hydrates and/or solvates.
[00523] As used herein, the term “solvate” refers to compounds that further include a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. If the sol vent is water, the solvate is referred to as "hydrate.” Pharmaceutically acceptable solvates and hydrates are complexes that, for example, may include from 1 to about 100, or from 1 to about 10, or from one to about 2.3 or 4 molecules of water or a solvent. In some embodiments, the hydrate may be a channel hydrate. It should be understood that the term “compound” in this application covers the compound and solvates of the compound, as well as mixtures thereof.
[00524] In some embodiments, the term “hydrate” includes, but is not limited to, hemihydrate, monohydrate, dihydrate, trihydrate and the like.
[00525] "Subject" refers to an animal, including, but not limited to, a primate (e.g., human, monkey, chimpanzee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, and hamsters), lagomorphs (e.g., rabbit), swine (e.g., pig and miniature pig), equine, ferrets, parrots, canine, feline, bovine, ovine, caprine, and camelids. The terms "subject" and "patient" are used interchangeably herein when referencing, for example, a mammalian subject, such as a human patient.
[00526] Thus, besides being useful for human treatment, the compounds of the invention and formulations comprising the same as disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals. In some embodiments, the animals include horses, dogs, and cats.
[00527] In some embodiments, the subject in the method of the invention is a mammal. In other embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a companion animal, an exotic animal, or a farm animal. In certain embodiments, the subject is a horse, a dog, a cat, or a ferret. In some embodiments, the subject is a dog.
[00528] The term “treatment” or “treating” as used herein refers to the administering of a therapeutic effective amount of the composition of the present invention which is effective to
ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
[00529] In some embodiments, the phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[00530] The present invention also includes “pharmaceutically' acceptable salts” of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds -wherein the parent compound is modified by converting an existing acid or base moiety' to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the compound of the invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the compound of the invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; for example, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile.
[00531] The pharmaceutically acceptable salts of the compound of the invention can be formed by conventional means, such as by reacting the free base or free acid form of the product with one or more equivalents of the appropriate acid or base in a solvent or medium in which the salt is insoluble or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the ions of a existing salt for another ion or suitable ion-exchange resin.
[00532] Possible pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19, 1977; incorporated herein by reference.
[00533] Typically, a pharmaceutically acceptable salt form of a compound can be prepared in situ during the final isolation and purification of the compound, or separately by reacting the free base functionality with a suitable organic or inorganic acid.
[00534] Suitable acids for preparation of the pharmaceutically acceptable salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
[00535] Other pharmaceutically acceptable salts can include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[00536] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and quaternary ammonium salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[00537] Suitable bases for use in the preparation of pharmaceutically acceptable salts, including, but not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, or sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine,
diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, N-methyl-glucamine, hydrabamine, IH-imidazole, L-lysine, morpholine, 4-(2- hydroxyethyl)-morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, l -(2- hydroxyethyl)-pyrrolidine, pyridine, quinnclidine, quinoline, isoquinoline, secondary amines, triethanolamine, trimethylamine, triethylamine, N-methyl-D-glucamine, 2-amino-2- (hydroxymethyl)-l ,3-propanediol, and tromethamine.
[00538] The invention further includes derivatives of the compound of the invention. The term “derivatives” includes but is not limited to ether derivatives, acid derivatives, amide derivatives, ester derivatives and the like.
[00539] The invention further includes metabolites of the compound of the invention. The term “metabolite” means any substance produced from another substance by metabolism or a metabolic process.
[00540] The invention further includes pharmaceutical products of the compound of the invention. The term “pharmaceutical product” means a composition suitable for pharmaceutical use (pharmaceutical composition), as defined herein.
[00541] The invention further includes prodrugs of the compound of the invention. The term “■prodrug” means a substance which can be converted in vivo into a biologically active agent by such reactions as hydrolysis, esterification, de-esterification, activation, salt formation and the like.
[00542] It is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. When a range of values is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,'' it will be understood that the particular value forms another embodiment. .411 ranges are inclusive and combinable. Further, reference to values stated in ranges includes each and every value within that range. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any combination.
[00543] The invention further provides processes for the preparation of compounds of the invention as described herein. For example, the compound of the invention can be prepared using methods known in the art, including, for example, by referring to the following Schemes.
[00544] The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention.
Example 1: Preparation of Compounds of Invention
[00545] Schemes 1 - 6 provide processes for the preparation of compounds (1-4), (1-6), (1-7),
(1-14) and (1-20):
Scheme 2: Process for the preparation of compound (1-4)
Scheme 4: Process for the preparation of compound (I- 7)
Scheme 5: Process for the preparation of compound (1-14)
Scheme 6: Process for the preparation of compound (1-20)
[00546] Schemes 7- 11 provide processes for the preparation of compounds (II--4), (II-6), (II-7), and (II- 16):
Deuterium Exchange catalysed by transition metals (such as Pd-C)
6 d3-THC
Scheme 9: Process for the preparation of compound (11-7)
1) CD3MgBr
2) H3O+
Scheme 10: Process for the preparation of compound (II-7)
Scheme 1 1 : Process for the preparation of compound (11-16)
[00549] The processes for the preparation of compounds of the invention can further follow the procedures disclosed in Molecules, 2014, 19, 13526-13540 and Can J. Chem 1982, 60, 2804, which are herein incorporated by reference.
Example 2: Preparation of Compounds of Invention
[00550] The invention further provides the processes for the preparation of compounds of the present invention. Schemes Al -A3 provide processes for the preparation of compounds (A8), (Al 3), and (Al 8).
Scheme Al: Process for the preparation of compound (A8)
Scheme A2: Process for the preparation of compound (A13)
Scheme A3: Process for the preparation of compound (Al 8)
[00551] The process tor the preparation of compounds can also follow the procedure disclosed in Can. J. Chem. 193, 61 , 1053 and Recuelldes Trav. Chim. Des Pays-Bas, 1981, 100(9), 342-343, which are herein incorporated by reference.
Example 3: Preparation of Compounds of Invention
[00552] The invention further provides the processes for the preparation of compounds of the present invention. Schemes AA1- AA4 provide processes for the preparation of compounds (AA7), (AA11), (AA16) and (AA20).
Scheme AA1 : Process for the preparation of compound (AA7)
Scheme AA2: Process for the preparation of compound (AA11)
Scheme AA3: Process for the preparation of compound (AA16)
Scheme A A4: Process for the preparation of compound (AA20)
[00553] The process for the preparation of compounds can also follow the procedure disclosed in J. Pharm. Sei. 1982, 71(12), 1319-1323, which are herein incorporated by reference.
Example 4: Biological Activity Assays
In vitro Liver Microsomal Stability Assay
[00554] Liver microsomal stability’ assays are conducted at 1 mg per mL liver microsome protein with an NADPH-generating system in 2% sodium bicarbonate (2.2 mM NADPH, 25.6 mM glucose 6-phosphate, 6 units per mL glucose 6-phosphate dehydrogenase and 3.3 mM magnesium chloride). Test compounds are prepared as solutions in 20% acetonitrile-water and added to the assay? mixture (final assay concentration 5 microgram per mL) and incubated at 37° C. Final concentration of acetonitrile in the assay? should be <1%. Aliquots (50 pL) are taken out at times 0, 15, 30, 45, and 60 minutes, and diluted with ice cold acetonitrile (200 pL) to stop the reactions. Samples are centrifuged at 12,000 RPM for 10 minutes to precipitate proteins. Supernatants are transferred to microcentrifuge tubes and stored for LC/MS/MS analysis of the degradation half- life of the test compounds.
In Vitro Metabolism Using Human Cytochrome P450 Enzymes
[00555] The cytochrome P450 enzymes are expressed from the corresponding human cDNA using a baculovirus expression system (BD Biosciences, San Jose, Calif.). A 0.25 milliliter reaction mixture containing 0.8 milligrams per milliliter protein, 1.3 millimolar NADP4, 3.3 millimolar glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 3.3 millimolar magnesium chloride and 0.2 millimolar of a compound as disclosed herein, the corresponding non-isotopically enriched compound or standard or control in 100 millimolar potassium phosphate (pH 7.4) is incubated at 37° C. for 20 minutes. After incubation, the reaction is stopped by the addition of an appropriate solvent (e.g., acetonitrile, 20% trichloroacetic acid, 94% acetonitrile/6% glacial acetic acid, 70% perchloric acid, 94% acetonitrile/6% glacial acetic acid) and centrifuged (10,000 g) for 3 minutes. The supernatant is analyzed by HPLC/MS/MS.
Monooamine Oxidase B Inhibition and Oxidative Turnover
[00556] The procedure is earned out as described in Uebelhack et al., Pharmacopsychiatry, 1998, 31(5), 187-192, which is hereby incorporated by reference in its entirety.
CB2 Radioligand Binding Assay
[00557] The procedure is earned out as described in Yao et al., Brit. J. Pharmacol. 2006, (149), 145-154, which is hereby incorporated by reference in its entirety.
CB 1 Radioligand Binding Assay
[00558] The procedure is carried out as described in Yao et al., Brit. J. Pharmacol. 2006, (149), 145-154, which is hereby incorporated by reference in its entirety'.
CB2 Cyclase Functional Assay
[00559] The procedure is carried out as described in Yao et al., Brit. J. Pharmacol. 2006, (149), 145-154, which is hereby incorporated by reference in its entirety.
CB1 cAMP Assay
[00560] The procedure is earned out as described in Steffens et al., Brit. J Pharmacol. 2004, (141), 1 193-1203, which is hereby incorporated by reference in its entirety.
Pharmacokinetics (PK) in rats or mice
[00561] Rats or mice receive a single intravenous dose of THC or deuterated compounds at a dose of 1 mg/kg body weight, or a single oral dose of THC or deuterated compounds at a dose of 10-50 mg/kg body weight Plasma samples are collected at different times following dosing and the plasma concentrations of THC or deuterated compounds is determined by HPLC-MS/MS analysis using standards methods. Clearance, half-life, volume of distribution and oral bioavailability' are calculated from the plasma concentration-time course data using established methods.
[00562] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims
What is claimed is:
1 . A compound represented by a compound of formula (A) wherein R1-R14 and R15-Rao are each independently H or D; and R15 is D or OH; provided that when R3 is H, R15 is OH.
A compound represented by a compound of formula (I)
wherein R1- R14 are each independently H or D; and R15 is D or OH; provided that when R3 is H, R15 is OH.
3. The compound according to claim 1 or claim 2, wherein R1 and R2 are D.or R3 is D.
4. The compound according to claim 1 or claim 2, wherein R4 and R5 are D or R4-R14 are
D.
5. The compound according to claim 1 or ciaim 2, wherein said compound is
6. A compound represented by a compound of formula (B):
(B) wherein R1-R9 and R15-Ru are each independently H or D; and R15 is D or OH.
A compound represented by a compound of formula (II): wherein R1-R9 and R31 are each independently H or D; and R15 is D or OH.
The compound according to claim 6 or claim 7, wherein R16 is D or R16, is OH. The compound according to claim 6 or claim 7, wherein R19 is D or R17 and R15 are D. The compound according to claim 6 or claim 7, wherein R20 and R21 are D or R20-R26 are D. The compound according to any one of claims 6-10, wherein Rie is D. The compound according to claim 6 or claim 7, wherein said compound is
13. A compound represented by a compound of formula (A A)
(AA) wherein R1-R32 are each independently H or D, provided that at least one of R1-R17 is D.
14. A compound represented by a compound of formula (Al) wherein R1-R20 are each independently H or D, provided that at least one of R1-R17 is D.
15. The compound according to claim 13 or claim 14, wherein R1-R6 are D or R1-R17 are
16. The compound according to claim 13 or claim 14, wherein R1-R6, Ri 3, and R14 are D or R7 and R8 are D.
17. The compound according to claim 13 or claim 14, wherein said compound is:
18. A compound represented by a compound of formula (AAA)
wherein R1-R30 are each independently H or D, provided that at least one of R1-R25 is D.
19. A compound represented by a compound of formula (AAI) wherein R1-R25 are each independently H or D, provided that at least one of R1-R25 is D.
20. The compound according to claim 18 or claim 19, wherein R.-R15 are D or R8-R13 are D.
21. The compound according to claim 18 or claim 19, wherein R8-R13, R20, and R21 are D or R8- R24 are D.
22. The compound according to claim 18 or claim 19, wherein said compound is compound AA7, AAI 1, AA16, AA20, AA21, AA22, AA23, or AA24
23. A pharmaceutical composition comprising a compound according to any one of claims 1 -22 and a pharmaceutically acceptable carrier.
24. The pharmaceutical composition according to claim 23, wherein said composition is in an oral dosage unit form.
25. A pharmaceutical composition of claim 24, wherein said dosage unit form comprises a compound of any one of claims xxx in an amount of from about 0.01 mg to about 250 mg or from about 5 mg to about 250 mg.
26. A method of preventing or treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-12, wherein said disease or disorder is fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric
disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, chemotherapy-induced emesis, neuropathic pain, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, or emesis, or any combination thereof, or wherein said disease or disorder is selected from the group consisting of non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia circadian rhythm-related disorders, depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, cancer, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, general anxiety disorder, seasonal affective disorder, attention deficit hyperactivity disorder, Alzheimer’s, Angelman syndrome, schizophrenia, autism, epilepsy, migraine, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency, or wherein said disease or disorder is selected from the group consisting of osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.
27. A method of treating or preventing pain or inflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of any one of claims 1-22.
28. The method of claim 27, wherein said pain or inflammation is associated with osteoarthritis or is a postoperative pain or postoperative inflammation.
29. The method of claim 28, wherein said postoperative pain or inflammation is associated with orthopedic surgery, soft-tissue surgery, or dental surgery.
30. The method of any one of claim 26 or claim 27, wherein said subject is a human patient or a non-human animal.
31. The method of claim 30, wherein said non-human animal is a horse, a dog, or a cat.
32. A method of treating or preventing seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of claims 1-22.
33. A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of any one of claims 1-22, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
34. The method of claim 32 or claim 33, wherein said animal is a dog.
35. A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of any one of claims 1-22, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
36. The method of claim 35, -wherein said subject is a cat.
37. A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of any one of claims 1-22, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety1, aggression, compulsive disorders, phobias, epilepsy, or seizures.
38. The method of claim 37, wherein the anorexia is acute anorexia, chronic anorexia, a primary anorexia, a secondary anorexia, or an anorexia associated with chronic renal insufficiency.
39. The method of claim 37, wherein said aggression is dominance aggression, fear aggression, intraspecific aggression, or territorial aggression.
40. The method of claim 37, wherein said subject is a dog or a cat.
41. A method for preventing or treating a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of any one of claims 1-22 and at least one additional therapeutic agent, wherein said disease or disorder is selected from the group consisting of fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, anxiety, migraine, viral infection, fungal infection, bacterial infection, cancer, depression, inflammation, ischemia, psychiatric disorder, spasm, bone degradation, neurodegenerative disorder, pain, convulsion, neuropathic pain, musculoskeletal pain, osteoarthritis, multiple sclerosis, spasticity, Alzheimer's disease, nausea, vomiting, affective disorders, anorexia, dementia, cachexia, HIV wasting syndrome, Tourette's syndrome, and emesis, non-24-hour sleep wake disorder, Smith-Magenis syndrome, major depressive disorder, primary insomnia, circadian rhythm-related disorders, jet-lag, work-shift syndrome, sleep disorders, glaucoma, reproductive disorders, benign prostatic hyperplasia, immune disorders, neuroendocrine disorders, dysthymia, bipolar disorder, delayed sleep phase disorder, attention deficit hyperactivity disorder, Angelman syndrome, schizophrenia, autism, night-time hypertension, obesity, type 2 diabetes, and testosterone insufficiency; musculoskeletal disorders, Parkinson's disease, Huntington's disease, seizures, epilepsy, osteoporosis, cardiovascular disorders, and metabolic syndrome-related disorders, fear, phobias, aggression, compulsive disorders, or any combination thereof.
42. The method according to claim 41, wherein said additional therapeutic agent is an analgesic agent, an anti-anxiety agent, an anti-cancer agent, an anti-bacterial agent, an anti- convulsive agent, anti-epileptics, an anti-inflammatory agent, an anti-depressant agent, an antiemetic agent, an anti-ischemic agent, an anti-psychotic agent, an anti-spasmodic agent, an immunosuppressive agent, an agent for treatment of neurodegenerative diseases or disorders, an anti-dyskensia agent, a chemotherapeutic agent, an immunosuppressive agent, an antidiabetic agent, a cholesterol/lipid lowering agent, an orexigenic agent, an ocular hypotensive agent, an anti-osteoporosis agent, or a cardiovascular agent.
43. The method according to claim 41 or claim 42, wherein said disease or disorder is anorexia, glaucoma, anxiety, aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
44. The method of claim 43. wherein said subject is a dog.
45. The method according to claim 41 or claim 42, wherein said disease or disorder is anorexia, anxiety, epilepsy, osteoarthritis, or glaucoma.
46. The method according to claim 45, wherein said subject is a cat.
47. The method according to claim 41 or claim 42, wherein the disease or disorder is seizures, epilepsy, aggression, fear, phobias, generalized anxiety disorder, or separation anxiety’.
48. The method according to claim 47, wherein said subject is a dog.
49. The method according to claim 41 or claim 42, wherein said disease or disorder is anorexia, neoplastic disease, degenerative disorders, auto-immune diseases, allergies, metabolic disorders, infection, inflammation, trauma, toxicity, nutritional imbalance, idiopathic conditions, iatrogenic problems, glaucoma, anxiety', aggression, compulsive disorders, noise phobias, epilepsy, or seizures.
50. The method according to claim 49, wherein said subject is an animal.
51. The method according to claim 50, wherein said subject is a dog.
52. The method according to claim 41 or claim 42, wherein said disease or disorder is anorexia, anxiety, epilepsy, or glaucoma.
53. The method according to claim 52, wherein said subject is an animal.
54. The method according to claim 53, wherein said subject is a cat,
55. The method according to claim 1, wherein said disease or disorder is pain or inflammation.
56. The method according to claim 41 or claim 42, wherein said analgesic agent is an opioid analgesic agent or a non-opioid analgesic agent.
57. The method according to claim 26, wherein said non-opioid analgesic agent is meloxicam, acetaminophen, aspirin, ibuprofen, carprofen, fenbuprofen, flubiprofen, ketaprofen, ketorolac, loxoprofen, naproxen, suprofen, carbamazepine, gabapentin, or pregabalin.
58. The method according to claim 26, wherein said opioid analgesic agent is hydrocodone, oxycodone, acetyldihydrocodeinone, diamorphine, codeine, pethidine, alfentanil, buprenorphine, butorphanol, dezocine, fentanyl, hydromorphone, levomethadyl acetate, levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, or tramadol.
59. The method according to claim 41 or claim 42, wherein said agent for treatment of neurodegenerative diseases or disorder is resveratrol, anthocyanin, levodopa, pergolide, ephenedrine sulfate, pemoline, mazindol, a-methylphenethylamine, methylphenidate, pramipexole, modafinil, or ropinirole.
60. The method according to claim 41 or claim 42, wherein said anti-dyskensia agent is baclofen, botulinum toxin, clonazepam, or diazepam.
61. The method according to claim 41 or claim 42, wherein said anti-cancer agent is an chemotherapeutic agent, wherein said chemotherapeutic agent is adrimycin, doxorubicin, 5- fluorouracil, cytosine arabinoside (“Ara-C”), cyclophosphamide, thiotepa, taxotere (docetaxel), bulsulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycine, esperamicins, or melphalan.
62. The method according to claim 41 or claim 42, wherein said anti-cancer agent is a cytostatic drug, selected from busulfan, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, 5-fluorouracil, gemcitabine, pemetrexed, doxorubicin, daunorubicin, mitomycin, actinomycin D, bleomycin, paclitaxel, docetaxel, vinblastine, vincristine, etoposide, cisplatin, carboplatin, and oxaliplatin.
63. The method according to claim 41 or claim 42, wherein said immunosuppressive agent is azathioprine, cyclophosphamide, bromocriptine, glutaraldehyde, cyclosporin A, prednisone, prednisolone, methylprednisone, dexamethasone, heterologous anti-lymphocyte globulin, deoxyspergualin, or rapamycin.
64. The method according to claim 41 or claim 42, wherein said anti-spasmodic agent is carbamatepine, oxcarbazepine, ferbocate, furboc acid, paroxamine, fibapramine, laxamide,
talapanib, retigabine, levethiracetam, tobinamide, zonisamide. barbiturates, benzodiazepines, or hydantoin.
65. The method according to claim 41 or claim 42, wherein said anti-diabetic agent is mefluminine hydrochloride, acarbose, migiitol, human insulin, pig insulin, bovine insulin, nateglinide, reglinide, glimepiride, glibenclamide, chlorpromide, tolazamide, or glipben.
66. The method according to claim 41 or claim 42, wherein said anti-convulsant agent and/or anti-epileptics is phenobarbital, pentobarbital, nitronazapine, clozapine acid salt, diazapine, saigabin, gabapentin, phenytoin, 5,5-diphenylhydantoin, carbamatepine, oxcarbazepine, falbockate, falbock acid, bifarin Pockic acid, paroxamide, fibamay, levethiracetam, tobinamide, zonisamide, lamtidine, mesylamine, ethoxyl , or ruitijiabin.
67. The method according to claim 41 or claim 42, wherein anticonvulsive agent and/or anti-epileptics is brivaracetam, carbamzepine, clobazam, rancedon, ethosuximide, nonammonia ester, gabapentin, lacosamide, lamotrigine, Levetiracetam, oxcarbazepine, phenobarbital, phenytoin sodium salt, pregabalin, desoxyphenobarbital, rotigotine, rufinamide, seletracetam, talampanel, tiagabine, topiramate, sodium valproate, vigabatrin, or zonisamide.
68. The method according to claim 41 or claim 42, wherein said anti-psychotic agent is risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide, clothiapine, molindone, loxapine, trifluoperazine, haloperidol, flupenthixol, chlorpromazine, chlorprothixene, clopenthixol, droperidol, perphenazine, fluphenazine, lithium, mesoridazine, spiperone, promazine, prochlorperazine, thioridazine, thiothixene, triflupromazine, or raclopride.
69. The method according to claim 41 or claim 42, wherein said cholesterol/lipid lowering agent is pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, cholestyramine, colestipol, gemfibrozil, clofibrate, fenofibrate, benzafibrate, rosiglitazone, or ezetimibe.
70. The method according to claim 41 or claim 42, wherein said anti-inflammatory agent is meloxicam, carprofen, tepoxalin, firocoxib, deracoxib, etodolac, ibuprofen, naproxen, ketoprofen, celecoxib, rofecoxib, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoprofen, piroprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen,
aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufen ami c acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, or acetaminophen.
71. The method according to claim 41 or claim 42, wherein said anti-bacterial agent is selected from the group consisting of erythromycin, aji azithromycin, clarithromycin, telithromycin, penicillin G, penicillin V, methicillin, toluene oxazinmycin, o-chloropenicillin, diclofenac, phenoxypenicillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, Piperacillin, azlocillin, temocillin, cepalothin, cefepinie, cefacyclohexene, ceftizodine, cefazolin, cefotaxazole, cephalosporin, cephalosporin IV, cefprozil, cloxacromycin, loracarbef, cefotaxime, cefinetazole, ceftazidime cefotaxime, cefizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cetpodoxime, cetazide, ceftibuten, cefdinir, cefpirome, cefepime, aztreonam, imipeneni, meropenem, meropenem penicillin (ertapenem), doricane (doripenem), cephalosporin ceftobiprole and ceftaroline, citric acid, porphyrin, norfloxacin, pefloxacin, enoxacin, oufumycin, levofloxacin, ciprofloxacin, tiproxoxacin temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, and rufosa trovafloxacin), clinafloxacin, gatifloxacin, moxifloxacin, sitar Sitafloxacin, garenoxacin, gemifloxacin, pazufloxacin, p-aminobenzoic acid, sulfadiazine, sulfonamide azole, sulfamethine oxazole and sulfonamide, streptomycin, neomycin, kenmycin, baromycin, gentamicin, tobramycin, butyl Amine kanamycin, netilmicin, spectinomycin, perillamycin, dardamycin and ezeparin, tetracycline, chlortetracycline, chlorotetracycline, go Mechlorin, minocycline, oxytetracycline, methicillin, tigcycline, doxycycline, rifampicin, rifampin, rifapentine, rifabutin, bezoxazinorifamycin and rifaximin, lincomycin, kesendamycin, telavancin, vancomycin, ticlosin, daptomycin, quinupristin and darfapolis Daflopristin, linoleide, polymyxin, colistin, colin, trimethoprim, and bacitracin.
72. The method according to claim 41 or claim 42, wherein said anti-emetics is dolasetron, granisetron, ondansetron, tropisetron, palonosetron, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide, alizapride, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine, dronabinol, midazolam, lorazepam, hyoscine, dexamethasone, aprepitant, casopitant, trimethobenzamide, or propofol.
73. The method according to claim 41 or claim 42, wherein said anti-depressants is selected from the group consisting of adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, beforaline, bifemelane, binodaline, bipenamol, brofaromine bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, fluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine, and zometapine.
74. The method according to claim 41 or claim 42, wherein said anti-anxiety agent is comipramine hydrochloride, fluoxetine hydrochloride, salprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam prazepam, buspirone, flesinoxan, gepirone and ipsapirone, pindolol, carbamazepine, lamotrigine, valproate, clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol, vigabatrin, or barbiturates.
75. The method according to claim 41 or claim 42, wherein said sleeping agent is zolpidem, alpidem, zopiclone, or indiflon.
76. The method according to claim 41 or claim 42, wherein said anti-migraine agent is sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, probatriptan, or alrnotriptan.
77. The method according to claim 41 or claim 42, the orexigenic agent is rnegestrol or oxandrolone.
78. The method according to claim 41 or claim 42, the ocular hypotensive agent is bimatoprost, latanoprost, travoprost, timolol, betaxolol, dorzolamide, brinzolamide, pilocarpine, brimonidine, latanoprost, travoprost, or bimatoprost.
79. The method according to claim 41 or claim 42, the anti -osteoporosis agent is alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, bazedoxifene, teriparatide, abaloparatide, or denosumab.
80. The method according to ciaim 41 or claim 42, wherein said cardiovascular agent is avasimibe, pactimibe, captopril, enalapril, enalaprilat, tradolapril, moexipril, ramipril, hinapril, perindopril, lisinopril, benazepril, fosinopril, eplerenone, aldactone, doxazosin, methyldofo, clonidine, prazosin, terazosin, candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, eprosartan, adenosine, amiodarone, digoxin, disopyramide, flecainide, lidocaine, niexiletine, procainamide, quinidine gluconate, propafenone hydrochloride, or tocainide.
81. The method according to any one of claims 41 -80, wherein the therapeutically effective amount, of said additional therapeutic agent administered to the subject is less than the therapeutically effective amount of said additional therapeutic agent when administered in the absence of the compound of any one of claims 1 -22
82. The method according to any one of claims 41-80, wherein the therapeutically effective amount of said additional therapeutic agent administered to the subject is 0% to 90%, 5% to
90%, or 10% to 90% less than the therapeutically effective amount of said additional therapeutic agent when administered in the absence of the compound of any one of claims 1- 22.
83. The method according to any one of claims 41-80, wherein the therapeutically effective amount, of said additional therapeutic agent administered to the subject is at least 20% less than the therapeutically effective amount of said additional therapeutic agent when administered in the absence of the compound of any one of claims 1-22.
84. The method according to any one of claims 41-80, wherein the therapeutically effective amount of said additional therapeutic agent, administered to the subject is at. least. 40% less than the therapeutically effective amount of said additional therapeutic agent when administered in the absence of the compound of any one of claims 1-22.
85. The method according to any one of claims 41-80, wherein the therapeutically effective amount of said additional therapeutic agent is at least 50% less than the therapeutically effective
amount of said additional therapeutic agent when administered in the absence of the compound of any one of claims 1-22.
86. The method according to any one of claims 1-55, wherein said additional therapeutic agent and the compound of any one of claims 1-22 are administered concurrently.
87. The method according to any one of claims 1-55, wherein the additional therapeutic agent and the compound of any one of claims 1-22 are formulated in the same pharmaceutical composition.
88. The method according to any one of claims 1-55, wherein said additional therapeutic agent is formulated in a first pharmaceutical composition and the compound of any one of claims 1-22 is formulated in a second pharmaceutical composition.
89. The method according to any one of claims 41-88, wherein said subject is a human patient.
90. The method according to any one of claims 41-88, wherein said subject is a non-human animal.
91. The method according to claim 90, wherein said subject is a dog or a cat.
92. The method according to claim 41, wherein said additional therapeutic agent is an agent for treating fragile X syndrome.
93. The method according to claim 41 , wherein said additional therapeutic agent is an agent for treating autism spectrum disorder.
94. The method according to claim 41 , wherein said additional therapeutic agent is an agent for treating lysosomal storage diseases.
95. The method according to claim 41 , wherein said additional therapeutic agent is an agent for treating leukodystrophies.
96. The method according to claim 41 , wherein said additional therapeutic agent is an agent for treating Rett syndrome.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163139239P | 2021-01-19 | 2021-01-19 | |
US202163139220P | 2021-01-19 | 2021-01-19 | |
US63/139,239 | 2021-01-19 | ||
US63/139,220 | 2021-01-19 | ||
US202163151145P | 2021-02-19 | 2021-02-19 | |
US202163151127P | 2021-02-19 | 2021-02-19 | |
US202163151159P | 2021-02-19 | 2021-02-19 | |
US202163151138P | 2021-02-19 | 2021-02-19 | |
US63/151,127 | 2021-02-19 | ||
US63/151,138 | 2021-02-19 | ||
US63/151,145 | 2021-02-19 | ||
US63/151,159 | 2021-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022159504A1 true WO2022159504A1 (en) | 2022-07-28 |
Family
ID=82549032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/012997 WO2022159504A1 (en) | 2021-01-19 | 2022-01-19 | Deuterated cannabinoid compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022159504A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024030866A1 (en) * | 2022-08-01 | 2024-02-08 | Invizyne Technologies, Inc. | Biosynthesis of substituted compounds and cannabinoids |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020123976A1 (en) * | 2018-12-14 | 2020-06-18 | Natural Extraction Systems, LLC | Compositions and methods related to anionic cannabinoid molecules |
WO2020163138A2 (en) * | 2019-02-06 | 2020-08-13 | Lighthouse Strategies, LLC | Cannabinoid emulsions, beverages and foods |
US20200405660A1 (en) * | 2019-06-28 | 2020-12-31 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
WO2021207843A1 (en) * | 2020-04-15 | 2021-10-21 | Eye3Concepts Inc. | Nanomaterials for electrochemical detection of phenolic analytes |
-
2022
- 2022-01-19 WO PCT/US2022/012997 patent/WO2022159504A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020123976A1 (en) * | 2018-12-14 | 2020-06-18 | Natural Extraction Systems, LLC | Compositions and methods related to anionic cannabinoid molecules |
WO2020163138A2 (en) * | 2019-02-06 | 2020-08-13 | Lighthouse Strategies, LLC | Cannabinoid emulsions, beverages and foods |
US20200405660A1 (en) * | 2019-06-28 | 2020-12-31 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
WO2021207843A1 (en) * | 2020-04-15 | 2021-10-21 | Eye3Concepts Inc. | Nanomaterials for electrochemical detection of phenolic analytes |
Non-Patent Citations (1)
Title |
---|
DATABASE PubChem substance ANONYMOUS : "(+/-)-11-hydroxy-delta9-thc", XP055958719, retrieved from NCBI Database accession no. 349735049 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024030866A1 (en) * | 2022-08-01 | 2024-02-08 | Invizyne Technologies, Inc. | Biosynthesis of substituted compounds and cannabinoids |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6049931B2 (en) | Cyclopropyl modulator of the P2Y12 receptor | |
US10689370B2 (en) | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | |
US7863308B2 (en) | Substituted thiophenes | |
US10568965B2 (en) | Aminopyrimidine inhibitors of tyrosine kinase | |
CA2981743A1 (en) | Deuterium-substituted oxadiazoles | |
US20100135956A1 (en) | Steroid modulators of progesterone receptor and/or glucocorticoid receptor | |
EP3126331A1 (en) | Oxindole inhibitors of tyrosine kinase | |
US20100291025A1 (en) | Indazole inhibitors of tyrosine kinase | |
TW202139996A (en) | Methods of treating apol-1 dependent focal segmental glomerulosclerosis | |
US20200290992A1 (en) | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | |
TW201629029A (en) | Cyclopropyl dihydrobenzofuran modulators of melatonin receptors | |
US20100111901A1 (en) | Triazole inhibitors of aromatase | |
WO2022159504A1 (en) | Deuterated cannabinoid compounds | |
US20110195066A1 (en) | Quinoline inhibitors of tyrosine kinase | |
WO2022159506A1 (en) | Deuterated cannabidiol compounds | |
WO2022159507A1 (en) | Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders | |
US20100075950A1 (en) | Phenylpropanone modulators of dopamine receptor | |
US20110091459A1 (en) | Imidazole modulators of muscarinic acetylcholine receptor m3 | |
US20100130615A1 (en) | Sulfonylurea inhibitors of atp-sensitive potassium channels | |
US20100124541A1 (en) | Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv | |
US20100120861A1 (en) | Benzoic acid inhibitors of atp-sensitive potassium channels | |
TW201625638A (en) | 3-fluoro-benzonitrile inhibitors of 11-[beta]-hydroxylase | |
WO2010060041A2 (en) | Phenylalanine amide inhibitors of atp-sensitive potassium channels | |
CN114621119A (en) | Crystalline forms of 1- (acyloxy) -alkyl carbamate drug conjugates of naproxen and pregabalin | |
WO2010011868A2 (en) | Pyridine sulfonamide modulators of endothelin-a-receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22743112 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22743112 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22743112 Country of ref document: EP Kind code of ref document: A1 |